WO2020138336A1 - コドン拡張のための変異tRNA - Google Patents
コドン拡張のための変異tRNA Download PDFInfo
- Publication number
- WO2020138336A1 WO2020138336A1 PCT/JP2019/051241 JP2019051241W WO2020138336A1 WO 2020138336 A1 WO2020138336 A1 WO 2020138336A1 JP 2019051241 W JP2019051241 W JP 2019051241W WO 2020138336 A1 WO2020138336 A1 WO 2020138336A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trna
- codon
- compound
- amino acid
- anticodon
- Prior art date
Links
- 108020004705 Codon Proteins 0.000 title claims abstract description 553
- 108020004566 Transfer RNA Proteins 0.000 claims abstract description 713
- 150000001413 amino acids Chemical class 0.000 claims abstract description 279
- 238000013519 translation Methods 0.000 claims abstract description 215
- 108020005098 Anticodon Proteins 0.000 claims abstract description 168
- VWSLLSXLURJCDF-UHFFFAOYSA-N 2-methyl-4,5-dihydro-1h-imidazole Chemical compound CC1=NCCN1 VWSLLSXLURJCDF-UHFFFAOYSA-N 0.000 claims abstract description 82
- NHQSDCRALZPVAJ-HJQYOEGKSA-N agmatidine Chemical compound NC(=N)NCCCCNC1=NC(=N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHQSDCRALZPVAJ-HJQYOEGKSA-N 0.000 claims abstract description 66
- 239000002777 nucleoside Substances 0.000 claims description 183
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 140
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 118
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 73
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 73
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 73
- 150000007523 nucleic acids Chemical class 0.000 claims description 71
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 60
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 58
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 57
- 230000004048 modification Effects 0.000 claims description 53
- 238000012986 modification Methods 0.000 claims description 53
- 125000003835 nucleoside group Chemical group 0.000 claims description 46
- 230000000295 complement effect Effects 0.000 claims description 44
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 32
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 30
- 229940029575 guanosine Drugs 0.000 claims description 30
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 29
- 229960005305 adenosine Drugs 0.000 claims description 29
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 27
- 230000002068 genetic effect Effects 0.000 claims description 27
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 27
- 229940045145 uridine Drugs 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 102000003960 Ligases Human genes 0.000 claims description 9
- 108090000364 Ligases Proteins 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000001177 diphosphate Substances 0.000 abstract description 33
- 235000011180 diphosphates Nutrition 0.000 abstract description 18
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract description 17
- 238000001308 synthesis method Methods 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 description 331
- 229940024606 amino acid Drugs 0.000 description 266
- 235000001014 amino acid Nutrition 0.000 description 262
- 230000014616 translation Effects 0.000 description 209
- 238000000034 method Methods 0.000 description 147
- -1 pyridinecarbonyl Chemical group 0.000 description 144
- 239000002904 solvent Substances 0.000 description 117
- 239000000203 mixture Substances 0.000 description 88
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 83
- 239000000243 solution Substances 0.000 description 77
- 238000006243 chemical reaction Methods 0.000 description 72
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 72
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 68
- 238000003786 synthesis reaction Methods 0.000 description 66
- 239000003153 chemical reaction reagent Substances 0.000 description 61
- 125000006239 protecting group Chemical group 0.000 description 61
- 108020004999 messenger RNA Proteins 0.000 description 58
- 230000015572 biosynthetic process Effects 0.000 description 57
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 54
- 238000004458 analytical method Methods 0.000 description 48
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 47
- 230000014759 maintenance of location Effects 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 43
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 40
- 125000001424 substituent group Chemical group 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000012634 fragment Substances 0.000 description 37
- 239000002585 base Substances 0.000 description 36
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 36
- 239000007864 aqueous solution Substances 0.000 description 34
- 239000012071 phase Substances 0.000 description 33
- 238000010898 silica gel chromatography Methods 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000012043 crude product Substances 0.000 description 30
- 239000012299 nitrogen atmosphere Substances 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 238000010586 diagram Methods 0.000 description 27
- 125000000217 alkyl group Chemical group 0.000 description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 25
- 125000003118 aryl group Chemical group 0.000 description 24
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 23
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 22
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 21
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 21
- 238000005886 esterification reaction Methods 0.000 description 21
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 20
- 125000002947 alkylene group Chemical group 0.000 description 20
- 108010067902 Peptide Library Proteins 0.000 description 19
- 238000009835 boiling Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 230000032050 esterification Effects 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 230000002441 reversible effect Effects 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 125000003710 aryl alkyl group Chemical group 0.000 description 18
- 229910052799 carbon Inorganic materials 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 239000004472 Lysine Substances 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 17
- 229960003646 lysine Drugs 0.000 description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 description 17
- 125000000304 alkynyl group Chemical group 0.000 description 16
- 125000003277 amino group Chemical group 0.000 description 16
- 125000006309 butyl amino group Chemical group 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 16
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 16
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 229960000310 isoleucine Drugs 0.000 description 15
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 15
- 229910021642 ultra pure water Inorganic materials 0.000 description 15
- 239000012498 ultrapure water Substances 0.000 description 15
- 229910001868 water Inorganic materials 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 14
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 14
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 14
- 229930182817 methionine Natural products 0.000 description 14
- OVYNGSFVYRPRCG-KQYNXXCUSA-N 2'-O-methylguanosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 OVYNGSFVYRPRCG-KQYNXXCUSA-N 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 13
- 125000004450 alkenylene group Chemical group 0.000 description 13
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 12
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 12
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 12
- 239000003759 ester based solvent Substances 0.000 description 12
- 239000004210 ether based solvent Substances 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 12
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 12
- 239000005453 ketone based solvent Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- ILKFHZRKLTWFKR-UHFFFAOYSA-N benzyl n-benzylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)NCC1=CC=CC=C1 ILKFHZRKLTWFKR-UHFFFAOYSA-N 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 10
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 229960001153 serine Drugs 0.000 description 10
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 102000006382 Ribonucleases Human genes 0.000 description 9
- 108010083644 Ribonucleases Proteins 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- 229960005190 phenylalanine Drugs 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- 241000203069 Archaea Species 0.000 description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 125000004434 sulfur atom Chemical group 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 6
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 6
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 6
- 101150065749 Churc1 gene Proteins 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 102100038239 Protein Churchill Human genes 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- MJIATCLHNDSDRK-UHFFFAOYSA-N n-ethyl-4-methylpentan-2-amine Chemical compound CCNC(C)CC(C)C MJIATCLHNDSDRK-UHFFFAOYSA-N 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 229930010555 Inosine Natural products 0.000 description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 5
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 239000012620 biological material Substances 0.000 description 5
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 5
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 5
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229960003786 inosine Drugs 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- NHIGMSVSERTXAH-DEOSSOPVSA-N (2S)-2-[[4-[[2-(4-fluorophenyl)acetyl]amino]phenyl]methoxycarbonyl-methylamino]-4-phenylbutanoic acid Chemical compound CN([C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)OCC2=CC=C(C=C2)NC(=O)CC3=CC=C(C=C3)F NHIGMSVSERTXAH-DEOSSOPVSA-N 0.000 description 4
- GRGPYLKGDDKRIV-QFIPXVFZSA-N (2S)-3-(3-chlorophenyl)-2-[[4-[[2-(4-fluorophenyl)acetyl]amino]phenyl]methoxycarbonylamino]propanoic acid Chemical compound C1=CC(=CC(=C1)Cl)C[C@@H](C(=O)O)NC(=O)OCC2=CC=C(C=C2)NC(=O)CC3=CC=C(C=C3)F GRGPYLKGDDKRIV-QFIPXVFZSA-N 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 4
- 101100366707 Arabidopsis thaliana SSL11 gene Proteins 0.000 description 4
- 101100366710 Arabidopsis thaliana SSL12 gene Proteins 0.000 description 4
- 101100366711 Arabidopsis thaliana SSL13 gene Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- NIDVTARKFBZMOT-PEBGCTIMSA-N N(4)-acetylcytidine Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NIDVTARKFBZMOT-PEBGCTIMSA-N 0.000 description 4
- 101100366561 Panax ginseng SS11 gene Proteins 0.000 description 4
- 101100366562 Panax ginseng SS12 gene Proteins 0.000 description 4
- 101100366563 Panax ginseng SS13 gene Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001371 alpha-amino acids Chemical class 0.000 description 4
- 235000008206 alpha-amino acids Nutrition 0.000 description 4
- YQFTVQRPXGWRST-VZDZRGPCSA-N benzyl (2S)-6-[[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(phenylmethoxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(phenylmethoxycarbonylamino)hexanoate Chemical compound C1=CC=C(C=C1)COC(=O)[C@H](CCCCN=C2N=C(C=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NC(=O)OCC4=CC=CC=C4)NC(=O)OCC5=CC=CC=C5 YQFTVQRPXGWRST-VZDZRGPCSA-N 0.000 description 4
- VDIHJSBUMFZHNJ-WXQJYUTRSA-N benzyl N-[2-[4-[bis(phenylmethoxycarbonylamino)methylideneamino]butylimino]-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-4-yl]carbamate Chemical compound C1=CC=C(C=C1)COC(=O)NC2=NC(=NCCCCN=C(NC(=O)OCC3=CC=CC=C3)NC(=O)OCC4=CC=CC=C4)N(C=C2)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O VDIHJSBUMFZHNJ-WXQJYUTRSA-N 0.000 description 4
- SYZFQLUYDBIQCR-UHFFFAOYSA-N chloromethoxy-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)OCCl SYZFQLUYDBIQCR-UHFFFAOYSA-N 0.000 description 4
- FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- ANPWLBTUUNFQIO-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphanyl-n-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1COP(N(C(C)C)C(C)C)OCC1=CC=CC=C1 ANPWLBTUUNFQIO-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- QQXQGKSPIMGUIZ-AEZJAUAXSA-N queuosine Chemical group C1=2C(=O)NC(N)=NC=2N([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=C1CN[C@H]1C=C[C@H](O)[C@@H]1O QQXQGKSPIMGUIZ-AEZJAUAXSA-N 0.000 description 4
- 230000014626 tRNA modification Effects 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- OUAQUXDHDSSVQH-IBGZPJMESA-N (2S)-1-[[4-[[2-(4-fluorophenyl)acetyl]amino]phenyl]methoxycarbonyl]piperidine-2-carboxylic acid Chemical compound C1CCN([C@@H](C1)C(=O)O)C(=O)OCC2=CC=C(C=C2)NC(=O)CC3=CC=C(C=C3)F OUAQUXDHDSSVQH-IBGZPJMESA-N 0.000 description 3
- NVXKJPGRZSDYPK-JTQLQIEISA-N (2s)-2-(methylamino)-4-phenylbutanoic acid Chemical compound CN[C@H](C(O)=O)CCC1=CC=CC=C1 NVXKJPGRZSDYPK-JTQLQIEISA-N 0.000 description 3
- SMCWNPAVVQIDBM-YFKPBYRVSA-N (2s)-piperidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCCN1C(O)=O SMCWNPAVVQIDBM-YFKPBYRVSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- HXVKEKIORVUWDR-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methylaminomethyl)-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HXVKEKIORVUWDR-FDDDBJFASA-N 0.000 description 3
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 description 3
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 3
- VZQXUWKZDSEQRR-SDBHATRESA-N 2-methylthio-N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C12=NC(SC)=NC(NCC=C(C)C)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VZQXUWKZDSEQRR-SDBHATRESA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 3
- SNNBPMAXGYBMHM-JXOAFFINSA-N 5-methyl-2-thiouridine Chemical compound S=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SNNBPMAXGYBMHM-JXOAFFINSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 101100096719 Arabidopsis thaliana SSL2 gene Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 3
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- 101000642815 Homo sapiens Protein SSXT Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- SISQLNCPQVIOJA-UHFFFAOYSA-N N#CCCOP(N(NC(C)C)NC(C)C)OCCC#N Chemical compound N#CCCOP(N(NC(C)C)NC(C)C)OCCC#N SISQLNCPQVIOJA-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 101100366560 Panax ginseng SS10 gene Proteins 0.000 description 3
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 3
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 3
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 3
- 102100035586 Protein SSXT Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 101000662518 Solanum tuberosum Sucrose synthase Proteins 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- UUBWXCHLJHRYJT-LNAOLWRRSA-N [(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(phosphonooxymethyl)oxolan-3-yl] [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 UUBWXCHLJHRYJT-LNAOLWRRSA-N 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 125000000732 arylene group Chemical group 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- JNLKSAMFGRDHPJ-UHFFFAOYSA-N benzyl N-[N'-(4-aminobutyl)-N-phenylmethoxycarbonylcarbamimidoyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(=NCCCCN)NC(=O)OCC1=CC=CC=C1 JNLKSAMFGRDHPJ-UHFFFAOYSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 3
- 125000005549 heteroarylene group Chemical group 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- NCGWKCHAJOUDHQ-UHFFFAOYSA-N n,n-diethylethanamine;formic acid Chemical compound OC=O.OC=O.CCN(CC)CC NCGWKCHAJOUDHQ-UHFFFAOYSA-N 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000001302 tertiary amino group Chemical group 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- UFUQAIBNROSFES-ZETCQYMHSA-N (2S)-2-amino-3-(2-chlorophenoxy)propanoic acid Chemical compound OC(=O)[C@@H](N)COC1=CC=CC=C1Cl UFUQAIBNROSFES-ZETCQYMHSA-N 0.000 description 2
- PDFLYUQIITUCNI-IINAIABHSA-N (2S)-2-amino-6-[[4-amino-1-[(2R,3R,4S,5R)-3-hydroxy-4-phosphonooxy-5-(phosphonooxymethyl)oxolan-2-yl]pyrimidin-2-ylidene]amino]hexanoic acid Chemical compound C1=CN(C(=NCCCC[C@@H](C(=O)O)N)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)OP(=O)(O)O)O PDFLYUQIITUCNI-IINAIABHSA-N 0.000 description 2
- GPTUGCGYEMEAOC-IBZYUGMLSA-N (2s,3r)-2-amino-n-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]-methylcarbamoyl]-3-hydroxybutanamide Chemical compound C1=NC=2C(N(C)C(=O)NC(=O)[C@@H](N)[C@H](O)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GPTUGCGYEMEAOC-IBZYUGMLSA-N 0.000 description 2
- UTAIYTHAJQNQDW-KQYNXXCUSA-N 1-methylguanosine Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTAIYTHAJQNQDW-KQYNXXCUSA-N 0.000 description 2
- FPUGCISOLXNPPC-UHFFFAOYSA-N 2'-O-Methyladenosine Natural products COC1C(O)C(CO)OC1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-UHFFFAOYSA-N 0.000 description 2
- RFCQJGFZUQFYRF-UHFFFAOYSA-N 2'-O-Methylcytidine Natural products COC1C(O)C(CO)OC1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-UHFFFAOYSA-N 0.000 description 2
- RFCQJGFZUQFYRF-ZOQUXTDFSA-N 2'-O-methylcytidine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-ZOQUXTDFSA-N 0.000 description 2
- WGNUTGFETAXDTJ-OOJXKGFFSA-N 2'-O-methylpseudouridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O WGNUTGFETAXDTJ-OOJXKGFFSA-N 0.000 description 2
- YUCFXTKBZFABID-WOUKDFQISA-N 2-(dimethylamino)-9-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-3h-purin-6-one Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=NC2=O)N(C)C)=C2N=C1 YUCFXTKBZFABID-WOUKDFQISA-N 0.000 description 2
- VHXUHQJRMXUOST-PNHWDRBUSA-N 2-[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]acetamide Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(N)=O)=C1 VHXUHQJRMXUOST-PNHWDRBUSA-N 0.000 description 2
- SFFCQAIBJUCFJK-UGKPPGOTSA-N 2-[[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]methylamino]acetic acid Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCC(O)=O)=C1 SFFCQAIBJUCFJK-UGKPPGOTSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 2
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 2
- RDPUKVRQKWBSPK-UHFFFAOYSA-N 3-Methylcytidine Natural products O=C1N(C)C(=N)C=CN1C1C(O)C(O)C(CO)O1 RDPUKVRQKWBSPK-UHFFFAOYSA-N 0.000 description 2
- JJDJLFDGCUYZMN-QMMMGPOBSA-N 3-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(Cl)=C1 JJDJLFDGCUYZMN-QMMMGPOBSA-N 0.000 description 2
- RDPUKVRQKWBSPK-ZOQUXTDFSA-N 3-methylcytidine Chemical compound O=C1N(C)C(=N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RDPUKVRQKWBSPK-ZOQUXTDFSA-N 0.000 description 2
- YBBDRHCNZBVLGT-FDDDBJFASA-N 4-amino-1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2-oxopyrimidine-5-carbaldehyde Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C(C=O)=C1 YBBDRHCNZBVLGT-FDDDBJFASA-N 0.000 description 2
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 description 2
- YHRRPHCORALGKQ-UHFFFAOYSA-N 5,2'-O-dimethyluridine Chemical compound COC1C(O)C(CO)OC1N1C(=O)NC(=O)C(C)=C1 YHRRPHCORALGKQ-UHFFFAOYSA-N 0.000 description 2
- VSCNRXVDHRNJOA-PNHWDRBUSA-N 5-(carboxymethylaminomethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCC(O)=O)=C1 VSCNRXVDHRNJOA-PNHWDRBUSA-N 0.000 description 2
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 2
- ZYEWPVTXYBLWRT-UHFFFAOYSA-N 5-Uridinacetamid Natural products O=C1NC(=O)C(CC(=O)N)=CN1C1C(O)C(O)C(CO)O1 ZYEWPVTXYBLWRT-UHFFFAOYSA-N 0.000 description 2
- ZYEWPVTXYBLWRT-VPCXQMTMSA-N 5-carbamoylmethyluridine Chemical compound O=C1NC(=O)C(CC(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZYEWPVTXYBLWRT-VPCXQMTMSA-N 0.000 description 2
- HLZXTFWTDIBXDF-PNHWDRBUSA-N 5-methoxycarbonylmethyl-2-thiouridine Chemical compound S=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HLZXTFWTDIBXDF-PNHWDRBUSA-N 0.000 description 2
- YIZYCHKPHCPKHZ-PNHWDRBUSA-N 5-methoxycarbonylmethyluridine Chemical compound O=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YIZYCHKPHCPKHZ-PNHWDRBUSA-N 0.000 description 2
- HXVKEKIORVUWDR-UHFFFAOYSA-N 5-methylaminomethyl-2-thiouridine Natural products S=C1NC(=O)C(CNC)=CN1C1C(O)C(O)C(CO)O1 HXVKEKIORVUWDR-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- USVMJSALORZVDV-UHFFFAOYSA-N 6-(gamma,gamma-dimethylallylamino)purine riboside Natural products C1=NC=2C(NCC=C(C)C)=NC=NC=2N1C1OC(CO)C(O)C1O USVMJSALORZVDV-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- FNXXQNGLPFUMPW-DEOSSOPVSA-N CN([C@@H](CCc1ccccc1)C(O)=O)C(=O)OCC1c2ccccc2-c2ccccc12 Chemical compound CN([C@@H](CCc1ccccc1)C(O)=O)C(=O)OCC1c2ccccc2-c2ccccc12 FNXXQNGLPFUMPW-DEOSSOPVSA-N 0.000 description 2
- 241000228124 Desulfitobacterium hafniense Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102000029793 Isoleucine-tRNA ligase Human genes 0.000 description 2
- 101710176147 Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 2
- 241000205284 Methanosarcina acetivorans Species 0.000 description 2
- 241000205274 Methanosarcina mazei Species 0.000 description 2
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 description 2
- SLEHROROQDYRAW-KQYNXXCUSA-N N(2)-methylguanosine Chemical compound C1=NC=2C(=O)NC(NC)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SLEHROROQDYRAW-KQYNXXCUSA-N 0.000 description 2
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 2
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 2
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-Methyltyrosine Chemical compound CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 2
- GOSWTRUMMSCNCW-UHFFFAOYSA-N N6-(cis-hydroxyisopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1OC(CO)C(O)C1O GOSWTRUMMSCNCW-UHFFFAOYSA-N 0.000 description 2
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 2
- VZQXUWKZDSEQRR-UHFFFAOYSA-N Nucleosid Natural products C12=NC(SC)=NC(NCC=C(C)C)=C2N=CN1C1OC(CO)C(O)C1O VZQXUWKZDSEQRR-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101710149031 Probable isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 2
- YXNIEZJFCGTDKV-UHFFFAOYSA-N X-Nucleosid Natural products O=C1N(CCC(N)C(O)=O)C(=O)C=CN1C1C(O)C(O)C(CO)O1 YXNIEZJFCGTDKV-UHFFFAOYSA-N 0.000 description 2
- JLPXBBAPIDPXAI-UHFFFAOYSA-N [(2,5-dioxopyrrolidin-1-yl)-(9H-fluoren-9-yl)methyl] hydrogen carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1C(OC(=O)O)N1C(=O)CCC1=O JLPXBBAPIDPXAI-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- 150000001576 beta-amino acids Chemical class 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- KVOHELKOUKIEGM-DEOSSOPVSA-N cyanomethyl (2S)-3-(3-chlorophenyl)-2-[[4-[[2-(4-fluorophenyl)acetyl]amino]phenyl]methoxycarbonylamino]propanoate Chemical compound ClC=1C=C(C=CC1)C[C@@H](C(=O)OCC#N)NC(=O)OCC1=CC=C(C=C1)NC(CC1=CC=C(C=C1)F)=O KVOHELKOUKIEGM-DEOSSOPVSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- MDWUIKMWKDMPDE-IINAIABHSA-N lysidine zwitterion Chemical compound OC(=O)[C@@H](N)CCCCNC1=NC(=N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MDWUIKMWKDMPDE-IINAIABHSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- JNVLKTZUCGRYNN-LQGIRWEJSA-N methyl 2-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]-2-hydroxyacetate Chemical compound O=C1NC(=O)C(C(O)C(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 JNVLKTZUCGRYNN-LQGIRWEJSA-N 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 239000011022 opal Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229920006108 tRNAGlu Polymers 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical compound OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 description 1
- HOKKHZGPKSLGJE-VKHMYHEASA-N (2s)-2-(methylamino)butanedioic acid Chemical compound CN[C@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-VKHMYHEASA-N 0.000 description 1
- VLSSHNVJWTYJAV-VIFPVBQESA-N (2s)-3-(3-chlorophenyl)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C(O)=O)CC1=CC=CC(Cl)=C1 VLSSHNVJWTYJAV-VIFPVBQESA-N 0.000 description 1
- PVXYVWVFWHBBMH-VIFPVBQESA-N (2s)-3-(4-chlorophenyl)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C(O)=O)CC1=CC=C(Cl)C=C1 PVXYVWVFWHBBMH-VIFPVBQESA-N 0.000 description 1
- QESMMBKGCOSBNL-JTQLQIEISA-N (2s)-3-(4-methoxyphenyl)-2-(methylazaniumyl)propanoate Chemical compound CN[C@H](C(O)=O)CC1=CC=C(OC)C=C1 QESMMBKGCOSBNL-JTQLQIEISA-N 0.000 description 1
- MYUOTPIQBPUQQU-CKTDUXNWSA-N (2s,3r)-2-amino-n-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methylsulfanylpurin-6-yl]carbamoyl]-3-hydroxybutanamide Chemical compound C12=NC(SC)=NC(NC(=O)NC(=O)[C@@H](N)[C@@H](C)O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MYUOTPIQBPUQQU-CKTDUXNWSA-N 0.000 description 1
- XBBQCOKPWNZHFX-TYASJMOZSA-N (3r,4s,5r)-2-[(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl]oxy-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O([C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C=2N=CN=C(C=2N=C1)N)C1O[C@H](CO)[C@@H](O)[C@H]1O XBBQCOKPWNZHFX-TYASJMOZSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- MUCPGEPGWYOKRO-UHFFFAOYSA-N 1,3,2-diazaborinine Chemical compound B1=NC=CC=N1 MUCPGEPGWYOKRO-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 1
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- OVYNGSFVYRPRCG-UHFFFAOYSA-N 2'-O-Methylguanosine Natural products COC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 OVYNGSFVYRPRCG-UHFFFAOYSA-N 0.000 description 1
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- IQZWKGWOBPJWMX-UHFFFAOYSA-N 2-Methyladenosine Natural products C12=NC(C)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O IQZWKGWOBPJWMX-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- IQZWKGWOBPJWMX-IOSLPCCCSA-N 2-methyladenosine Chemical compound C12=NC(C)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O IQZWKGWOBPJWMX-IOSLPCCCSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- YXNIEZJFCGTDKV-JANFQQFMSA-N 3-(3-amino-3-carboxypropyl)uridine Chemical compound O=C1N(CCC(N)C(O)=O)C(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YXNIEZJFCGTDKV-JANFQQFMSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- OCMSXKMNYAHJMU-JXOAFFINSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidine-5-carbaldehyde Chemical compound C1=C(C=O)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OCMSXKMNYAHJMU-JXOAFFINSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 1
- ZXQHKBUIXRFZBV-FDDDBJFASA-N 5-methylaminomethyluridine Chemical compound O=C1NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXQHKBUIXRFZBV-FDDDBJFASA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- PEMQXWCOMFJRLS-UHFFFAOYSA-N Archaeosine Natural products C1=2NC(N)=NC(=O)C=2C(C(=N)N)=CN1C1OC(CO)C(O)C1O PEMQXWCOMFJRLS-UHFFFAOYSA-N 0.000 description 1
- 241000796533 Arna Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 1
- 241000205275 Methanosarcina barkeri Species 0.000 description 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 1
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- SCIFESDRCALIIM-UHFFFAOYSA-N N-Me-Phenylalanine Natural products CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 1
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
- UNUYMBPXEFMLNW-DWVDDHQFSA-N N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine Chemical compound C1=NC=2C(NC(=O)N[C@@H]([C@H](O)C)C(O)=O)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UNUYMBPXEFMLNW-DWVDDHQFSA-N 0.000 description 1
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 1
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 1
- JXNORPPTKDEAIZ-QOCRDCMYSA-N O-4''-alpha-D-mannosylqueuosine Chemical compound NC(N1)=NC(N([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)C=C2CN[C@H]([C@H]3O)C=C[C@@H]3O[C@H]([C@H]([C@H]3O)O)O[C@H](CO)[C@H]3O)=C2C1=O JXNORPPTKDEAIZ-QOCRDCMYSA-N 0.000 description 1
- 241000975417 Oscinella frit Species 0.000 description 1
- 108010026809 Peptide deformylase Proteins 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- MEGPURSNXMUDAE-UHFFFAOYSA-N Scopoline Natural products C1C(O2)CC3N(C)C1C2C3O MEGPURSNXMUDAE-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- ISPNGVKOLBSRNR-DBINCYRJSA-N [(2r,3r,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O([C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C=NC=2C(=O)N=C(NC=21)N)C1O[C@H](CO)[C@@H](O)[C@H]1O ISPNGVKOLBSRNR-DBINCYRJSA-N 0.000 description 1
- XEGNZSAYWSQOTR-TYASJMOZSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O([C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C=2N=CN=C(C=2N=C1)N)C1O[C@H](CO)[C@@H](O)[C@H]1O XEGNZSAYWSQOTR-TYASJMOZSA-N 0.000 description 1
- TVGUROHJABCRTB-MHJQXXNXSA-N [(2r,3s,4r,5s)-5-[(2r,3r,4r,5r)-2-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O([C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C=NC=2C(=O)N=C(NC=21)N)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O TVGUROHJABCRTB-MHJQXXNXSA-N 0.000 description 1
- MVMZFAIUUXYFGY-FYZYNONXSA-N [(5s)-5-carboxy-5-(9h-fluoren-9-ylmethoxycarbonylamino)pentyl]azanium;chloride Chemical compound Cl.C1=CC=C2C(COC(=O)N[C@@H](CCCCN)C(O)=O)C3=CC=CC=C3C2=C1 MVMZFAIUUXYFGY-FYZYNONXSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000006323 alkenyl amino group Chemical group 0.000 description 1
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 description 1
- 125000005193 alkenylcarbonyloxy group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000005136 alkenylsulfinyl group Chemical group 0.000 description 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
- 125000005108 alkenylthio group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005130 alkyl carbonyl thio group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000006319 alkynyl amino group Chemical group 0.000 description 1
- 125000005095 alkynylaminocarbonyl group Chemical group 0.000 description 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
- 125000005088 alkynylcarbonylamino group Chemical group 0.000 description 1
- 125000005198 alkynylcarbonyloxy group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 description 1
- 125000005134 alkynylsulfinyl group Chemical group 0.000 description 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 1
- 125000005109 alkynylthio group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- PEMQXWCOMFJRLS-RPKMEZRRSA-N archaeosine Chemical compound C1=2NC(N)=NC(=O)C=2C(C(=N)N)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O PEMQXWCOMFJRLS-RPKMEZRRSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- GCKQVXGRLKRLHJ-IBGZPJMESA-N benzyl (2s)-6-amino-2-(phenylmethoxycarbonylamino)hexanoate Chemical compound N([C@@H](CCCCN)C(=O)OCC=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 GCKQVXGRLKRLHJ-IBGZPJMESA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 125000000707 boryl group Chemical group B* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- SAXJPWAYAZXZNM-SANMLTNESA-N cyanomethyl (2S)-2-[[4-[[2-(4-fluorophenyl)acetyl]amino]phenyl]methoxycarbonyl-methylamino]-4-phenylbutanoate Chemical compound FC1=CC=C(C=C1)CC(=O)NC1=CC=C(COC(=O)N([C@H](C(=O)OCC#N)CCC2=CC=CC=C2)C)C=C1 SAXJPWAYAZXZNM-SANMLTNESA-N 0.000 description 1
- SFFDITYNQBKGDV-UHFFFAOYSA-N cyanomethyl propanoate Chemical compound CCC(=O)OCC#N SFFDITYNQBKGDV-UHFFFAOYSA-N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 description 1
- 125000005145 cycloalkylaminosulfonyl group Chemical group 0.000 description 1
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 description 1
- 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 description 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006200 ethylation reaction Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 description 1
- 125000005204 heteroarylcarbonyloxy group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000002824 mRNA display Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- HLZXTFWTDIBXDF-UHFFFAOYSA-N mcm5sU Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=S)[nH]c1=O HLZXTFWTDIBXDF-UHFFFAOYSA-N 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- POPACFLNWGUDSR-UHFFFAOYSA-N methoxy(trimethyl)silane Chemical compound CO[Si](C)(C)C POPACFLNWGUDSR-UHFFFAOYSA-N 0.000 description 1
- WCNMEQDMUYVWMJ-UHFFFAOYSA-N methyl 4-[3-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4,6-dimethyl-9-oxoimidazo[1,2-a]purin-7-yl]-3-hydroperoxy-2-(methoxycarbonylamino)butanoate Chemical compound C1=NC=2C(=O)N3C(CC(C(NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O WCNMEQDMUYVWMJ-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- MEGPURSNXMUDAE-RLMOJYMMSA-N scopoline Chemical compound C([C@H](O1)C2)[C@@H]3N(C)[C@H]2[C@H]1[C@H]3O MEGPURSNXMUDAE-RLMOJYMMSA-N 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- RVCNQQGZJWVLIP-VPCXQMTMSA-N uridin-5-yloxyacetic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(OCC(O)=O)=C1 RVCNQQGZJWVLIP-VPCXQMTMSA-N 0.000 description 1
- YIZYCHKPHCPKHZ-UHFFFAOYSA-N uridine-5-acetic acid methyl ester Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=O)[nH]c1=O YIZYCHKPHCPKHZ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Definitions
- the present disclosure relates to a tRNA and a translation system and a method of using the same.
- Display library is a very useful technology that can efficiently acquire molecules that bind to target proteins through evolutionary engineering.
- a display library In order to obtain a molecule showing a high binding ability to an arbitrary target molecule using a display library, or to obtain many kinds of molecules each of which binds to a plurality of epitopes, high diversity is required. Panning from your library is required.
- a reconstituted cell-free translation system such as PURESYSTEM (Non-patent document 1) is capable of adjusting the concentration of constituent components such as amino acids, tRNA, and aminoacyl-tRNA synthetase (ARS), and thus natural The codon-amino acid mapping of can be changed.
- PURESYSTEM Non-patent document 1
- ARS aminoacyl-tRNA synthetase
- Non-Patent Document 2 there is “play” in the pairing of the third letter of the codon and the first letter of the anticodon, and it is called wobble base pair in addition to Watson-Crick base pair. Pairing between G and U is possible. Therefore, the anticodon GNN decodes the codons of NNU and NNC, and the anticodon UNN decodes the codons of NNA and NNG. Therefore, these codons cannot be read and the amino acid that can be introduced into one codon box The type is limited to a maximum of 2 amino acids (Non-Patent Document 2).
- Non-Patent Document 4 isoleucine tRNA- Raishijin synthase; but is introduced by (tRNA Ile -lysidine synthetase TilS) (Non-Patent Document 4), since the tRNA to be its substrate is limited to tRNA Ile2, the other tRNA It is not easy to introduce lysine (Non-Patent Document 5).
- the codons of AUA and AUG are distinguished by the introduction of lysidine at position 34 (the first letter of the anticodon).
- lysidine the codons of NNA and NNG are distinguished by some artificial means.
- the present invention has been made in view of such a situation, and an object of the present disclosure is to provide a new means that enables the codons of NNA and NNG to be distinguished.
- the present inventors ligated the chemically synthesized tRNA fragment and lysidine (also known as 2-lysylcytidine) by an enzymatic reaction to introduce lysidine at the 34th position, and also at the 35th and 36th positions (the anticodon second character and TRNAs having various sequences in the (Letter) were prepared.
- lysidine also known as 2-lysylcytidine
- the present inventors ligated the chemically synthesized tRNA fragment and lysidine (also known as 2-lysylcytidine) by an enzymatic reaction to introduce lysidine at the 34th position, and also at the 35th and 36th positions (the anticodon second character and TRNAs having various sequences in the (Letter) were prepared.
- the translation system containing these tRNAs was reconstituted and amino acids were translated, it was found that the NNA and NNG codons could be distinguished in any translation system.
- the tRNA having the UNN anticodon
- k2C lysidine
- N 1 before modification is cytidine (C), and the modification from cytidine (C) to lysidine (k2C) is performed by lysidine synthase (tRNA Ile- lysidine) having an amino acid sequence of SEQ ID NO: 51. synthetase; TilS) is a mutant tRNA according to [1], which cannot be catalyzed.
- N 1 before modification is cytidine (C)
- the modification from the cytidine (C) to agmatidine (agm2C) is carried out by agmatidine synthase (tRNA Ile -agmatidine) having an amino acid sequence of SEQ ID NO: 52.
- the anticodon is k2CN 2 N 3 or agm2CN 2 N 3 (wherein the first nucleoside of the anticodon is lysidine (k2C) or agmatidine (agm2C), and the second nucleoside (N 2 ) is 3 letters.
- the mutated tRNA according to [4], which is represented by the nucleoside (N 3 ) of the eye is complementary to M 2 and M 1 , respectively.
- [7] The mutant tRNA according to any one of [1] to [6], wherein the tRNA is a starting tRNA or an extended tRNA.
- M 1 and M 2 are selected from the codons that form the codon box in which the codon in which the nucleoside of the third letter is A and the codon in which both are G encode the same amino acid.
- the mutant tRNA according to any one of [4] to [8].
- M 1 and M 2 are selected from the codons that form the codon box in which the codon in which the third letter nucleoside is U and the codon in which both are A encode the same amino acid.
- the codon box in which the nucleoside of the third letter is U, the codon C, the codon A, and the codon G all constitute a codon box encoding the same amino acid.
- M 1 and M 2 are selected from the codons that form the codon box in which the codon in which the third letter nucleoside is A and the codon in which G is different from each other are encoded.
- the mutant tRNA according to any one of [4] to [8].
- M 1 and M 2 are selected from codons that form a codon box in which the codon in which the third letter nucleoside is A and/or the codon in which G is a stop codon, The mutant tRNA according to any one of [4] to [8].
- Natural amino acids include glycine (Gly), alanine (Ala), serine (Ser), threonine (Thr), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phe), tyrosine (Tyr). ), tryptophan (Trp), histidine (His), glutamic acid (Glu), aspartic acid (Asp), glutamine (Gln), asparagine (Asn), cysteine (Cys), methionine (Met), lysine (Lys), arginine ( The mutant tRNA according to [31], which is selected from the group consisting of Arg) and proline (Pro).
- Natural amino acids include glycine (Gly), alanine (Ala), serine (Ser), threonine (Thr), valine (Val), leucine (Leu), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp). ), histidine (His), glutamic acid (Glu), aspartic acid (Asp), glutamine (Gln), asparagine (Asn), cysteine (Cys), lysine (Lys), arginine (Arg), proline (Pro).
- the mutant tRNA according to [32], which is further selected.
- [34] A translation system containing a plurality of different types of tRNA, which comprises the mutant tRNA according to any one of [1] to [33].
- mutation tRNA compared to the codons different from the codon represented by M 1 M 2 A, it is possible to selectively translate codons represented by M 1 M 2 A, and M 1
- the translation system according to [34], wherein the codon represented by M 2 A can be selectively translated by the mutant tRNA as compared with a tRNA different from the mutant tRNA.
- [36] (a) containing the mutant tRNA according to any one of [1] to [33], and (b) a tRNA having an anticodon complementary to the codon represented by M 1 M 2 G, [34] Alternatively, the translation system according to [35].
- [37] [36] anticodon of the tRNA according to (b) is CN 2 N 3, ac4CN 2 N 3 or CmN 2 N 3 (where,, AC4C is N4- acetyl cytidine, Cm is 2'-O- methyl (Representing cytidine), the translation system according to [36].
- the translation system according to [36] or [37], which can be translated into [39] The translation system according to any one of [36] to [38], wherein the amino acids or amino acid analogs bound to the tRNAs according to [36](a) and [36](b) are different from each other.
- the anticodon of the tRNA described in (c) is AN 2 N 3 , GN 2 N 3 , QN 2 N 3 , and GluQN 2 N 3 (where Q is queuosine and GluQ is glutamyl cue).
- the translation system according to [42] which is selected from the group consisting of oscine (representing glutamyl-queuosine).
- the tRNA according to [42] (c) has M 1 M 2 U or M 1 M 2 C
- a tRNA capable of selectively translating the codon represented by and the codon represented by M 1 M 2 U or M 1 M 2 C is different from the tRNA described in [42](c).
- the three types of amino acids are translatable from a codon box constituted by M 1 M 2 U, M 1 M 2 C, M 1 M 2 A, and M 1 M 2 G, [45] Translation system.
- the translation system as described in any one of.
- a method for producing a peptide which comprises translating a nucleic acid using the translation system according to any of [34] to [52].
- a method for producing a peptide library which comprises translating a nucleic acid library using the translation system according to any of [34] to [52].
- a method for identifying a peptide having a binding activity to a target molecule which comprises contacting the target molecule with the peptide library according to [57].
- a nucleic acid-peptide complex comprising a peptide and a nucleic acid encoding the peptide, wherein the nucleic acid encoding the peptide contains the three types of codons described in (A) or (B) below.
- A M 1 M 2 U, M 1 M 2 A, and M 1 M 2 G; (B) M 1 M 2 C, M 1 M 2 A, and M 1 M 2 G, The nucleic acid-peptide complex, wherein the types of amino acids corresponding to the three types of codons are different on the peptide.
- a method for producing a mutant tRNA having lysidine at position 34 of the tRNA numbering rule which comprises a step of ligating the compound according to [61] and a nucleic acid fragment constituting tRNA by an enzymatic reaction.
- a mutation having lysidine at position 34 of the tRNA numbering rule which comprises a step of ligating the compound according to [61], one or more nucleic acid fragments constituting tRNA, and an amino acid or an amino acid analog by an enzymatic reaction.
- a method for producing a mutant tRNA having agmatidine at position 34 of the tRNA numbering rule which comprises a step of ligating the compound according to [64] and a nucleic acid fragment constituting tRNA by an enzymatic reaction.
- a mutation having agmatidine at position 34 of the tRNA numbering rule which comprises a step of ligating the compound according to [64], one or more nucleic acid fragments constituting tRNA, and an amino acid or an amino acid analog by an enzymatic reaction.
- [69] A mutant tRNA produced by the method according to [63], [66], or [67], in which an amino acid or an amino acid analog is bound to the 3'end.
- [70] A translation system containing the mutant tRNA according to [68] and/or [69].
- [71] A method for producing a peptide, which comprises translating a nucleic acid using the translation system according to [70].
- R 1 and R 2 are each independently H or C 1 -C 3 alkyl
- L is C 2 -C 6 straight chain alkylene or C 2 -C 6 straight chain alkenylene optionally substituted by one or more substituents selected from the group consisting of hydroxy and C 1 -C 3 alkyl
- the carbon atom of the C 2 -C 6 linear alkylene may be substituted by one oxygen atom or sulfur atom
- M is a single bond
- the wavy line indicates the point of attachment to the carbon atom
- * indicates the point of attachment to the hydrogen atom
- ** indicates the point of attachment to the nitrogen atom, provided that when M is a single bond, it is attached to M.
- a step of obtaining a compound represented by Acetonide is removed from the compound represented by the formula F1A or F1B, and PG 14 and PG 15 are introduced to give a compound represented by the following formula G1A or G1B:
- R 2 is C 1 -C 3 alkyl
- PG 14 is a hydroxyl-protecting group
- PG 15 is a hydroxyl-protecting group
- R 1 , L, M, PG 11 , PG 12 , and PG 13 are the same as above.
- a step of obtaining a compound represented by The compound of formula I1A or I1B is phosphite esterified and then oxidized to give the following formula J1A or J1B:
- R 2 is C 1 -C 3 alkyl
- PG 17 is a hydroxyl-protecting group
- R 1 , L, M, PG 11 , PG 12 , PG 13 , and PG 16 are the same as above.
- a step of obtaining a compound represented by PG 11 , PG 12, PG 13 and PG 17 are removed from the compound represented by the formula J1A, or PG 11 , PG 13 and PG 17 are removed from the compound represented by the formula J1B, K1: (In the formula, R 2 is H or C 1 -C 3 alkyl, R 1 , R 2 , L, M, and PG 16 are the same as above. ) And a step of removing PG 16 from the compound of formula K1 to obtain a compound of formula A.
- the compound represented by the formula A is lysidine diphosphate: Or Agmatidine diphosphate: The method of [72].
- L is —(CH 2 ) 3 —, —(CH 2 ) 4 —, —(CH 2 ) 5 , —(CH 2 ) 2 —O—CH 2 —, —(CH 2 ) 2 —S—
- CH 2 —, —CH 2 CH(OH)(CH 2 ) 2 —, or —CH 2 CH ⁇ CH— (cis or trans).
- R 1 and R 2 are each independently H or C 1 -C 3 alkyl
- L is C 2 -C 6 straight chain alkylene or C 2 -C 6 straight chain alkenylene optionally substituted by one or more substituents selected from the group consisting of hydroxy and C 1 -C 3 alkyl
- the carbon atom of the C 2 -C 6 linear alkylene may be substituted by one oxygen atom or sulfur atom
- M is a single bond
- the wavy line indicates the point of attachment to the carbon atom
- * indicates the point of attachment to the hydrogen atom
- ** indicates the point of attachment to the nitrogen atom, provided that when M is a single bond, it is attached to M.
- a step of obtaining a compound represented by Acetonide is removed from the compound represented by the formula E2A or E2B, and PG 24 and PG 25 are introduced to give a compound represented by the following formula F2A or F2B:
- R 2 is C 1 -C 3 alkyl
- PG 24 is a hydroxyl-protecting group
- PG 25 is a hydroxyl-protecting group
- PG 21 , PG 22 and PG 23 are the same as above.
- the compound of formula H2A or H2B is phosphite esterified and then oxidized to give a compound of formula I2A or I2B:
- R 2 is C 1 -C 3 alkyl
- PG 27 is a hydroxyl-protecting group
- R 1 , L, M PG 21 , PG 22 , PG 23 , and PG 26 are the same as above.
- a step of obtaining a compound represented by PG 21 , PG 22 , PG 23 , and PG 27 are removed from the compound represented by the formula I2A, or PG 21 , PG 23 , and PG 27 are removed from the compound represented by the formula I2B.
- PG 24 and PG 25 together form di-tert-butylsilyl, and the reagent used to introduce di-tert-butylsilyl is bis(trifluoromethanesulfonic acid)di-tert-butylsilyl.
- the method described. [108] The method according to [96], wherein PG 26 is tetrahydropyranyl, and the reagent used for introducing PG 26 is TFA and 3,4-dihydro-2H-pyran.
- the reagent used for removing PG 24 and PG 25 is tetrabutylammonium fluoride.
- FIG. 1 is a diagram showing a mass chromatogram of tRNA(Glu)uga-CA(UR-1) prepared by utilizing a ligation reaction as described in Example 10 and fragmented with RNase. ..
- the upper row shows the result of the fragment having the CCCUGp sequence, and the lower row shows the result of the fragment having the CCCUGp sequence.
- FIG. 2 is a diagram showing a mass chromatogram of tRNA(Glu)Lga-CA(LR-1) prepared by utilizing a ligation reaction as described in Example 10 and fragmented with RNase. ..
- FIG. 3 is a diagram showing a mass chromatogram of tRNA(Glu)Lag-CA(LR-2) prepared by utilizing a ligation reaction as described in Example 10 and fragmented with RNase. ..
- the upper row shows the result of the fragment having the sequence of CCCULAGp
- the middle row shows the result of the fragment having the sequence of CCCUAGp
- the lower row shows the result of the fragment having the sequence of CCCUUAGp.
- FIG. 4 is a diagram showing a mass chromatogram of tRNA(Glu)Lac-CA(LR-3) prepared by utilizing a ligation reaction as described in Example 10 and fragmented with RNase. ..
- the upper row shows the result of the fragment having the sequence of CCCULACACGp (SEQ ID NO: 197), the middle row shows the result of the fragment having the sequence of CCCUACACGp, and the lower row shows the result of the fragment having the sequence of CCCUUACACGp (SEQ ID NO: 198).
- FIG. 5 is a diagram showing a mass chromatogram of tRNA(Glu)Lcc-CA(LR-4) prepared by utilizing a ligation reaction as described in Example 10 and fragmented with RNase. ..
- FIG. 6 is a diagram showing a mass chromatogram of tRNA(Asp)Lag-CA(LR-5) prepared by utilizing a ligation reaction as described in Example 10.
- FIG. 7 is a diagram showing a mass chromatogram of tRNA(AsnE2)Lag-CA(LR-6) prepared by utilizing a ligation reaction as described in Example 10 and fragmented with RNase. ..
- the upper row shows the result of the fragment having the sequence of AOULAGP
- the middle row shows the result of the fragment having the sequence of AOUAGp
- the lower row shows the result of the fragment having the sequence of AOUUAGp.
- FIG. 8 is a diagram showing a mass chromatogram of tRNA(Glu)Lcg-CA(LR-7) prepared by utilizing a ligation reaction as described in Example 10 and fragmented with RNase. ..
- FIG. 9 is a diagram showing a mass chromatogram of tRNA(Glu)Lau-CA(LR-8) prepared by utilizing a ligation reaction as described in Example 10 and fragmented with RNase. ..
- FIG. 10 shows a mass chromatogram of tRNA(Glu)(Agm)ag-CA(AR-1) fragmented with RNase prepared using the ligation reaction as described in Example 10. It is a figure.
- FIG. 11 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box depending on the presence or absence of Lysidine modification, as described in Examples 12 to 13.
- the codons evaluated are UCU, UCA, UCG.
- the vertical axis of the graph shows the translation amount of the peptide obtained when translation was performed using each combination of the tRNA and mRNA described below (see Table 12 for specific measurement values).
- tRNA Compound AAtR-1 (anticodon: aga, amino: dA) Compound AAtR-2 (anticodon: uga, amino: SPh2Cl) Compound AAtR-5 (anticodon: cga, amino: nBuG) mRNA: mR-1 (including codons UCU) (including codon UCA) mR-2 mR-3 (including the codons for UCG) (in the drawing) tRNA: compound AAtR-1 (anticodon: aga, amino: dA) compound AAtR-3 (Anticodon: uga, Amino acid: SPh2Cl) Compound AAtR-5 (Anticodon: cga, Amino acid: nBuG) mRNA: mR-1 (including UCU codon) R (including UCA codon) mR-2 (including UCA codon) comprising codons) ( Figure right) tRNA: compound AAtR-1 (anticodon: aga
- FIG. 12 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box depending on the presence or absence of Lysidine modification, as described in Examples 12 to 13.
- the codons evaluated are CUU, CUA, CUG.
- the translation amount of the peptide obtained when translation is performed with each combination of tRNA and mRNA described below is shown on the vertical axis of the graph (see Table 13 for specific measurement values).
- FIG. 13 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box depending on the presence or absence of Lysidine modification, as described in Examples 12 to 13.
- the codons evaluated are GUU, GUA, GUG.
- the vertical axis of the graph shows the translation amount of the peptide obtained when translation was performed using each combination of tRNA and mRNA described below (see Table 14 for specific measurement values).
- tRNA Compound AAtR-10 (anticodon: aac, amino: nBuG) Compound AAtR-11 (anticodon: uac, amino: Pic2) Compound AAtR-13 (anticodon: cac, amino: dA) mRNA: mR-7 (including codons GUU) (including codons GUA) mR-8 mR-9 (including codon GUG)
- Figure right tRNA: compound AAtR-10 (anticodon: aac, amino: nBuG) compound AAtR-12 (Anticodon: Lac, Amino Acid: Pic2) Compound AAtR-13 (Anticodon: cac, Amino Acid: dA) mRNA: mR-7 (including GUU Codon) UG: mR-8 (including GUA Codon) (Including codon)
- FIG. 14 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box depending on the presence or absence of Lysidine modification, as described in Examples 12 to 13.
- the codons evaluated are GGU, GGA, GGG.
- the translation amount of the peptide obtained when the translation is performed with each combination of tRNA and mRNA described below is shown on the vertical axis of the graph (see Table 15 for specific measurement values).
- FIG. 15 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box depending on the presence or absence of Lysidine modification, as described in Examples 12 to 13.
- the codons evaluated are CUU, CUA, CUG.
- the translation amount of the peptide obtained when translation is performed with each combination of tRNA and mRNA described below is shown on the vertical axis of the graph (see Table 16 for specific measurement values).
- 16 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box depending on the presence or absence of Lysidine modification, as described in Examples 12 to 13.
- the codons evaluated are CUU, CUA, CUG.
- the translation amount of the peptide obtained when the translation is performed with each combination of tRNA and mRNA described below is shown on the vertical axis of the graph (see Table 17 for specific measurement values).
- 17 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box depending on the presence or absence of Lysidine modification, as described in Examples 12 to 13.
- the codons evaluated are CUU, CUA, CUG.
- the vertical axis of the graph shows the translation amount of the peptide obtained when the translation was performed using each combination of tRNA and mRNA described below (see Table 18 for specific measured values).
- FIG. 18 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box depending on the presence or absence of Lysidine modification, as described in Examples 12 to 13.
- the codons evaluated are CUU, CUA, CUG.
- the vertical axis of the graph shows the translation amount of the peptide obtained when translation was performed using each combination of tRNA and mRNA described below (see Table 19 for specific measurement values).
- tRNA compound AAtR-6 (anticodon: aag, amino acid: nBuG) compound AAtR-29 (anticodon: uag, amino acid: F3Cl): amino acid: F3Cl: anti-codon: aag: amino acid: F3Cl: anti-codon: ag: amino acid: F3Cl: anti-codon: ag: amino acid: F3Cl: anti-codon: ag: amino acid: F3Cl: anti-codon: aag: amino acid: F3Cl: anti-codon: aag: amino acid: F3Cl: anti-codon: aag: amino acid: F3Cl: anti-codon: aag: amino acid: F3Cl: anti-codon: aag: amino acid: F3Cl: anti-codon: aag: amino acid: F3Cl: anti-codon: aag: amino acid: F3C
- FIG. 19 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box depending on the presence or absence of Lysidine modification, as described in Examples 12 to 13.
- the codons evaluated are CUU, CUA, CUG.
- the translation amount of the peptide obtained when translation is performed with each combination of tRNA and mRNA described below is shown on the vertical axis of the graph (see Table 20 for specific measurement values).
- FIG. 20 is a diagram showing the results of translation evaluation of three amino acid readings in one codon box by Lysidine modification as described in Examples 12 to 13.
- the codons evaluated are CGU, CGA, CGG.
- the vertical axis of the graph shows the translation amount of the peptide obtained when translation was performed using each combination of tRNA and mRNA described below (see Table 21 for specific measurement values).
- FIG. 21 is a diagram showing the results of translation evaluation of 3 amino acid readings in one codon box by Lysidine modification as described in Examples 12 to 13. The codons evaluated are AUU, AUA, AUG.
- the vertical axis of the graph shows the translation amount of the peptide obtained when translation was performed using each combination of tRNA and mRNA described below (see Table 22 for specific measurement values).
- tRNA Compound AAtR-36 (anticodon: aau, amino acid: nBuG)
- Compound AAtR-37 (anticodon: Lau, amino acid: Pic2)
- Compound AAtR-38 (anticodon: cau, amino acid: dA) mRNA: mRNA-16 (AUU codon) )), mR-17 (including the AUA codon), mR-18 (including the AUG codon)
- FIG. 22 is a diagram showing the results of translational evaluation of three amino acid readings in one codon box depending on the presence or absence of Agmatidine modification, as described in Examples 12 to 13.
- the codons evaluated are CUU, CUA, CUG.
- the vertical axis of the graph shows the translation amount of the peptide obtained when translation was performed using each combination of tRNA and mRNA described below (see Table 23 for specific measurement values).
- tRNA Compound AAtR-6 (anticodon: aag, amino: nBuG) Compound AAtR-39 (anticodon: uag, amino: SPh2Cl) Compound AAtR-9 (anticodon: cag, amino: dA) mRNA: mR-4 (including codon CUU) (including codons CUA) mR-5 mR-6 (including codon CUG)
- Figure right tRNA compound AAtR-6 (anticodon: aag, amino: nBuG) compound AAtR-40 (Anticodon: (Agm)ag, amino acid: SPh2Cl) compound AAtR-9 (anticodon: cag, amino acid: dA) mRNA: mR-4 (including CUU codon) mR-5 (including CUA codon) mR-5 (CUA codon) (Including CUG codon)
- Codon is a combination (triplet) of three nucleosides corresponding to each amino acid when the in vivo genetic information is translated into a protein.
- DNA four types of bases are used: adenine (A), guanine (G), cytosine (C), and thymine (T), and in the case of mRNA, adenine (A), guanine (G), cytosine Four types of bases (C) and uracil (U) are used.
- the table showing the correspondence between each codon and amino acid is called the genetic code table or codon table, and 20 kinds of amino acids are assigned to 61 kinds of codons excluding the stop codon (Table 1).
- the genetic code table shown in Table 1 is commonly used in almost all organisms in eukaryotes and prokaryotes (eubacteria and archaea), and is therefore called a standard genetic code table or a universal genetic code table. ..
- a genetic code table used in a naturally-occurring organism is referred to as a natural genetic code table, and an artificially reprogrammed genetic code table (the correspondence between codons and amino acids is modified) is used. Distinguish.
- four codons that are common to the first and second letters but differ only in the third letter are usually grouped into one box, which is called a codon box.
- a codon in mRNA may be represented by “M 1 M 2 M 3 ”.
- M 1 , M 2 , and M 3 represent the first letter, second letter, and third letter nucleoside of the codon, respectively.
- Anticodon is three consecutive nucleosides on tRNA that correspond to codons on mRNA. Similar to mRNA, four types of bases, adenine (A), guanine (G), cytosine (C), and uracil (U), are used as the anticodon. Furthermore, modified bases obtained by modifying them may be used. When the codon is specifically recognized by the anticodon, the genetic information on the mRNA is read and translated into a protein.
- the 5'to 3'codon sequence on the mRNA and the 5'to 3'anticodon sequence on the tRNA bind complementarily, so the first, second, and third nucleosides of the codon , Complementary nucleotide pairs are formed between the 3rd, 2nd, and 1st nucleosides of the anticodon.
- the anticodon in tRNA may be represented by “N 1 N 2 N 3 ”.
- N 1 , N 2 , and N 3 represent the first letter, second letter, and third letter nucleoside of the anticodon, respectively.
- N 1 , N 2 , and N 3 are numbered at positions 34, 35, and 36 of tRNA, respectively.
- a combination of nucleic acids capable of forming thermodynamically stable base pairs is said to be “complementary” to each other.
- Watson-Crick base pairs such as adenosine and uridine (AU), guanosine and cytidine (GC), guanosine and uridine (GU), inosine and uridine (IU), inosine and adenosine (IA), inosine and cytidine (IC)
- AU adenosine and uridine
- GC guanosine and uridine
- GUI guanosine and uridine
- IA inosine and adenosine
- IC inosine and cytidine
- nucleic acid combinations that form non-Watson-Crick base pairs such as).
- “Messenger RNA (mRNA)” is RNA that has genetic information that can be translated into protein. Genetic information is coded on mRNA as codons, and they correspond to all 20 kinds of amino acids. Protein translation begins at the start codon and ends at the stop codon. In principle, the start codon in eukaryotes is AUG, but in prokaryotes (eubacteria and archaea), GUG and UUG may also be used as start codons in addition to AUG. AUG is a codon that encodes methionine (Met), and in eukaryotes and archaea, translation is initiated directly from methionine.
- Method methionine
- initiation codon AUG corresponds to N-formylmethionine (fMet), so that translation is initiated from formylmethionine.
- fMet N-formylmethionine
- stop codons There are three types of stop codons: UAA (ochre), UAG (amber), and UGA (opal).
- RF translation termination factor
- Transfer RNA is a short RNA of 100 bases or less that mediates peptide synthesis using mRNA as a template. In terms of secondary structure, it has a cloverleaf-like structure consisting of three stem loops (D arm, anticodon arm, T arm) and one stem (acceptor stem). Depending on the tRNA, an additional variable loop may be included.
- the anticodon arm has a region consisting of three consecutive nucleosides called an anticodon, and the codon is recognized by forming a base pair with the codon on the mRNA.
- a nucleic acid sequence composed of cytidine-cytidine-adenosine exists at the 3'end of tRNA, and an amino acid is added to the adenosine residue at the end (specifically, ribose of adenosine residue).
- a tRNA with an amino acid added is called an aminoacyl tRNA.
- aminoacyl tRNA is also included in the definition of tRNA.
- a method is known in which the terminal two residues (C and A) are removed from the CCA sequence of tRNA and the resulting residue is used for the synthesis of aminoacyl-tRNA.
- Such a tRNA from which the CA sequence at the 3'end has been removed is also included in the definition of tRNA in the present disclosure.
- addition of amino acids to tRNA is performed by an enzyme called aminoacyl-tRNA synthetase (aaRS or ARS).
- aaRS aminoacyl-tRNA synthetase
- aaRS aminoacyl-tRNA synthetase
- there is one aminoacyl-tRNA synthetase for each amino acid and each aminoacyl-tRNA synthetase specifically recognizes only a specific tRNA as a substrate from multiple tRNAs. The correspondence with and is strictly controlled.
- Each nucleoside in tRNA is numbered according to the tRNA numbering rule (SRocl et al., Nucleic AcidsRes (1998) 26: 148-153). For example, anticodons are numbered 34-36 and CCA sequences are numbered 74-76.
- “Initiator tRNA (initiator tRNA)” is a specific tRNA used at the start of translation of mRNA.
- the initiation tRNA bound to the initiation amino acid is catalyzed by a translation initiation factor (IF), introduced into the ribosome, and binds to the initiation codon on the mRNA to initiate translation.
- IF translation initiation factor
- AUG which is a methionine codon
- the start tRNA has an anticodon corresponding to AUG.
- tRNA fMet SEQ ID NO: 10, 11
- Extended tRNA is tRNA used in the elongation reaction of the peptide chain in the translation process.
- the elongation tRNA bound with amino acids is sequentially transported to the ribosome by the GTP-translated elongation factor (EF) EF-Tu/eEF-1, which promotes the elongation reaction of the peptide chain.
- EF GTP-translated elongation factor
- Examples of the extended tRNA include tRNAs corresponding to various amino acids (SEQ ID NOs: 1 to 9 and 12 to 50).
- Lysidine is a type of modified nucleoside and is also described as 2-lysylcytidine (k2C or L). Lysidine is used as the first nucleoside of the anticodon in tRNA (tRNA Ile2) corresponding to isoleucine in eubacteria. After being synthesized in the precursor state with the anticodon of CAU, tRNAIle2 is treated with an enzyme called tRNAIle-lysidine synthetase (TilS), and the cytidine (the first letter of the anticodon is C) is modified (converted) into lysidine (k2C).
- tRNAIle2 an enzyme called tRNAIle-lysidine synthetase
- Agmatidine is a type of modified nucleoside and is also described as 2-agmatinylcytidine (2-agmatinylcytidine; agm2C or Agm).
- Agmatidine is used as the first nucleoside of the anticodon in tRNA (tRNA Ile2) corresponding to isoleucine in archaea.
- tRNAIle2 is synthesized by the enzyme called tRNAIle-agmatidine synthetase (TiaS).
- TiaS tRNAIle-agmatidine synthetase
- C) is modified (converted) to agmatidine (agm2C).
- tRNAIle2 with the anticodon of agm2CAU is completed (Ikeuchi et al., Nat Chem ChemBiol (2010)6(4):277-282).
- the anticodon of agm2CAU is known to specifically recognize only the codon AUA of isoleucine.
- isoleucyl-tRNA synthetase recognizes tRNAIle2 as a substrate and aminoacylation (addition of isoleucine) of tRNAIle2 occurs only when the anticodon is modified to agm2CAU.
- the amino acid sequence of TiaS of the archaebacterium Methanosarcina acetivorans is shown in SEQ ID NO: 52.
- alkyl is a monovalent group derived from an aliphatic hydrocarbon by removing one arbitrary hydrogen atom, and does not contain a hetero atom or an unsaturated carbon-carbon bond in the skeleton. , Having a subset of hydrocarbyl or hydrocarbon-based structures containing hydrogen and carbon atoms.
- the carbon chain length n is in the range of 1 to 20, and examples of the alkyl include C 2 -C 10 alkyl, C 1 -C 6 alkyl, C 1 -C 3 alkyl, and the like.
- cycloalkyl means a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, and includes a monocycle, a bicyclo ring and a spiro ring.
- Examples of cycloalkyl include C 3 -C 10 cycloalkyl, and specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl and the like. ..
- alkenyl is a monovalent group having at least one double bond (two adjacent SP2 carbon atoms). Depending on the arrangement of double bonds and substituents (if present), the double bond geometry can assume the Mais (E) or sixteen (Z), cis or trans configurations. Examples of the straight chain or branched chain alkenyl include a straight chain containing an internal olefin and the like.
- alkenyl examples include C 2 -C 10 alkenyl, C 2 -C 6 alkenyl and the like, and specifically, vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl (cis, (Including trans), 3-butenyl, pentenyl, hexenyl and the like.
- alkynyl is a monovalent group having at least one triple bond (two adjacent SP carbon atoms). Included are straight or branched chain alkynyls, including internal alkylenes. Examples of the alkynyl include C 2 -C 10 alkynyl, C 2 -C 6 alkynyl and the like, and specifically, ethynyl, 1-propynyl, propargyl, 3-butynyl, pentynyl, hexynyl, 3-phenyl-2- Propinyl, 3-(2'-fluorophenyl)-2-propynyl, 2-hydroxy-2-propynyl, 3-(3-fluorophenyl)-2-propynyl, 3-methyl-(5-phenyl)-4-pentynyl And so on.
- aryl means a monovalent aromatic hydrocarbon ring.
- examples of the aryl include C 6 -C 10 aryl, and specific examples thereof include phenyl and naphthyl (eg, 1-naphthyl, 2-naphthyl).
- heteroaryl means a monovalent group of an aromatic ring containing a hetero atom in the atoms constituting the ring, and may be partially saturated.
- the ring may be monocyclic or two fused rings (eg, bicyclic heteroaryl fused with benzene or monocyclic heteroaryl).
- the number of atoms constituting the ring is, for example, 5-10 (5-10 membered heteroaryl).
- the number of heteroatoms contained in the ring-constituting atoms is, for example, 1-5.
- heteroaryl specifically, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl.
- arylalkyl is a group containing both aryl and alkyl, and means, for example, a group in which at least one hydrogen atom of the alkyl is substituted with aryl.
- the aralkyl includes, for example, C 5 -C 10 aryl C 1 -C 6 alkyl", specifically, benzyl and the like.
- alkylene means a divalent group derived by removing one arbitrary hydrogen atom from the above “alkyl”, and may be linear or branched.
- straight chain alkylene include C 2 -C 6 straight chain alkylene, C 4 -C 5 straight chain alkylene and the like. Specifically, —CH 2 —, —(CH 2 ) 2 —, —(CH 2 ) 3 -, -(CH 2 ) 4 -, -(CH 2 ) 5 -, -(CH 2 ) 6- and the like.
- branched alkylene include C 2 -C 6 branched alkylene, C 4 -C 5 branched alkylene and the like.
- alkenylene means a divalent group derived by removing one arbitrary hydrogen atom from the above “alkenyl”, and may be linear or branched. Depending on the arrangement of double bonds and substituents (if present),
- E) or Z cis or trans configurations can be adopted.
- straight chain alkenylene include C 2 -C 6 straight chain alkenylene, C 4 -C 5 straight chain alkenylene, and the like.
- arylene means a divalent group derived by removing one arbitrary hydrogen atom from the aryl.
- the ring may be a single ring or a condensed ring.
- the number of atoms constituting the ring is not particularly limited, but is, for example, 6-10 (C 6 -C 10 arylene).
- Specific examples of arylene include phenylene and naphthylene.
- heteroarylene means a divalent group derived by removing one arbitrary hydrogen atom from the above heteroaryl.
- the ring may be a single ring or a condensed ring.
- the number of atoms constituting the ring is not particularly limited, but is, for example, 5-10 (5-membered to 10-membered heteroarylene).
- heteroarylene specifically, pyrrolediyl, imidazoldiyl, pyrazolediyl, pyridinediyl, pyridazinediyl, pyrimidinediyl, pyrazinediyl, triazolediyl, triazinediyl, isoxazolediyl, oxazolediyl, oxadiazolediyl, isothiazolediyl. , Thiazoldiyl, thiadiazolediyl, furandil, thiophenediyl and the like.
- Translation system in the present disclosure is defined as a concept including both a method for translating a peptide and a kit for translating a peptide.
- the translation system usually contains ribosome, translation factor, tRNA, amino acid, aminoacyl-tRNA synthetase (aaRS), and factors necessary for translation reaction of peptides such as ATP and GTP as constituent components.
- the main types of translation systems include translation systems that utilize living cells and translation systems that utilize cell extracts (cell-free translation systems).
- a translation system utilizing living cells for example, a system in which a desired aminoacyl-tRNA and mRNA are introduced into living cells such as Xenopus oocytes and mammalian cells by microinjection method or lipofection method to perform peptide translation is available.
- living cells such as Xenopus oocytes and mammalian cells by microinjection method or lipofection method to perform peptide translation.
- cell-free translation systems include E. coli (Chen et al., Methods Enzymol (1983) 101: 674-690), yeast (Gasior et al., J Biol Chem(1979) 254: 3965-3969), wheat germ.
- the cell-free translation system also includes a translation system (reconstituted cell-free translation system) constructed by isolating and purifying factors required for peptide translation and reconstructing them (Shimizu et al .,Nat Biotech (2001) 19:751-755).
- Reconstituted cell-free translation systems usually include ribosomes, amino acids, tRNAs, aminoacyl-tRNA synthetases (aaRS), translation initiation factors (eg IF1, IF2, IF3), translation elongation factors (eg EF-Tu, EF).
- RNA polymerase and the like may be further included.
- Various factors contained in the cell-free translation system can be isolated and purified by methods well known to those skilled in the art, and a reconstituted cell-free translation system can be appropriately constructed using them.
- a commercially available reconstituted cell-free translation system such as PUREfrex (registered trademark) from Gene Frontier or PURExpress (registered trademark) from New England BioLabs can be used.
- PUREfrex registered trademark
- PURExpress registered trademark
- New England BioLabs a commercially available reconstituted cell-free translation system
- a desired translation system can be constructed by reconstituting only necessary components among the components of the translation system.
- Aminoacyl-tRNA is synthesized by a specific combination of amino acid/tRNA/aminoacyl-tRNA synthetase, which is used for peptide translation. Instead of the above combination, aminoacyl-tRNA can be used as it is as a component of the translation system. In particular, when an amino acid that is difficult to aminoacylate with an aminoacyl-tRNA synthetase, such as an unnatural amino acid, is used for translation, it is desirable to use a tRNA previously aminoacylated with an unnatural amino acid as a constituent.
- the translation is started by adding mRNA to the translation system.
- An mRNA usually contains a sequence that encodes the peptide of interest, and further includes a sequence for increasing the efficiency of translation reaction (for example, a Shine-Dalgarno ( SD) sequence in prokaryotes, a true sequence). (For example, Kozac sequence in nuclear organisms) may be included.
- Pre-transcribed mRNA may be added directly to the system, or instead of mRNA, template DNA containing a promoter and an appropriate RNA polymerase (for example, T7 promoter and T7 RNA polymerase) can be added to the system to It may be transcribed from the template DNA.
- the present disclosure provides a modified tRNA.
- the present invention provides a mutant tRNA produced by modifying a tRNA.
- the modified tRNA may be a natural tRNA derived from any organism (for example, Escherichia coli), or may be a non-natural tRNA obtained by artificially synthesizing a sequence different from the natural tRNA. Alternatively, it may be a tRNA obtained by artificially synthesizing the same sequence as the natural tRNA.
- any modification introduced into tRNA is an artificial modification, and any mutant tRNA produced by the modification has a nucleic acid sequence that does not exist in nature.
- modification of tRNA in the present disclosure means introducing at least one kind of modification selected from the following group into one or more nucleosides constituting tRNA: ( i) addition (adding any new nucleoside to existing tRNA), (ii) deletion (deleting any nucleoside from existing tRNA), (iii) substitution (adding any nucleoside in existing tRNA) (Substitution with another arbitrary nucleoside), (iv) insertion (adding a new arbitrary nucleoside between any two nucleosides in existing tRNA), (v) modification (any nucleoside in existing tRNA) Part of the structure of (such as changing the base or sugar) to another structure).
- Modifications may be made to any structure of tRNA (eg, D arm, anticodon arm, T arm, acceptor stem, variable loop, etc.).
- tRNA modifications in this disclosure are made to anticodons contained in anticodon arms.
- tRNA modifications in the present disclosure are made to at least one of the first letter, second letter, and third letter nucleoside of the anticodon. According to the nucleoside numbering rule in tRNA, the first, second, and third nucleosides of the anticodon correspond to positions 34, 35, and 36 of tRNA, respectively.
- the first letter, second letter, and third letter nucleoside of the anticodon may be represented as N 1 , N 2 , and N 3 , respectively.
- tRNA modifications in this disclosure include modifications made to the first letter nucleoside of the anticodon.
- the number of nucleosides modified in the tRNA of the present disclosure can be any number greater than or equal to 1. In some embodiments, the number of nucleosides modified in the tRNA of the present disclosure is 20 or less, 15 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 Less than or equal to 1.
- the nucleic acid sequence of the modified tRNA is 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, as compared to the nucleic acid sequence before modification. , 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more.
- modification of tRNA in the present disclosure means substitution of one or more nucleosides constituting tRNA.
- the nucleoside after substitution may be any nucleoside present in the natural tRNA, or any nucleoside not present in the natural tRNA (artificially synthesized nucleoside). It may be.
- natural tRNA contains a modified product (modified nucleoside) obtained by modifying them.
- the nucleoside present in the natural tRNA can be selected from among the following nucleosides: adenosine (adenosine; A), cytidine ( C), guanosine (guanosine; G), uridine (uridine; U), 1-methyladenosine ( m1A), 2-methyladenosine (2-methyladenisine; m2A), N6-isopentenyladenosine (N6-isopentenyladenosine; i6A), 2-methylthio-N6-isopentenyladenosine ( 2-methylthio-N6-isopentenyladenosine; ms2i6A), N6-methyladenosine (N6-methyladenosine; m6A), N6-threonylcarbamoyladenosine ( t6A), N6-methyl-N6-threonylcarbamoyladenosine (N6- methyl)
- one or more nucleosides that make up the tRNA of the disclosure are replaced with lysidine or agmatidine.
- a nucleoside derivative obtained by modifying a part (for example, a base part) of the structure of the nucleoside existing in the above-mentioned natural tRNA can also be used for substitution.
- one or more nucleosides that make up the tRNA of the present disclosure are replaced with a lysidine or agmatidine derivative.
- the tRNA modified in the present disclosure can be appropriately selected from tRNAs having an arbitrary nucleic acid sequence.
- the tRNA is tRNAAla, tRNAArg, tRNAAsn, tRNAAsp, tRNACys, tRNAGlin, tRNAGlu, tRNA Gly, tRNA His, tRNAIle, tRNA Leu, tRNA Lys, tRNAMet, tRNA Phe, One of tRNAPro, tRNASer, tRNAThr, tRNATrp, tRNATyr, and tRNAVal.
- tRNA In addition to the above 20 types of tRNA, tRNA fMet, tRNA Sec (selenocysteine), tRNA Pyl (pyrrolicin), tRNA AsnE2 and the like can be used.
- the tRNA is any of tRNAGlu, tRNAAsp, tRNAAsnE2.
- exemplary nucleic acid sequences are shown in SEQ ID NOs: 1-50.
- the term "tRNA body" is sometimes used to refer to the main part of tRNA (the main structural part composed of nucleic acids).
- tRNA may be expressed as follows. -"TRNA Xxx" or "tRNA(Xxx)”... indicates a tRNA (full length) corresponding to the amino acid Xxx (for example, tRNA Glu or tRNA(Glu)). “TRNA(Xxx)nnn”... Indicates a tRNA corresponding to the amino acid Xxx and having an anticodon sequence of nnn (full length) (eg, tRNA(Glu)uga or tRNA(Glu)Lga).
- -"TRNA(Xxx)nnn-CA indicates a tRNA corresponding to the amino acid Xxx, in which the anticodon sequence is nnn (the CA sequence at the 3'end has been removed) (for example, tRNA(Glu )uga-CA and tRNA(Glu)Lga-CA).
- tRNA modifications in the present disclosure include modifications that substitute the first letter nucleoside (N 1 ) of the anticodon with either lysidine, a lysidine derivative, agmatidine, or an agmatidine derivative.
- a lysidine derivative is a molecule produced by modifying a part of the structure of lysidine (for example, a base part), and when used as a part of an anticodon, it has the same codon identification as lysidine.
- an agmatidine derivative is a molecule produced by modifying a part of the structure of agmatidine (for example, a base part), and when used as a part of an anticodon, it has a codon discrimination ability equivalent to that of agmatidine. It means a molecule having (ability to form complementary base pairs).
- Lysidine in natural tRNA is synthesized by the action of an enzyme called tRNA Ile-lysidine synthetase (TilS).
- TilS has the activity of specifically recognizing tRNA (tRNA Ile2) corresponding to isoleucine as a substrate, and modifying (converting) cytidine (C) in the first letter (N 1 ) of its anticodon to lysidine (k2C). doing.
- the lysidine in the tRNA of the present disclosure may be one synthesized via TilS or may be one synthesized without TilS.
- the tRNA of the present disclosure can be recognized by TilS as a substrate. That is, when N 1 in the tRNA before modification is cytidine, the cytidine can be modified to lysidine by TilS.
- cytidine at N 1 of a tRNA can be modified to lysidine by TilS, for example, by preparing TilS by genetic recombination technique or extracting TilS from biological material, the tRNA in which N 1 is cytidine It can be confirmed by detecting lysidine in the reaction product after the reaction with the appropriate conditions (see, for example, Suzuki et al., FEBS Lett (2010) 584: 272-277). ..
- a TRNA whose N 1 is cytidine was introduced into cells that endogenously express TilS or into cells that expressed TilS by a gene recombination technique, and reacted with intracellular TilS under appropriate conditions.
- lysidine contained in the tRNA can also be confirmed later by detecting lysidine contained in the tRNA.
- N 1 in the tRNA before modification was cytidine
- the modification of the cytidine to lysidine can be catalyzed by TilS.
- the tRNA of the present disclosure cannot be recognized as a substrate by TilS. That is, even if N 1 in the tRNA before modification is cytidine, the cytidine cannot be modified to lysidine by TilS. In that case, lysidine and tRNA containing the same can be synthesized by a method that does not use TilS (for example, a chemical synthesis method). An example of such a synthesis method is shown in Examples described later.
- the modification of the cytidine to lysidine cannot be catalyzed by TilS.
- the state that modification of cytidine to lysidine cannot be catalyzed by TilS for example, in 100 mM Hepes-KOH (pH 8.0), 10 mM KCl, 10 mM MgCl 2 , 2 mM DTT, 2 mM ATP, 100 ⁇ M Lysine.
- TilS When 10 ⁇ g/mL TilS was reacted with 1 ⁇ M tRNA at 37°C for 2 hours at 37°C, if the activity to modify the natural substrate tRNA Ile2 cytidine to lysidine is 1, TilS is the target tRNA cytidine. Can be expressed as a state in which the activity of converting to lysidine is reduced by 10 times or more, 20 times or more, 40 times or more, 100 times or more, 200 times or more, or 400 times or more.
- the TilS is TilS from E. coli.
- TilS is wild type TilS from E. coli having the amino acid sequence of SEQ ID NO:51.
- TilS has been reported to maintain a certain amount of lysidine synthesizing ability even for tRNA after some nucleosides in tRNAIle2 have been modified to other nucleosides (Ikeuchi et al., Mol Cell (2005) 19: 235-246).
- Agmatidine in natural tRNA is synthesized by the action of an enzyme called tRNA Ile-agmatidine synthetase (TiaS).
- TiaS specifically recognizes tRNA corresponding to isoleucine (tRNA Ile2) as a substrate, and has an activity of modifying (converting) cytidine (C) in the first letter (N 1 ) of its anticodon to agmatidine (agm2C). doing.
- Agmatidine in the tRNA of the present disclosure may be synthesized via TiaS or may be synthesized without TiaS.
- the tRNA of the present disclosure can be recognized by TiaS as a substrate. That is, when N 1 in the tRNA before modification is cytidine, the cytidine can be modified to agmatidine by TiaS. Whether cytidine at N 1 of a tRNA can be modified to agmatidine by TiaS, for example, by preparing TiaS by genetic recombination techniques, or extracting TiaS from biological material, which is a tRNA where N 1 is cytidine.
- agmatidine in the reaction product after reacting with a suitable condition with (for example, Ikeuchi et al., Nat Chem Biol (2010) 6(4): 277-282). See).
- a TRNA whose N 1 is cytidine was introduced into a cell that endogenously expresses TiaS or a cell that expressed TiaS by a gene recombination technique, and reacted with intracellular TiaS under appropriate conditions. Then, it can be confirmed by detecting agmatidine contained in the tRNA.
- N 1 in the tRNA before modification was cytidine
- the modification of the cytidine to agmatidine can be catalyzed by TiaS.
- the tRNA of the present disclosure cannot be recognized by TiaS as a substrate. That is, even if N 1 in the tRNA before modification is cytidine, the cytidine cannot be modified to agmatidine by TiaS. In that case, agmatidine and tRNA containing the same can be synthesized by a method without using TiaS (for example, a chemical synthesis method). In one embodiment of the present disclosure, when N 1 in the tRNA before modification was cytidine, the modification of the cytidine to agmatidine cannot be catalyzed by TiaS.
- the state that the modification from cytidine to agmatidine cannot be catalyzed by TiaS means that, for example, when TiaS has an activity of converting cytidine of tRNA Ile2, which is a natural substrate, to agmatidine, TiaS changes the cytidine of the target tRNA to agmatidine. It can be expressed as a state in which the activity of modifying is reduced by 10 times or more, 20 times or more, 40 times or more, 100 times or more, 200 times or more, or 400 times or more.
- the TiaS is TiaS from an archaea.
- the TiaS is a wild-type TiaS from the archaebacterium Methanosarcina acetivorans having the amino acid sequence of SEQ ID NO:52.
- TiaS maintains agmatidine synthesizing ability to some extent even for tRNAs after some nucleosides in tRNAIle2 have been modified to other nucleosides (Osawa et al., Nat Struct Mol Biol (2011) 18:1275-1280).
- the mutant tRNA of the present disclosure is an initiation tRNA or an extension tRNA.
- the mutant tRNA may be produced by modifying the starting tRNA or the extended tRNA, or the mutant tRNA produced by the modification may have a function as the starting tRNA or the extended tRNA. Whether or not a certain tRNA has a function as a starting tRNA is determined by (i) being introduced into the ribosome via IF2 when used in a translation system, and (ii) binding to the tRNA. It is possible to judge whether the peptide translation can be initiated by using the existing amino acid as a starting amino acid.
- tRNA has a function as an extended tRNA is determined by (i) when the tRNA is used in a translation system and is introduced into the ribosome via EF-Tu, and (ii) the tRNA. It can be judged whether or not the amino acid bound to is incorporated into the peptide chain and the peptide chain can be extended.
- the mutant tRNA of the present disclosure is a prokaryotic-derived tRNA or a eukaryotic-derived tRNA.
- a mutant tRNA may be produced by modifying a prokaryotic-derived tRNA or a eukaryotic-derived tRNA, and the mutant tRNA produced by the modification is most likely to be a prokaryotic-derived tRNA or a eukaryotic-derived tRNA. It may have a high nucleic acid sequence identity. Eukaryotes are further classified into animals, plants, fungi and protists.
- the mutant tRNA of the present disclosure may be, for example, a human-derived tRNA.
- Prokaryotes are further classified into eubacteria and archaebacteria.
- eubacteria include Escherichia coli, Bacillus subtilis, lactic acid bacteria, and Desulfitobacterium hafniense.
- archaea include highly halophilic bacteria, thermophilic bacteria, or methane bacteria (eg, Methanosarcina mazei, Methanosarcina barkeri, Methanocal dococcus jannaschii).
- the mutant tRNA of the present disclosure may be, for example, tRNA derived from Escherichia coli, Desulfitobacterium hafniense, or Methanosarcina mazei.
- the mutant tRNA of the present disclosure can be translated codons which are represented by M 1 M 2 A.
- the nucleoside (M 1 ) in the first letter and the nucleoside (M 2 ) in the second letter of the codon are each independently adenosine (A), guanosine (G), cytidine (C), or uridine (U).
- the third letter nucleoside is adenosine.
- the mutant tRNA of the present disclosure has an anticodon complementary to the specific codon represented by M 1 M 2 A.
- the mutant tRNA of the present disclosure has an anticodon represented by k2CN 2 N 3 or agm2CN 2 N 3.
- the first nucleoside of the anticodon is lysidine (k2C) or agmatidine (agm2C), and the second nucleoside (N 2 ) and the third nucleoside (N 3 ) are M 2 and It is a nucleoside complementary to M 1 .
- Lysidine and agmatidine are both known as nucleosides that bind complementarily to adenosine.
- N 2 and N 3 can each independently be selected from any of adenosine (A), guanosine (G), cytidine (C), uridine (U).
- N 2 (or M 1 ) when M 2 (or M 1 ) is adenosine, N 2 (or N 3 ) is uridine.
- M 2 (or M 1 ) when M 2 (or M 1 ) is guanosine, N 2 (or N 3 ) is cytidine.
- M 2 (or M 1 ) is cytidine, N 2 (or N 3 ) is guanosine.
- M 2 (or M 1 ) is uridine
- N 2 (or N 3 ) is adenosine.
- the aspect “a certain tRNA is capable of translating a specific codon” essentially includes the aspect “a certain tRNA has an anticodon complementary to the specific codon”. However, as long as the sequence of the anticodon on the tRNA is mentioned, these expressions can be replaced.
- the 1st letter nucleoside (M 1 ) and the 2nd letter nucleoside (M 2 ) of the codon translatable by the mutant tRNA of the present disclosure are the 1st letter nucleoside of the codon that constitutes a specific codon box in the genetic code table. (M 1 ) and the second letter nucleoside (M 2 ) respectively.
- the genetic code table is a standard genetic code table. In another embodiment, the genetic code table is the natural genetic code table.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, which form a codon box in which the codon in which the third letter is A and the codon in which G are both encoding the same amino acid. ..
- the codon in which the third letter is A (UUA) and the codon in which G is the same (UUG) both encode the same amino acid (Leu).
- the first letter nucleoside (U) and the second letter nucleoside (U) in the box-constituting codons can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, which form a codon box in which the third letter U and the A codon both encode the same amino acid. ..
- the codon (AUU) whose third letter is U and the codon (AUA) which is A both code the same amino acid (Ile).
- the first letter nucleoside (A) and the second letter nucleoside (U) in the box-constituting codons can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 form a codon box in which the third letter is a codon U, a codon C, a codon A, and a codon G all encode the same amino acid. It may be selected from the codons M 1 and M 2 , respectively.
- the third letter is a codon (UCU), a codon C (UCC), a codon A (UCA), and a codon G (UCG).
- UCU codon
- UCC codon C
- UA codon A
- UG codon G
- Ser the first letter nucleoside (U) and the second letter nucleoside (C) of the codons that make up the same codon box are selected as M 1 and M 2 , respectively. can do.
- M 1 and M 2 can be selected from the codons M 1 and M 2 , respectively, which form a codon box in which the codon in which the third letter is A and the codon in which G are different from each other encode different amino acids. ..
- the codon box whose codon is represented by AUN the codon (AUA) whose third letter is A and the codon (AUG) which is G code different amino acids (Ile and Met)
- the first letter nucleoside (A) and the second letter nucleoside (U) of the codons that compose the codon box can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, which form a codon box in which the third letter is an A and/or the G codon is a stop codon.
- the codon (UGA) in which the third letter is A is a stop codon (opal)
- the nucleoside of the first letter in the codons constituting the codon box ( U) and the second letter nucleoside (G) can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by UUN.
- the first letter nucleoside (U) and the second letter nucleoside (U) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by the UCN.
- the first letter nucleoside (U) and the second letter nucleoside (C) of the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by UAN.
- the first letter nucleoside (U) and the second letter nucleoside (A) of the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by UGN.
- the first letter nucleoside (U) and the second letter nucleoside (G) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by CUN.
- the first letter nucleoside (C) and the second letter nucleoside (U) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by CCN.
- the first letter nucleoside (C) and the second letter nucleoside (C) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by CAN.
- the first letter nucleoside (C) and the second letter nucleoside (A) of the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by CGN.
- the first letter nucleoside (C) and the second letter nucleoside (G) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by AUN.
- the first letter nucleoside (A) and the second letter nucleoside (U) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by ACN.
- the first letter nucleoside (A) and the second letter nucleoside (C) of the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 can be selected from the codons M 1 and M 2 , respectively, whose codons make up the codon box represented by AAN.
- the first letter nucleoside (A) and the second letter nucleoside (A) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by AGN.
- the first letter nucleoside (A) and the second letter nucleoside (G) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by GUN.
- the first letter nucleoside (G) and the second letter nucleoside (U) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by GCN.
- the first letter nucleoside (G) and the second letter nucleoside (C) in the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons constitute the codon box represented by GAN.
- the first letter nucleoside (G) and the second letter nucleoside (A) of the codon can be selected as M 1 and M 2 , respectively.
- M 1 and M 2 may be selected from the codons M 1 and M 2 , respectively, whose codons make up the codon box represented by GGN.
- the first letter nucleoside (G) and the second letter nucleoside (G) in the codon can be selected as M 1 and M 2 , respectively.
- Nucleosides third character anticodon in the mutant tRNA of the present disclosure (N 3) and the second character of the nucleoside (N 2) may be selected as a complementary nucleoside respectively M 1 and M 2.
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (U) and the second letter nucleoside (U), respectively, in the codons whose codons form the codon box represented by UUN. Can be done. Specifically, A can be selected as N 3 and A can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (U) and the second letter nucleoside (C), respectively, of the codons whose codon constitutes the codon box represented by UCN. Can be done. Specifically, A can be selected as N 3 and G can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (U) and the second letter nucleoside (A), respectively, of the codons whose codons represent the codon box represented by UAN. Can be done. Specifically, A can be selected as N 3 and U can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (U) and the second letter nucleoside (G), respectively, of the codons whose codons represent the codon box represented by UGN. Can be done. Specifically, A can be selected as N 3 and C can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (C) and the second letter nucleoside (U), respectively, of the codons whose codons represent the codon box represented by CUN. Can be done.
- G can be selected as N 3 and A can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (C) and the second letter nucleoside (C), respectively, of the codons whose codons represent the codon box represented by CCN. Can be done.
- G can be selected as N 3 and G can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (C) and the second letter nucleoside (A), respectively, of the codons whose codons represent the codon box represented by CAN. Can be done. Specifically, G can be selected as N 3 and U can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (C) and the second letter nucleoside (G), respectively, in the codons whose codons represent the codon box represented by CGN. Can be done. Specifically, G can be selected as N 3 and C can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary respectively to the first letter nucleoside (A) and the second letter nucleoside (U) in the codons whose codon constitutes the codon box represented by AUN. Can be done. Specifically, U can be selected as N 3 and A can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (A) and the second letter nucleoside (C), respectively, of the codons whose codons represent the codon box represented by ACN. Can be done. Specifically, U can be selected as N 3 and G can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (A) and the second letter nucleoside (A), respectively, in the codons whose codons form the codon box represented by AAN. Can be done. Specifically, U can be selected as N 3 and U can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (A) and the second letter nucleoside (G), respectively, of the codons whose codons represent the codon box represented by AGN. Can be done. Specifically, U can be selected as N 3 and C can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (G) and the second letter nucleoside (U), respectively, of the codons whose codons represent the codon box represented by GUN. Can be done. Specifically, C can be selected as N 3 and A can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (G) and the second letter nucleoside (C), respectively, in the codons whose codons represent the codon box represented by GCN. Can be done. Specifically, C can be selected as N 3 and G can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary to the first letter nucleoside (G) and the second letter nucleoside (A), respectively, of the codons whose codons represent the codon box represented by GAN. Can be done. Specifically, C can be selected as N 3 and U can be selected as N 2 .
- N 3 and N 2 are selected as nucleosides complementary respectively to the first letter nucleoside (G) and the second letter nucleoside (G) in the codons whose codon constitutes the codon box represented by GGN. Can be done.
- C can be selected as N 3 and C can be selected as N 2 .
- an amino acid or amino acid analog is attached to the mutant tRNA of the present disclosure.
- the amino acid or amino acid analog is usually attached to the 3'end of the tRNA, more specifically to the adenosine residue of the CCA sequence at the 3'end.
- the specific type of amino acid or amino acid analog bound to the mutant tRNA can be appropriately selected from the following amino acids or amino acid analogs,
- the amino acids in the present disclosure include ⁇ -amino acids, ⁇ -amino acids, ⁇ -amino acids and the like.
- the three-dimensional structure includes both L-type amino acids and D-type amino acids.
- Amino acids in the present disclosure also include natural and unnatural amino acids.
- the natural amino acids are the following 20 ⁇ -amino acids: glycine (Gly), alanine (Ala), serine (Ser), threonine (Thr), valine (Val), leucine (Leu), isoleucine ( Ile), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), histidine (His), glutamic acid (Glu), aspartic acid (Asp), glutamine (Gln), asparagine (Asn), cysteine (Cys), methionine. (Met), lysine (Lys), arginine (Arg), and proline (Pro).
- the natural amino acids in the present disclosure may be those obtained by removing any one or more kinds of amino acids from the above 20 kinds of amino acids.
- the natural amino acids consist of 19 amino acids except isoleucine.
- the natural amino acids consist of 19 amino acids except methionine.
- the natural amino acids consist of 18 amino acids except isoleucine and methionine. Natural amino acids are usually L-type amino acids.
- an unnatural amino acid refers to all amino acids except the above-mentioned natural amino acids consisting of 20 kinds of ⁇ -amino acids.
- unnatural amino acids include ⁇ -amino acids, ⁇ -amino acids, D-type amino acids, ⁇ -amino acids whose side chains differ from natural amino acids, ⁇ , ⁇ -disubstituted amino acids, and amino acids whose main chain amino group has a substituent. (N-substituted amino acid) and the like.
- the side chain of the unnatural amino acid is not particularly limited, but may have, for example, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, cycloalkyl, etc., in addition to the hydrogen atom.
- two side chains may form a ring.
- these side chains may have one or more substituents.
- the substituents can be selected from any functional group containing a halogen atom, O atom, S atom, N atom, B atom, Si atom, or P atom.
- C 1 -C 6 alkyl having substituent halogen in the present disclosure, it means a “C 1 -C 6 alkyl” in which at least one hydrogen atom is substituted with a halogen atom in an alkyl, specifically Include, for example, trifluoromethyl, difluoromethyl, fluoromethyl, pentafluoroethyl, tetrafluoroethyl, trifluoroethyl, difluoroethyl, fluoroethyl, trichloromethyl, dichloromethyl, chloromethyl, pentachloroethyl, tetrachloroethyl, trichloro.
- C 5 -C 10 arylC 1 -C 6 alkyl having a substituent means “C 5 -C 10 arylC in which at least one hydrogen atom in aryl and/or alkyl is substituted with a substituent.
- “having two or more substituents” means having a certain functional group (for example, a functional group containing an S atom) as a substituent, and the functional group having another substituent (for example, amino or halogen). It also includes having a substituent).
- WO2013/100132, WO2018/143145 and the like can be referred to.
- the amino group of the main chain of the unnatural amino acid may be an unsubstituted amino group (NH 2 group) or a substituted amino group (NHR group).
- R represents alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or cycloalkyl which may have a substituent.
- the carbon chain bonded to the N atom of the amino group of the main chain and the ⁇ -position carbon atom may form a ring.
- the substituent can be selected from any functional group containing a halogen atom, O atom, S atom, N atom, B atom, Si atom, or P atom.
- Examples of the alkyl substitution of the amino group include N-methylation, N-ethylation, N-propylation, N-butylation and the like, and examples of the aralkyl substitution include N-benzylation and the like.
- Specific examples of N-methylamino acid include N-methylalanine, N-methylglycine, N-methylphenylalanine, N-methyltyrosine, N-methyl-3-chlorophenylalanine, N-methyl-4-chlorophenylalanine, Examples thereof include N-methyl-4-methoxyphenylalanine, N-methyl-4-thiazolealanine, N-methylhistidine, N-methylserine and N-methylaspartic acid.
- substituent containing a halogen atom examples include fluoro (-F), chloro (-Cl), bromo (-Br), iodo (-I) and the like.
- oxy examples include alkoxy, cycloalkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, aralkyloxy and the like.
- carbonyl examples include formyl (—C ⁇ O—H), alkylcarbonyl, cycloalkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aralkylcarbonyl and the like. ..
- Examples of oxycarbonyl include alkyloxycarbonyl, cycloalkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl and the like.
- carbonyloxy examples include alkylcarbonyloxy, cycloalkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, aralkylcarbonyloxy and the like. ..
- thiocarbonyl examples include alkylthiocarbonyl, cycloalkylthiocarbonyl, alkenylthiocarbonyl, alkynylthiocarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, aralkylthiocarbonyl and the like.
- carbonylthio examples include alkylcarbonylthio, cycloalkylcarbonylthio, alkenylcarbonylthio, alkynylcarbonylthio, arylcarbonylthio, heteroarylcarbonylthio, aralkylcarbonylthio and the like. ..
- aminocarbonyl examples include alkylaminocarbonyl, cycloalkylaminocarbonyl, alkenylaminocarbonyl, alkynylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl and the like.
- Examples of carbonylamino include alkylcarbonylamino, cycloalkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, aralkylcarbonylamino and the like. .. Further, the H atom bonded to the N atom in —NH—C ⁇ O—R is substituted with a substituent selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. May be.
- Examples of oxycarbonylamino include alkoxycarbonylamino, cycloalkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, aralkyloxy. Carbonylamino and the like can be mentioned. Further, the H atom bonded to the N atom in —NH—C ⁇ O—OR is substituted with a substituent selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. May be.
- sulfonylamino examples include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, aralkylsulfonylamino and the like.
- the H atom bonded to the N atom in —NH—SO 2 —R is substituted with a substituent selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. Good.
- aminosulfonyl examples include alkylaminosulfonyl, cycloalkylaminosulfonyl, alkenylaminosulfonyl, alkynylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl and the like.
- the H atom bonded to the N atom in —SO 2 —NHR may be substituted with a substituent selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. ..
- sulfamoylamino examples include alkylsulfamoylamino, cycloalkylsulfamoylamino, alkenylsulfamoylamino, alkynylsulfamoylamino, arylsulfamoylamino, hetero Arylsulfamoylamino, aralkylsulfamoylamino and the like can be mentioned.
- At least one of the two H atoms bonded to the N atom in —NH—SO 2 —NHR is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. It may be substituted with a substituent. When two H atoms are substituted together, a substituent may be independently selected, and these two substituents may form a ring.
- substituent containing an S atom examples include thiol (—SH), thio (—S—R), sulfinyl (—S ⁇ O—R), sulfonyl (—S(O) 2 —R), sulfo (— SO 3 H) and the like.
- thio examples include alkylthio, cycloalkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, aralkylthio and the like.
- sulfinyl examples include alkylsulfinyl, cycloalkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heteroarylsulfinyl, aralkylsulfinyl and the like.
- sulfonyl examples include alkylsulfonyl, cycloalkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl and the like.
- secondary amino examples include alkylamino, cycloalkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, aralkylamino and the like.
- the two substituents R and R'on the N atom in the tertiary amino are each independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. can do.
- Examples of tertiary amino include alkyl(aralkyl)amino and the like. These two substituents may form a ring.
- the three substituents R, R′, and R′′ on the N atom in the substituted amidino are hydrogen atom, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, Each can be independently selected from the group consisting of heteroaryl and aralkyl.
- substituted amidino include, for example, alkyl(aralkyl)(aryl)amidino and the like. These substituents may form a ring with each other.
- the four substituents R, R', R", and R" on the N atom in the substituted guanidino are hydrogen atom, alkyl , Cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. These substituents may form a ring with each other.
- the three substituents R, R', and R" on the N atom in aminocarbonylamino are hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, hetero. Each can be independently selected from the group consisting of aryl and aralkyl. These substituents may form a ring with each other.
- substituent containing a B atom examples include boryl (-BR(R')) and dioxyboryl (-B(OR)(OR')).
- the two substituents R and R'on the B atom can each be independently selected from the group consisting of hydrogen atom, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and aralkyl. These substituents may form a ring with each other.
- Examples of amino acid analogs in the present disclosure include hydroxycarboxylic acid (hydroxy acid).
- the hydroxycarboxylic acid includes ⁇ -hydroxycarboxylic acid, ⁇ -hydroxycarboxylic acid, ⁇ -hydroxycarboxylic acid and the like.
- a side chain other than a hydrogen atom may be bonded to the carbon at the ⁇ -position in the hydroxycarboxylic acid, as with amino acids.
- the three-dimensional structure can include both L-type and D-type.
- the structure of the side chain can be defined similarly to the side chain of the above-mentioned natural amino acid or unnatural amino acid.
- Examples of hydroxycarboxylic acids include hydroxyacetic acid, lactic acid, phenyllactic acid and the like.
- the amino acid in the present disclosure may be a translatable amino acid, and the amino acid analog may be a translatable amino acid analog.
- a “translatable” amino acid or amino acid analog (sometimes referred to collectively as an amino acid, etc.) can be incorporated into a peptide by translational synthesis (eg, using the translation system described in this disclosure). It means possible amino acids and the like. Whether a certain amino acid or the like is translatable can be confirmed by a translation synthesis experiment using a tRNA to which the amino acid or the like is bound. A reconstituted cell-free translation system may be used in the translation synthesis experiment (see, for example, WO2013100132).
- the unnatural amino acid or amino acid analog according to the present disclosure can be prepared by a conventionally known chemical synthesis method, a synthesis method described in Examples below, or a synthesis method similar thereto.
- tRNA for example, a DNA encoding a desired tRNA gene is prepared, an appropriate promoter such as T7, T3, or SP6 is placed upstream thereof, and RNA polymerase adapted to each promoter is used using the DNA as a template. Can be synthesized by performing a transcription reaction. TRNA can also be prepared by purification from biological material. For example, tRNA can be recovered by preparing an extract from a material containing tRNA such as cells and adding a probe containing a sequence complementary to the nucleic acid sequence of tRNA thereto. At this time, it is also possible to prepare an expression vector capable of expressing a desired tRNA, and prepare cells using the expression vector as a material.
- TRNAs synthesized by in vitro transcription usually contain only four typical nucleosides, adenosine, guanosine, cytidine, and uridine.
- the tRNA synthesized in cells may also contain modified nucleosides obtained by modifying them. It is considered that modified nucleosides (eg, lysidine) in natural tRNA are specifically introduced into the tRNA by the action of an enzyme (eg, TilS) for modifying the tRNA after it is synthesized by transcription. There is.
- tRNA can also be prepared by a method in which a fragment synthesized by transcription or a chemically synthesized fragment or the like is ligated by an enzymatic reaction as described in Examples below.
- Aminoacyl-tRNA can also be prepared by chemical and/or biological synthetic methods.
- aminoacyl-tRNA synthetase ARS
- ARS aminoacyl-tRNA synthetase
- the amino acid may be a natural amino acid or an unnatural amino acid as long as it can serve as a substrate for ARS.
- the natural amino acid may be bound to the tRNA and then chemically modified.
- mutant ARS may be used to bind an amino acid to tRNA.
- the CA sequence is removed from the 3'end of tRNA, and aminoacylated pdCpA (a dinucleotide composed of deoxycytidine and adenosine) is ligated thereto using RNA ligase.
- Aminoacyl-tRNA can be synthesized by (pdCpA method; Hecht et al., JJ Biol Chem (1978) 253: 4517-4520).
- a method using pCpA (dinucleotide composed of cytidine and adenosine) instead of pdCpA is also known (pCpA method; Wang et al., ACS Chem Biol (2015)10: 2187-2192).
- aminoacyl-tRNA can also be synthesized by binding an unnatural amino acid previously activated by esterification to tRNA using an artificial RNA catalyst (flexizyme) (WO2007/066627).
- the present disclosure provides a set of tRNAs suitable for peptide translation.
- a set of tRNAs contains multiple different types of tRNAs, from which multiple different types of amino acids can be translated.
- the disclosure provides a composition comprising a plurality of different types of tRNA suitable for peptide translation.
- the present disclosure provides a method of translating a peptide, comprising providing a plurality of different types of tRNA suitable for peptide translation.
- the present disclosure provides a translation system comprising a plurality of different types of tRNA suitable for peptide translation.
- among the plurality of different types of tRNAs described above are mutant tRNAs of the present disclosure. The following description relates to tRNAs, compositions, translation methods, and translation systems suitable for translating these peptides.
- the mutant tRNA in the present disclosure has either lysidine (k2C), lysidine derivative, agmatidine (agm2C), or agmatidine derivative in the first letter (N 1 ) of the anticodon. Since lysidine and agmatidine form a complementary base pair with adenosine (A), the role at the codon is considered to correspond to uridine (U).
- the mutant tRNA of the present disclosure as compared to other codons, can be selectively translated codon represented by M 1 M 2 A.
- the other codon is a codon different from the codon represented by M 1 M 2 A, for example, one represented by M 1 M 2 U, M 1 M 2 C, or M 1 M 2 G. be able to.
- a mutant tRNA of the present disclosure is represented by M 1 M 2 A as compared to any of the codons represented by M 1 M 2 U, M 1 M 2 C, and M 1 M 2 G. Can be selectively translated.
- whether or not a certain mutant tRNA can selectively translate the codon represented by CUA [the translation amount of the CUA codon by the tRNA] is [the translation amount of the CUG codon by the tRNA].
- the translation amount of the CUA codon by the tRNA is [the translation amount of the CUG codon by the tRNA].
- M 1 M 2 and the mRNA codons are included in a, M 1 M 2 a codon same nucleic acid sequence as all the mRNA except that has been replaced by a codon of the M 1 M 2 G Can be performed by preparing another mRNA having the following: and translating those two mRNAs under the same conditions, and comparing the synthetic amounts of the two resulting peptides.
- UN 2 N 3 anticodon means that the first letter (N 1 ) of the anticodon is uridine, and the second letter (N 2 ) and the third letter (N 3 ) of the anticodon are M 2 and M 1 , respectively.
- the codon other than M 1 M 2 A can be any of the codons represented by M 1 M 2 U, M 1 M 2 C, or M 1 M 2 G.
- [translation amount of CUG codon by the tRNA] is [tRNA having an UN 2 N 3 anticodon.
- Translation amount of CUG codon by the following), for example, 1/2 or less, 1/3 or less, 1/4 or less, 1/5 or less, 1/6 or less, 1/7 or less, 1/8 or less, 1/ 9 or less, 1/10 or less, 1/15 or less, 1/20 or less, 1/30 or less, 1/40 or less, 1/50 or less, 1/60 or less, 1/70 or less, 1/80 or less, 1/ It can be judged by whether it is 90 or less, or 1/100 or less.
- the codon represented by M 1 M 2 A can be selectively translated by the mutant tRNA of the present disclosure over other tRNAs.
- Other tRNA is a tRNA capable of translating a codon different from the codon represented by M 1 M 2 A, for example, any codon of M 1 M 2 U, M 1 M 2 C, or M 1 M 2 G Can be a tRNA capable of translating.
- the codon represented by M 1 M 2 A is a tRNA capable of translating the M 1 M 2 U codon, a tRNA capable of translating the M 1 M 2 C codon, and a M 1 M 2 G codon. It can be selectively translated by the mutant tRNAs of the present disclosure over any tRNA that can translate codons.
- the codon represented by M 1 M 2 A can be selectively translated by a certain mutant tRNA, and the [translation amount of the codon of M 1 M 2 A by the tRNA] is Amount of translation of M 1 M 2 A codon by other tRNA], for example, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, 9 times or more , 10 times or more, 15 times or more, 20 times or more, 30 times or more, 40 times or more, 50 times or more, 60 times or more, 70 times or more, 80 times or more, 90 times or more, or 100 times or more .
- whether or not the codon represented by CUA can be selectively translated by a certain mutant tRNA is determined by [translation amount of CUA codon by the tRNA] [tRNA capable of translating CUG codon (for example, CAG Translation amount of CUA codon by tRNA having anticodon)], for example, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, 9 times or more, 10 times or more, 15 times or more, 20 times or more, 30 times or more, 40 times or more, 50 times or more, 60 times or more, 70 times or more, 80 times or more, 90 times or more, or 100 times or more can do.
- tRNA capable of translating CUG codon for example, CAG Translation amount of CUA codon by tRNA having anticodon
- a translation system containing the mutant tRNA of the present disclosure may have the above two characteristics in combination. That is, in a particular embodiment, in the translation system of the present disclosure, (i) the mutant tRNA can selectively translate the codon represented by M 1 M 2 A as compared with other codons, and , (Ii) the codon represented by M 1 M 2 A can be selectively translated by the mutant tRNA of the present disclosure over other tRNAs.
- the peptide translation using the mutant tRNA of the present disclosure and the peptide translation using the other tRNA do not interact with each other. It can be said that they are in an orthogonal relationship (orthogonal relationship).
- the translation system in the present disclosure further includes a tRNA having an anticodon complementary to the codon represented by M 1 M 2 G (hereinafter, this tRNA is also referred to as “tRNA-G”).
- this tRNA is also referred to as “tRNA-G”.
- the translation system in this disclosure comprises (a) a mutant tRNA described in this disclosure, and (b) at least two tRNAs of tRNA-G described in this disclosure.
- the anticodon complementary to the codon represented by M 1 M 2 G includes, for example, CN 2 N 3 , ac 4CN 2 N 3 , or CmN 2 N 3 .
- the first letter nucleoside of each anticodon is cytidine (C), N4-acetylcytidine (ac4C), or 2'-O-methylcytidine (Cm), and the second letter nucleoside (N 2 ) And the third letter nucleoside (N 3 ) is the nucleoside complementary to M 2 and M 1 above, respectively.
- the mutant tRNA and tRNA-G described in the present disclosure may have the same nucleic acid sequence other than the anticodon, or may have different nucleic acid sequences. When the nucleic acid sequences other than the anticodon are the same, the physicochemical properties of these two tRNAs may be similar to each other, and thus it is possible to construct a translation system with more homogeneous and stable reactivity.
- tRNA-G in the present disclosure can be selectively translated codon represented by M 1 M 2 G.
- the other codon is a codon different from the codon represented by M 1 M 2 G, for example, the codon represented by M 1 M 2 U, M 1 M 2 C, or M 1 M 2 A. be able to.
- the tRNA-G of the present disclosure is represented by M 1 M 2 G as compared to any codon represented by M 1 M 2 U, M 1 M 2 C, and M 1 M 2 A. Can be selectively translated.
- whether or not a certain mutant tRNA can selectively translate the codon represented by CUG [the translation amount of the CUG codon by the tRNA] is [the translation amount of the CUA codon by the tRNA].
- the translation amount of the CUG codon by the tRNA is [the translation amount of the CUA codon by the tRNA].
- the codon represented by M 1 M 2 G can be selectively translated by tRNA-G in the present disclosure over other tRNAs.
- Other tRNA is a tRNA capable of translating a codon different from the codon represented by M 1 M 2 G, for example, any codon of M 1 M 2 U, M 1 M 2 C, or M 1 M 2 A.
- the codon represented by M 1 M 2 G is a tRNA capable of translating the M 1 M 2 U codon, a tRNA capable of translating the M 1 M 2 C codon, and a M 1 M 2 A codon. It can be selectively translated by tRNA-G in the present disclosure over any tRNA that can translate codons.
- the codon represented by M 1 M 2 G can be selectively translated by a certain tRNA, [the translation amount of the codon of M 1 M 2 G by the tRNA] is [other Translation amount of M 1 M 2 G codon by tRNA], for example, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, 9 times or more, It means 10 times or more, 15 times or more, 20 times or more, 30 times or more, 40 times or more, 50 times or more, 60 times or more, 70 times or more, 80 times or more, 90 times or more, or 100 times or more.
- [translation amount of the codon of CUG by the tRNA] is [tRNA that can translate the codon of CUA (for example, k2CAG Translation amount of CUG codon by tRNA having anticodon), for example, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, 9 times or more, 10 times or more.
- Judgment based on whether there are more than 20 times, 15 times or more, 20 times or more, 30 times or more, 40 times or more, 50 times or more, 60 times or more, 70 times or more, 80 times or more, 90 times or more, or 100 times or more be able to.
- the translation system containing tRNA-G may have the above two features in combination. That is, in a specific embodiment, in the translation system of the present disclosure, (i) tRNA-G can selectively translate the codon represented by M 1 M 2 G as compared with other codons, Furthermore, (ii) the codon represented by M 1 M 2 G can be selectively translated by the tRNA-G of the present disclosure over other tRNAs.
- the peptide translation using tRNA-G and the peptide translation using other tRNAs are independent relationships that do not interact with each other. That is, it can be said that they have an orthogonality (orthogonal) relationship.
- the establishment of orthogonality between tRNA-G and other tRNAs can be one of the important characteristics.
- an amino acid bound to the mutant tRNA of the present disclosure (hereinafter, this amino acid is also referred to as “amino acid-A”) and an amino acid bound to tRNA-G (hereinafter, this amino acid is referred to as “amino acid- The amino acid type may be different from each other.
- the mutant tRNA and tRNA-G in the present disclosure when the above-mentioned orthogonal relationship is established, in the present translation system, the codon of M 1 M 2 A and amino acid -A, and M 1 M 2 G Each codon and amino acid-G have a one-to-one correspondence. That is, in the translation system of the present disclosure, two different amino acids can be translated from two codons (i) M 1 M 2 A and (ii) M 1 M 2 G that are present in the same codon box. It is possible.
- the translation system in the present disclosure is a tRNA having an anticodon complementary to the codon represented by M 1 M 2 U or M 1 M 2 C (hereinafter, this tRNA is also referred to as “tRNA-U/C”). Further).
- the translation system in this disclosure comprises (a) a mutant tRNA described in this disclosure, (b) a tRNA-G described in this disclosure, and (c) a tRNA-U/C described in this disclosure. Containing at least 3 tRNAs of.
- the anticodon complementary to the codon represented by M 1 M 2 U includes, for example, AN 2 N 3 , GN 2 N 3 , QN 2 N 3 , or GluQN 2 N 3 .
- the first nucleoside of each anticodon is adenosine (A), guanosine (G), queuosine (Q), or glutamyl cuocosine (GluQ), and the second nucleosides (N 2 ) and 3
- the letter nucleoside (N 3 ) is a nucleoside complementary to M 2 and M 1 described above, respectively.
- the anticodon complementary to the codon represented by M 1 M 2 C includes, for example, GN 2 N 3 , QN 2 N 3 or GluQN 2 N 3 . Since the anticodons complementary to the codons of M 1 M 2 U and M 1 M 2 C often overlap with each other, it is possible in the present disclosure to treat these two codons as one codon. .. In a particular embodiment, the anticodon complementary to the codon represented by M 1 M 2 U or M 1 M 2 C includes AN 2 N 3 , GN 2 N 3 , QN 2 N 3 , or GluQN 2 N 3. Are listed.
- mutant tRNA, tRNA-G, and tRNA-U/C described in the present disclosure may all have the same nucleic acid sequence other than the anticodon, or may have different nucleic acid sequences.
- nucleic acid sequences other than the anticodon are the same, the physicochemical properties of these three tRNAs may be similar to each other, and thus it is possible to construct a translation system with more homogeneous and stable reactivity.
- tRNA-U/C in the present disclosure is capable of selectively translating the codon represented by M 1 M 2 U or M 1 M 2 C relative to other codons.
- the other codon is a codon different from the codon represented by M 1 M 2 U or M 1 M 2 C, for example, the codon represented by M 1 M 2 A or M 1 M 2 G
- a tRNA-U/C in the present disclosure is M 1 M 2 U or M 1 M 2 C compared to any codon represented by M 1 M 2 A and M 1 M 2 G.
- the represented codons can be selectively translated.
- a tRNA is capable of selectively translating the codon of M 1 M 2 U or M 1 M 2 C, by [M 1 M 2 U or M 1 M 2 by the tRNA is described.
- the translation amount of the C codon] is, for example, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times more than [the translation amount of the other codon by the tRNA].
- whether or not a tRNA can selectively translate a codon represented by CUU or CUC is determined by [amount of translation of CUU or CUC codon by the tRNA] [of codon of CUA by the tRNA. More than 2 times, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, 9 times or more, 10 times or more, 15 times or more, 20 times or more , 30 times or more, 40 times or more, 50 times or more, 60 times or more, 70 times or more, 80 times or more, 90 times or more, or 100 times or more.
- the codon represented by M 1 M 2 U or M 1 M 2 C can be selectively translated by tRNA-U/C in the present disclosure over other tRNAs.
- Other tRNA is a tRNA capable of translating a codon different from the codon represented by M 1 M 2 U or M 1 M 2 C, for example, a codon of either M 1 M 2 A or M 1 M 2 G. It can be a translatable tRNA.
- the codon represented by M 1 M 2 U or M 1 M 2 C is either a tRNA capable of translating the M 1 M 2 A codon or a tRNA capable of translating the M 1 M 2 G codon. Can be selectively translated by the tRNA-U/C in the present disclosure over the tRNA of the present invention.
- a codon represented by M 1 M 2 U or M 1 M 2 C can be selectively translated by a tRNA, as follows: [M 1 M 2 U or M 1 M by the tRNA] 2 C codon translation amount) is, for example, 2 times or more, 3 times or more, 4 times or more, 5 times more than [the translation amount of the M 1 M 2 U or M 1 M 2 C codon by other tRNA]. Above, 6 times or more, 7 times or more, 8 times or more, 9 times or more, 10 times or more, 15 times or more, 20 times or more, 30 times or more, 40 times or more, 50 times or more, 60 times or more, 70 times or more, It means 80 times or more, 90 times or more, or 100 times or more.
- [translation amount of the codon of CUU or CUC by the tRNA] is [tRNA that can translate the codon of CUA (For example, translation amount of CUU or CUC codon by tRNA having anticodon of k2CAG)], for example, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more , 9 times or more, 10 times or more, 15 times or more, 20 times or more, 30 times or more, 40 times or more, 50 times or more, 60 times or more, 70 times or more, 80 times or more, 90 times or more, or 100 times or more Whether or not it can be determined.
- the translation system containing tRNA-U/C may have both of the above two characteristics. That is, in a particular embodiment, in the translation system of the present disclosure, (i) tRNA-U/C selects a codon represented by M 1 M 2 U or M 1 M 2 C as compared to other codons. And (ii) the codon represented by M 1 M 2 U or M 1 M 2 C is selectively translated by the tRNA-U/C of the present disclosure over other tRNAs. Can be done.
- peptide translation using tRNA-U/C and peptide translation using other tRNAs are independent and do not interact with each other. It can be said that they are in a relationship having an orthogonality (orthogonal).
- establishment of orthogonality between tRNA-U/C and other tRNAs may be one of the important characteristics.
- amino acid-A amino acid bound to the mutant tRNA of the present disclosure
- amino acid-G amino acid bound to tRNA-G
- amino acid-U/C amino acid bound to tRNA-U/C
- the codon and amino acid of M 1 M 2 A-A, The M 1 M 2 G codon and amino acid-G, and the M 1 M 2 U or M 1 M 2 C codon and amino acid-U/C all have a one-to-one correspondence. That is, in the translation system of the present disclosure, (i) M 1 M 2 A, (ii) M 1 M 2 G, and (iii) M 1 M 2 U or M 1 M 2 C existing in the same codon box It is possible to translate three different amino acids from the three codons. Alternatively, in the translation system of the present disclosure, three different amino acids are translated from the codon box composed of M 1 M 2 U, M 1 M 2 C, M 1 M 2 A, and M 1 M 2 G. It is possible.
- an unnatural amino acid may be bound to at least one of the mutant tRNA, tRNA-G, and tRNA-U/C in the present disclosure.
- the mutant tRNAs of the present disclosure may be assigned to codons that make up at least one codon box in the genetic code.
- the mutant tRNAs of the present disclosure may be assigned to the codons that make up the multiple codon boxes in the genetic code.
- a plurality of codon boxes for example, 2, 3, 4, 5, 6, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, Or it can be a 16 codon box.
- tRNA-G may be assigned to other codons that form the same codon box (a codon different from the codon to which the mutant tRNA is assigned), or tRNA-U/C may have the same codon.
- TRNAs assigned to codons that constitute different codon boxes have different N 2 and N 3 .
- the tRNAs assigned to the codons forming different codon boxes may have the same nucleic acid sequence other than the anticodon, or may have different nucleic acid sequences from each other.
- the physicochemical properties of these tRNAs may be similar to each other, and thus it is possible to construct a translation system with more homogeneous and stable reactivity.
- one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen from the translation system of the present disclosure. It can translate 14 kinds, 15 kinds, 16 kinds, 17 kinds, 18 kinds, 19 kinds, or 20 kinds of amino acids. Alternatively, more than 20 kinds of amino acids can be translated by using the mutant tRNA of the present disclosure to distinguish the codons of M 1 M 2 A and M 1 M 2 G in one codon box.
- the translation system of the present disclosure for example, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 31, 32, 33 Translates 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, or 48 amino acids It is possible to
- the translation system of the present disclosure is a cell-free translation system.
- the translation system of the present disclosure is a reconstituted cell-free translation system.
- the cell extract in the cell-free translation system and the factors required for peptide translation for example, ribosome
- those derived from various biological materials can be used. Examples of such biological materials include Escherichia coli, yeast, wheat germ, rabbit reticulocytes, HeLa cells, and insect cells.
- the present disclosure provides a method for producing a peptide, the method including translating a nucleic acid using the translation system described in the present disclosure.
- Compounds in which two or more amino acids are linked by an amide bond can be included in the peptides of this disclosure.
- a compound in which an amino acid analog such as hydroxycarboxylic acid instead of an amino acid is linked by an ester bond may be included in the peptide of the present disclosure.
- the number of amino acids or amino acid analogs contained in the peptide is not particularly limited as long as it is 2 or more, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 Above, 9 or more, 10 or more, 11 or more, and also 100 or less, 80 or less, 50 or less, 30 or less, 25 or less, 20 or less, 19 or less, 18 Hereinafter, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less and the like can be mentioned. Alternatively, it is possible to select from 9, 10, 11, and 12.
- the peptide of the present disclosure may contain N-substituted amino acids, and the number of N-substituted amino acids contained in the peptide is, for example, 2, 3, 4, 5, 6, 6, 7, It can be 8, 9, 10, etc.
- the peptide of the present disclosure may include amino acids that are not N-substituted, and the number of amino acids that are not N-substituted is, for example, 1, 2, 3, 4, etc.
- peptides of the present disclosure may include both N-substituted and N-unsubstituted amino acids.
- the peptide of the present disclosure may be a linear peptide or a peptide having a cyclic part.
- a peptide having a cyclic portion means that the main chain or side chain of an amino acid or amino acid analog existing on a peptide chain is bonded to the main chain or side chain of another amino acid or amino acid analog existing on the same peptide chain. By doing so, it means a peptide in which a cyclic structure is formed in the molecule.
- the peptide having a cyclic portion may be composed of only the cyclic portion, or may include both the cyclic portion and the linear portion.
- the number of amino acids or amino acid analogs contained in the cyclic portion is, for example, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, and 14 or less, 13 or less. Below, it can be 12 or less, 11 or less, and so on. Alternatively, it is possible to select from 9, 10, and 11.
- the number of amino acids or amino acid analogs contained in the linear portion is, for example, 0 or more, and may be 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, etc. it can. Alternatively, it can be selected from 0, 1, 2, and 3.
- a peptide bond formed from an amino group and a carboxyl group can be used.
- Amine bond, C ⁇ N—C bond, lactam bridge, carbamoyl bond, urea bond, thiourea bond, thioamide bond, sulfinyl bond, sulfonyl bond, triazole bond, benzoxazole bond and the like can be used.
- the carbon-carbon bond can be formed by a transition metal-catalyzed reaction such as a Suzuki reaction, a Heck reaction, and a Sonogashira reaction.
- the peptides of the present disclosure include at least one set of functional groups capable of forming the above bond in the molecule.
- the formation of the cyclic portion may be performed by producing a linear peptide using the translation system of the present disclosure and then separately performing a reaction for binding the above functional groups.
- the nucleic acid translated in the translation system of the present disclosure is mRNA.
- a peptide having a desired amino acid sequence may be encoded in mRNA.
- the mRNA can be translated into a peptide.
- an RNA polymerase for transcribing DNA into mRNA is included in the translation system, by adding the DNA to the translation system of the present disclosure, transcription of the DNA into mRNA and conversion of the mRNA into a peptide Translation can be done at the same time.
- Methionine usually exists at the N-terminal of the translated peptide as a starting amino acid, but some methods for introducing an amino acid other than methionine to the N-terminal have been reported. They may be used in combination with the methods for producing the peptides described in this disclosure. Examples of such a method include a method of translating a peptide starting from a desired amino acid using an initiation tRNA aminoacylated with an amino acid other than methionine (Initiation suppression). Particularly, the degree of acceptability of an exogenous amino acid is higher at the time of translation initiation than at the time of elongation of the peptide chain.
- a peptide library starting from methionine is prepared, and the above enzyme is allowed to act on the peptide library to prepare a peptide library starting from an amino acid having a random N-terminal.
- the present disclosure provides a peptide produced by the method for producing a peptide described in the present disclosure.
- Peptides obtained by further chemically modifying the peptide produced by the method described in the present disclosure are also included in the peptides provided by the present disclosure.
- the present disclosure provides a method for producing a peptide library, comprising translating a nucleic acid library using the translation system described in the present disclosure.
- a method for producing a nucleic acid library comprising translating a nucleic acid library using the translation system described in the present disclosure.
- the size of the library is not particularly limited, and examples thereof include 10 6 or more, 10 7 or more, 10 8 or more, 10 9 or more, 10 10 or more, 10 11 or more, 10 12 or more, 10 13 or more, 10 14 or more. be able to.
- the nucleic acid may be DNA or RNA. RNA is usually mRNA.
- DNA is translated into peptides via transcription into mRNA.
- a nucleic acid library can be prepared by a method known to those skilled in the art or a method analogous thereto.
- a mixed base By using a mixed base at a desired position when synthesizing a nucleic acid library, a plurality of nucleic acid molecules rich in nucleic acid sequence diversity can be easily prepared. Examples of codons using mixed bases are, for example, NNN (where N represents a mixture of 4 bases A, T, G, C) and NNW (where W is a mixture of 2 bases A and T).
- NNM where W is a mixture of two bases A and C
- NNK where K is a mixture of two bases G and T
- NNS where S is C, G is a mixture of two bases
- the peptide library described in the present disclosure is a library in which peptides are displayed on nucleic acids (nucleic acid display library, or simply display library).
- a display library is a library characterized in that a phenotype and a genotype are associated with each other by binding one peptide with a nucleic acid encoding the peptide to form one complex.
- Examples of major display libraries include mRNA display method (Roberts and Szostak, Proc Natl Acad Sci USA(1997)94: 12297-12302), in vitro virus method (Nemoto et al., FEBS Lett (1997) 414: 405 -408), cDNA display method (Yamaguchi et al., Nucleic AcidsRes (2009)37: e108), ribosome display method (Mattheakis et al, Proc Natl Acad Sci USA (1994) 91: 9022-9026), covalent display method (Reiersen et.al.,Nucleic AcidsRes (2005)33: e10), CIS display method (Odegrip et.al., ProcNatl Acad Sci USA (2004)101: 2806-2810) You can Alternatively, a library prepared by using the in vitro compartmentalization method (Tawfik and Griffiths, Nat Biotechnol (1998) 16:652-656) can be mentioned
- the present disclosure provides a peptide library produced by the method for producing a peptide library described in the present disclosure.
- the present disclosure provides a method for identifying a peptide having binding activity to a target molecule, the method including contacting the target molecule with a peptide library described in the present disclosure.
- the target molecule is not particularly limited and can be appropriately selected from, for example, low molecular weight compounds, high molecular weight compounds, nucleic acids, peptides, proteins, sugars, lipids and the like.
- the target molecule may be a molecule existing outside the cell or a molecule existing inside the cell. Alternatively, it may be a molecule existing in the cell membrane, in which case any of the extracellular domain, the transmembrane domain and the intracellular domain may be the target.
- the target molecule In the step of bringing the peptide library into contact with the target molecule, the target molecule is usually immobilized on some solid-phase carrier (for example, a microtiter plate or microbeads). Then, the peptide that does not bind to the target molecule is removed and only the peptide that binds to the target molecule is recovered, whereby the peptide having the binding activity to the target molecule can be selectively concentrated ( Panning method).
- the peptide library used is a nucleic acid display library
- the nucleic acid encoding the genetic information is bound to the recovered peptides, and therefore the nucleic acid encoding the recovered peptide is isolated and analyzed. Sequences and amino acid sequences can be readily identified. Furthermore, based on the obtained nucleic acid sequence or amino acid sequence, the identified peptides can be individually produced by chemical synthesis or gene recombination techniques.
- the disclosure provides a nucleic acid-peptide complex comprising a peptide and a nucleic acid encoding the peptide, the complex having the following characteristics: (i) the nucleic acid sequence encoding the peptide contains two codons M 1 M 2 A and M 1 M 2 G, and (ii) In the amino acid sequence of the peptide, the types of amino acids corresponding to the M 1 M 2 A codon and the amino acids corresponding to the M 1 M 2 G codon are different from each other.
- M 1 and M 2 represent the first letter and the second letter of a specific codon, respectively (except for the codon in which M 1 is A and M 2 is U).
- the disclosure provides a nucleic acid-peptide complex comprising a peptide and a nucleic acid encoding the peptide, the complex having the following characteristics: (i) in the nucleic acid sequence encoding a peptide, it contains three codons of M 1 M 2 U, M 1 M 2 A and M 1 M 2 G, and, (ii) In the amino acid sequence of the peptide, the amino acid corresponding to the M 1 M 2 U codon, the amino acid corresponding to the M 1 M 2 A codon, and the amino acid corresponding to the M 1 M 2 G codon are all Different from each other.
- M 1 and M 2 represent the first and second letters of a particular codon, respectively.
- the present disclosure provides a nucleic acid-peptide complex comprising a peptide and a nucleic acid encoding the peptide, the complex having the following characteristics: (i) in the nucleic acid sequence encoding a peptide, it contains three codons of M 1 M 2 C, M 1 M 2 A and M 1 M 2 G, and, (ii) In the amino acid sequence of the peptide, the amino acid corresponding to the M 1 M 2 C codon, the amino acid corresponding to the M 1 M 2 A codon, and the amino acid corresponding to the M 1 M 2 G codon are all Different from each other.
- M 1 and M 2 represent the first and second letters of a particular codon, respectively.
- the nucleic acid-peptide complex described above can be included therein as one of the elements that make up a peptide library (particularly a nucleic acid display library).
- the present disclosure provides a library (a peptide library or a nucleic acid display library) comprising the nucleic acid-peptide complex described in the present disclosure.
- the nucleic acid-peptide complexes and libraries described above can be made using the mutant tRNA described in this disclosure or the translation system described in this disclosure.
- the present disclosure provides the following compounds: lysidine-diphosphate (pLp), or salts thereof.
- a compound can be used for preparing a mutant tRNA into which lysidine has been introduced.
- the present disclosure relates to a method for producing a mutant tRNA having lysidine introduced therein using lysidine-diphosphate, and a mutant tRNA produced by the method.
- the present disclosure provides a method for producing a mutant tRNA into which a lysidine is introduced, which has an amino acid or an amino acid analog bound (aminoacyl mutant tRNA), using lysidine-diphosphate, and the method. It relates to an aminoacyl mutant tRNA produced.
- Such mutant tRNA and/or aminoacyl mutant tRNA can be used in the translation system in the present disclosure. Accordingly, the present disclosure relates to translation systems that include such mutant tRNAs and/or aminoacyl mutant tRNAs.
- the present disclosure also provides methods for producing peptides or peptide libraries using the translation system.
- the present disclosure also provides peptides or peptide libraries produced by the method.
- lysidine may be introduced at position 34 of tRNA (based on tRNA numbering rules).
- a mutant tRNA in which lysidine is introduced at position 34 of the tRNA numbering rule is prepared by preparing one or more (e.g., 2, 3, 4, 5, or more) tRNA nucleic acid fragments and lysidine-diphosphate.
- they can be obtained by ligating them by a method known to those skilled in the art. Specifically, as an example, a nucleic acid fragment consisting of bases 1 to 33 of tRNA, lysidine-diphosphate, 35 to 76 of tRNA (or 35 to 75 of tRNA, 35 to 74 of tRNA). Ligation is performed in this order from the 5′ side of the nucleic acid fragment consisting of the base at the position). The CA sequence at the 3'end may be removed.
- the present disclosure provides the following compounds: Agmatidine-diphosphate (p(Agm)p), or salts thereof.
- a compound can be used for the preparation of a mutant tRNA into which agmatidine has been introduced.
- the present disclosure relates to a method for producing an agmatidine-introduced mutant tRNA using agmatidine-diphosphate, and a mutant tRNA produced by the method.
- the present disclosure also provides a method for producing a mutant tRNA in which agmatidine is introduced, which is a mutant tRNA having an amino acid or an amino acid analog bound (aminoacyl mutant tRNA), using agmatidine-diphosphate, and the method.
- mutant tRNA and/or aminoacyl mutant tRNA can be used in the translation system in the present disclosure. Accordingly, the present disclosure relates to translation systems that include such mutant tRNAs and/or aminoacyl mutant tRNAs.
- the present disclosure also provides methods for producing peptides or peptide libraries using the translation system.
- the present disclosure also provides peptides or peptide libraries produced by the method.
- agmatidine may be introduced at position 34 of tRNA (based on the tRNA numbering rule).
- a mutant tRNA in which agmatidine is introduced at position 34 of the tRNA numbering rule is prepared by preparing one or more (eg, 2, 3, 4, 5, or more) tRNA nucleic acid fragments and agmatidine-diphosphate.
- they can be obtained by ligating them by a method known to those skilled in the art. Specifically, as an example, a nucleic acid fragment consisting of bases 1 to 33 of tRNA, agmatidine-diphosphate, 35 to 76 of tRNA (or 35 to 75 of tRNA, 35 to 74 of tRNA). Ligation is performed in this order from the 5′ side of the nucleic acid fragment consisting of the base at the position). The CA sequence at the 3'end may be removed.
- the compound of the present disclosure can be a free substance or a salt.
- Salts of compounds of the present disclosure include, for example, hydrochloride; hydrobromide; hydroiodide; phosphate; phosphonate; sulfate; methanesulfonate, p-toluenesulfonate, etc.
- the salt of the compound of the present disclosure is produced, for example, by contacting the compound of the present disclosure with an acid or a base.
- the compounds of the present disclosure may be hydrates, and such hydrates are also included in the salts of the compounds of the present disclosure.
- the compounds of the present disclosure may be solvates, and such solvates are also included in the salts of the compounds of the present disclosure.
- the present invention relates to a method for producing lysidine diphosphate represented by the following formula A or a derivative thereof, or agmatidine diphosphate or a derivative thereof.
- R 1 and R 2 are each independently H or C 1 -C 3 alkyl, and it is preferred that both R 1 and R 2 are H.
- L is a C 2 -C 6 straight chain alkylene or C 2 -C optionally substituted by one or more substituents selected from the group consisting of hydroxy and C 1 -C 3 alkyl 6 straight chain alkenylene, wherein the carbon atom of the C 2 -C 6 straight chain alkylene may be substituted by one oxygen atom or sulfur atom.
- the C 2 -C 6 straight chain alkylene is preferably C 4 -C 5 straight chain alkylene
- the C 2 -C 6 straight chain alkenylene is preferably C 4 -C 5 straight chain alkenylene.
- L examples include, for example, —(CH 2 ) 3 —, —(CH 2 ) 4 —, —(CH 2 ) 5 , —(CH 2 ) 2 —O—CH 2 —, —( CH 2 ) 2 —S—CH 2 —, —CH 2 CH(OH)(CH 2 ) 2 —, —CH 2 CH ⁇ CH— (cis or trans) and the like.
- M is a single bond, Is.
- the wavy line indicates a bonding point with a carbon atom, * indicates a bonding point with a hydrogen atom, and ** indicates a bonding point with a nitrogen atom. If M is a single bond, then there is no H attached to M.
- M is Where the compound of formula A is: Can be expressed as Where the compound of formula A is: When M is a single bond, the compound of formula A can be represented by: Can be expressed as
- the compound represented by the formula A is preferably lysidine diphosphate, agmatidine diphosphate, or a salt thereof.
- Step 1 of Scheme 1 is a step of intramolecularly cyclizing the compound represented by the formula B1 to obtain a compound represented by the formula C1.
- the reaction mixture is stirred in the presence of an intramolecular cyclization reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably 0° C. to 180° C. for 15 minutes to 48 hours. It can be carried out.
- Compounds of formula B1 can be obtained from commercial suppliers or can be prepared using methods known in the literature.
- PG 11 in Formula B1 is a protecting group for an amino group, and any protecting group can be used as long as it does not interfere with the progress of the reaction according to the above Scheme 1, and for example, an acid or a fluoride ion may be used. Protecting groups that are not deprotected are preferred. Specific examples of PG 11 include p-bromobenzoyl, optionally substituted benzoyl, pyridinecarbonyl, acetyl and the like.
- the intramolecular cyclization reagent is not particularly limited, but diisopropyl azodicarboxylate and triphenylphosphine can be preferably used.
- the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents and ketone solvents, and dichloromethane can be preferably used.
- Step 2 of Scheme 1 is a step of introducing the amine represented by the formula D1 into the compound represented by the formula C1 to obtain the compound represented by the formula E1.
- This step is performed by stirring the reaction mixture in the presence of an amine-introducing reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably 0° C. to 180° C. for 15 minutes to 48 hours.
- the amine-introducing reagent is not particularly limited, but lithium chloride and DBU can be preferably used.
- the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, and ketone solvents, and tetrahydrofuran is preferably used in this step.
- Steps 3A and 3B of Scheme 1 are steps of introducing PG 12 and/or PG 13 into the compound represented by formula E1 to obtain the compound represented by formula F1A or formula F1B.
- R 2 of formula E1 is alkyl
- PG 13 is introduced to formula F1A
- R 2 of formula E1 is hydrogen
- PG 12 and PG 13 are introduced to give formula F1B.
- This step is performed by stirring the reaction mixture in the presence of a reagent for introducing a protecting group in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably 0° C. to 180° C. for 15 minutes to 48 hours. be able to.
- PG 12 is a protecting group for amino group
- PG 13 is a protecting group for carboxyl group or imino group.
- any protecting group can be used as long as it does not interfere with the progress of the reaction according to the above scheme 1, and for example, a protecting group that is not deprotected by an acid or a fluoride ion is preferable.
- Fmoc is preferably used as PG 12
- M is used as PG 13.
- M is methyl, ethyl, or optionally substituted benzyl
- M is In the case of, optionally substituted benzyl, Cbz or optionally substituted benzyloxycarbonyl is preferably used.
- PG 12 and PG 13 may be introduced simultaneously or sequentially.
- PG 12 or PG 13 may be introduced first, but it is preferable to introduce PG 12 and then PG 13 .
- the method described in “Greene's, “Protective Groups in Organic Synthesis” (5th edition, John Wiley & Sons 2014)” can be used for introducing the protecting group, but when PG 12 is Fmoc.
- Steps 4A and 4B of Scheme 1 are steps of removing acetonide from the compound represented by formula F1A or formula F1B and introducing PG 14 and PG 15 to obtain the compound represented by formula G1A or formula G1B. ..
- Acetonide is removed in the presence of an acid, and a protecting group is introduced in the presence of a protecting group-introducing reagent in a solvent at a temperature between -20°C and the boiling point of the solvent, preferably at a temperature of 0°C to 180°C. It can be performed by stirring the mixture for 15 minutes to 48 hours.
- PG 14 and PG 15 are each independently a hydroxyl-protecting group, and any protecting group can be used as long as it does not interfere with the progress of the reaction according to the above scheme 1, and deprotection with, for example, a fluoride ion is possible.
- the silyl-based protecting group described above can be preferably used. It is preferable that PG 14 and PG 15 together form a divalent protecting group, and specific examples of such a protecting group include di-tert-butylsilyl.
- the method described in “Greene's, “Protective Groups in Organic Synthesis” (5th edition, John Wiley & Sons 2014)” can be used.
- the acid used for removal is preferably TFA.
- PG 14 and PG 15 together form di-tert-butylsilyl, bis(trifluoromethanesulfonic acid)di-tert-butylsilyl is preferably used for introduction thereof.
- the solvent used for removing acetonide include water and carboxylic acid solvents, and a mixed solvent of water and TFA can be preferably used.
- a halogenated solvent, an ether solvent, a benzene solvent, an ester solvent, a ketone solvent and an amide solvent can be mentioned, and DMF is preferably used.
- Steps 5A and 5B of Scheme 1 are steps of introducing PG 16 into the compound represented by formula G1A or formula G1B to obtain the compound represented by formula H1A or formula H1B.
- PG 16 in the presence of a protecting group-introducing reagent, the reaction mixture is stirred in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 hours. Can be done at.
- PG 16 is a protective group for a hydroxyl group and/or an amino group, and any protective group can be used as long as it does not interfere with the progress of the reaction according to the above scheme 1, and for example, deprotection with a fluoride ion is performed. Protecting groups that are not are preferred.
- TOM is preferable as PG 16 .
- the method described in “Greene's, “Protective Groups in Organic Synthesis” (5th edition, John Wiley & Sons 2014)” can be used to introduce the protecting group, but when PG 16 is TOM. It is preferable to use DIPEA and (triisopropylsiloxy)methyl chloride for its introduction.
- the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and amide solvents, and dichloromethane is preferably used.
- Steps 6A and 6B of Scheme 1 are the steps of removing PG 14 and PG 15 from the compound represented by formula G1A or formula G1B to obtain the compound represented by formula I1A or formula I1B.
- PG 14 and PG 15 are removed by stirring the reaction mixture in the presence of a deprotecting reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 hours. Can be done by doing.
- any reagent can be used as long as it can selectively remove only PG 14 and PG 15, but when PG 14 and PG 15 are taken together to form di-tert-butylsilyl
- a reagent that produces fluoride ions for its removal specifically, for example, a hydrogen fluoride pyridine complex.
- the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents, and amide solvents, and THF is preferably used.
- Steps 7A and 7B of Scheme 1 are steps of phosphite esterification of a compound represented by formula I1A or I1B and subsequent oxidation to obtain a compound represented by formula J1A or J1B.
- the phosphite esterification is carried out by reacting the reaction mixture in the presence of a phosphite esterification reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 minutes. It can be performed by stirring for a time.
- the oxidation can be carried out by stirring the reaction mixture in the presence of an oxidizing reagent in a solvent at a temperature from ⁇ 20° C.
- PG 17 is a hydroxyl-protecting group, and any protecting group can be used as long as it does not interfere with the progress of the reaction according to the above scheme 1, PG 11 , PG 12 , and PG A protecting group capable of being deprotected simultaneously with 13 is preferable.
- Specific examples of PG 17 include cyanoethyl.
- a phosphite esterification reagent having a hydroxyl group protected by a protecting group may be used, or an unprotected phosphite esterification reagent may be used and then a protecting group may be introduced into the hydroxyl group.
- a protecting group for example, the method described in “Greene's, “Protective Groups in Organic Synthesis” (5th edition, John Wiley & Sons 2014)” can be used.
- bis(2-cyanoethyl)-N,N-diisopropylaminophosphoramidite is preferably used as the phosphite esterification reagent.
- the oxidizing agent used in the oxidation subsequent to phosphite esterification is not particularly limited, but tert-butyl hydroperoxide can be preferably used.
- the solvent include a halogenated solvent, an ether solvent, a benzene solvent, an ester solvent, a ketone solvent, and a nitrile solvent, and acetonitrile is preferably used.
- Steps 8A and 8B of Scheme 1 include removing PG 11 , PG 12, PG 13 , and PG 17 from the compound represented by formula J1A, or PG 11 , PG 13 , from the compound represented by formula J1B, And PG 17 are removed to obtain the compound represented by the formula K1.
- the reaction mixture is stirred in the presence of a deprotecting reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 hours. You can do that.
- a deprotecting reagent any reagent can be used as long as the above protecting group can be selectively removed.
- reagents include the use of bis-(trimethylsilyl)acetamide and DBU in combination.
- solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents, nitrile solvents, amine solvents, and pyridine is preferably used.
- Step 9 of Scheme 1 is a step of removing PG 16 from the compound represented by the formula K1 to obtain the compound represented by the formula A.
- PG 16 is removed by stirring the reaction mixture in the presence of a deprotecting reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 hours. Can be done at.
- a deprotecting reagent any reagent can be used as long as PG 16 can be selectively removed, and ammonium fluoride can be preferably used.
- the solvent examples include water, a halogenated solvent, an ether solvent, a benzene solvent, an ester solvent, a ketone solvent, and a nitrile solvent, and a mixed solvent of water and acetonitrile can be preferably used.
- Step 1 of Scheme 2 is a step of intramolecularly cyclizing the compound represented by the formula B2 to obtain a compound represented by the formula C2.
- the reaction mixture is stirred in the presence of an intramolecular cyclization reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably 0° C. to 180° C. for 15 minutes to 48 hours. It can be carried out.
- Compounds of formula B2 can be obtained from commercial suppliers or can be prepared using methods known in the literature.
- PG 21 in Formula B2 is a protecting group for an amino group, and any protecting group can be used as long as it does not interfere with the progress of the reaction according to the above Scheme 2, for example, by an acid or a fluoride ion. Protecting groups that are not deprotected are preferred. Specific examples of PG 21 include Cbz, optionally substituted benzyloxycarbonyl, and optionally substituted benzyl.
- the intramolecular cyclization reagent is not particularly limited, but diisopropyl azodicarboxylate and triphenylphosphine can be preferably used.
- the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents and ketone solvents, and dichloromethane can be preferably used.
- Step 2 of Scheme 2 is a step of introducing an amine represented by the formula D2A or D2B into the compound represented by the formula C2 to obtain a compound represented by the formula E2A or E2B.
- This step is performed by stirring the reaction mixture in the presence of an amine-introducing reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably 0° C. to 180° C. for 15 minutes to 48 hours.
- the amine-introducing reagent is not particularly limited, but lithium chloride and DBU can be preferably used.
- the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents and ketone solvents, and THF is preferably used in this step.
- Steps 3A and 3B of Scheme 2 are steps of removing acetonide from the compound represented by formula E2A or E2B and introducing PG 24 and PG 25 to obtain the compound represented by formula F2A or F2B.
- Acetonide is removed in the presence of an acid, and a protecting group is introduced in the presence of a protecting group-introducing reagent in a solvent at a temperature between -20°C and the boiling point of the solvent, preferably at a temperature of 0°C to 180°C. It can be performed by stirring the mixture for 15 minutes to 48 hours.
- PG 24 and PG 25 are each independently a hydroxyl-protecting group, and any protecting group can be used as long as it does not interfere with the progress of the reaction according to the above scheme 2, and for example, deprotection with a fluoride ion is performed.
- the silyl-based protecting group described above can be preferably used.
- PG 24 and PG 25 it is preferable that these are taken together to form a divalent protecting group, and specific examples of such a protecting group include di-tert-butylsilyl.
- the method described in “Greene's, “Protective Groups in Organic Synthesis” (5th edition, John Wiley & Sons 2014)” can be used.
- the acid used for removal is preferably TFA.
- PG 24 and PG 25 together form di-tert-butylsilyl, bis(trifluoromethanesulfonic acid)di-tert-butylsilyl is preferably used for the introduction thereof.
- the solvent used for removing acetonide include water and carboxylic acid solvents, and a mixed solvent of water and TFA can be preferably used.
- a halogenated solvent examples thereof include ether solvents, benzene solvents, ester solvents, ketone solvents and amide solvents, and DMF is preferably used.
- Steps 4A and 4B of Scheme 2 are steps of introducing PG 26 into the compound represented by the formula F2A or F2B to obtain the compound represented by the formula G2A or G2B.
- the reaction mixture is stirred in the presence of a protecting group-introducing reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 hours. Can be done at.
- PG 26 is a hydroxyl-protecting group, and any protecting group can be used as long as it does not interfere with the progress of the reaction according to the above scheme 2, and for example, a protecting group that is not deprotected by fluoride ion is preferable. ..
- PG 26 tetrahydropyranyl, tetrahydrofuranyl, or methoxymethyl is preferable.
- the method described in “Greene's, “Protective Groups in Organic Synthesis” (5th edition, John Wiley & Sons 2014)” can be used for introducing the protecting group, but PG 16 is tetrahydropyranyl. In some cases it is preferred to use TFA and 3,4-dihydro-2H-pyran for its introduction.
- the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and amide solvents, and dichloromethane is preferably used.
- Steps 5A and 5B of Scheme 2 are the steps of removing PG 24 and PG 25 from the compound represented by formula G2A or G2B to obtain the compound represented by formula H2A or H2B.
- PG 24 and PG 25 are removed by stirring the reaction mixture in the presence of a deprotecting reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 hours. Can be done by doing.
- a deprotecting reagent any reagent can be used as long as it can selectively remove only PG 24 and PG 25, but when PG 24 and PG 25 are combined to form di-tert-butylsilyl.
- a reagent which produces fluoride ions for its removal specifically tetrabutylammonium fluoride.
- the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents, and amide solvents, and THF is preferably used.
- Steps 6A and 6B of Scheme 2 are steps of phosphating a compound represented by the formula H2A or H2B and then oxidizing the compound to obtain a compound represented by the formula I2A or I2B.
- the phosphite esterification is carried out by reacting the reaction mixture in the presence of a phosphite esterification reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 minutes. It can be performed by stirring for a time.
- the oxidation can be carried out by stirring the reaction mixture in the presence of an oxidizing reagent in a solvent at a temperature from ⁇ 20° C.
- PG 27 is a protective group for a hydroxyl group, and any protective group can be used as long as it does not interfere with the progress of the reaction according to the above Scheme 2, PG 21 , PG 22 , and PG.
- a protecting group capable of being deprotected simultaneously with 23 is preferable.
- Specific examples of PG 27 include benzyl.
- a phosphite esterification reagent having a hydroxyl group protected by a protecting group may be used, or an unprotected phosphite esterification reagent may be used and then a protecting group may be introduced into the hydroxyl group.
- a protecting group for example, the method described in “Greene's, “Protective Groups in Organic Synthesis” (5th edition, John Wiley & Sons 2014)” can be used.
- dibenzyl N,N-diisopropylphosphoramidite is preferably used as the phosphite esterification reagent.
- the oxidizing agent used for the oxidation subsequent to phosphite esterification is not particularly limited, but Dess-Martin periodinane can be preferably used.
- the solvent include a halogenated solvent, an ether solvent, a benzene solvent, an ester solvent, a ketone solvent, and a nitrile solvent, and acetonitrile is preferably used.
- Steps 7A and 7B of Scheme 2 include removing PG 21 , PG 22 , PG 23 , and PG 27 from the compound represented by I2A, or PG 21 , PG 23 , and PG 27 is removed to obtain a compound represented by the formula J2.
- the reaction mixture is stirred in the presence of a deprotecting reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 hours. You can do that.
- Any method can be used for deprotection as long as the above protecting groups can be selectively removed. Specific examples of such a method include catalytic hydrogenation.
- a Pd-based catalyst such as palladium/carbon
- the solvent include water, alcohol solvents, halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents, nitrile solvents, amine solvents, and a mixture of water and methanol.
- a solvent can be preferably used.
- Step 8 of Scheme 2 is a step of removing PG 26 from the compound represented by the formula J2 to obtain the compound represented by the formula A.
- PG 26 is removed by stirring the reaction mixture in the presence of a deprotecting reagent in a solvent at a temperature from ⁇ 20° C. to around the boiling point of the solvent, preferably at a temperature from 0° C. to 180° C. for 15 minutes to 48 hours. Can be done at.
- a deprotecting reagent any reagent can be used as long as PG 26 can be selectively removed, and hydrochloric acid can be preferably used.
- the solvent examples include water, a halogenated solvent, an ether solvent, a benzene solvent, an ester solvent, a ketone solvent, and a nitrile solvent, and water can be preferably used. All prior art documents cited in the present specification are incorporated herein by reference.
- Lysidine diphosphate was synthesized for introducing a Lysidine unit at the 3'end of a tRNA fragment by the ligation method. That is, Lysidine-diphosphate (SS04, pLp) was synthesized according to the following scheme.
- reaction solution was concentrated, and the residue was purified by reverse-phase silica gel column chromatography (0.05% TFA aqueous solution/0.05% TFA acetonitrile solution), methyl N2-(((9H-fluoren-9-yl)methoxy).
- Hydrogen fluoride pyridine complex ( ⁇ 30% pyridine, ⁇ 70% hydrogen fluoride) (9.85 ⁇ l) diluted with pyridine (134.41 ⁇ l) was added at -80°C, and the reaction mixture was added at -15°C for 15 minutes. It was stirred. After cooling to ⁇ 80° C., methoxytrimethylsilane (7.0 ml) was added, and the obtained mixture was purified by reverse phase silica gel column chromatography (0.05% TFA aqueous solution/0.05% TFA acetonitrile solution). The obtained fraction was neutralized with saturated sodium hydrogen carbonate, and the target compound was extracted with ethyl acetate.
- Example 3 Synthesis of Lysidine-diphosphate for introducing a Lysidine unit at the 3'end of the tRNA fragment by the ligation method
- Alternative method Improved synthesis method of Lysidine diphosphate used for introducing a Lysidine unit at the 3'end of the tRNA fragment by the ligation method did. That is, Lysidine-diphosphate (SS04, pLp) was synthesized according to the following scheme.
- (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-hydroxy-5-( Benzyl (hydroxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]hexanoate (Compound SS29) (21.51 mg, 0.026 mmol) and 1H-tetrazole (22.
- the mixture was stirred under a hydrogen atmosphere at room temperature for 18 hours.
- the reaction solution was filtered through Celite and washed several times with ultrapure water.
- 1 mol/L hydrochloric acid (2.74 mL, 2.74 mmol) was added to the obtained filtrate (24.66 mL), and the mixture was allowed to stand at room temperature for 1 hour.
- the reaction solution was filtered through Celite and washed several times with ultrapure water.
- LCMS (ESI) m/z 530.1 (MH)- Retention time: 1.60 minutes (Analysis condition LTQTEA/HFIP05_02)
- the column is exchanged between the analysis of the compound SS04 synthesized in Example 2 and the analysis of the compound SS04 synthesized in Example 3.
- the compound SS04 synthesized in Example 2 was analyzed again after the column was exchanged, and it was confirmed to be the same as the compound SS04 synthesized in Example 3. The results are shown below.
- LCMS (ESI) m/z 530.1 (MH)- Retention time: 1.60 minutes (Analysis condition LTQTEA/HFIP05_02)
- Example 4 Synthesis of Agmatidine-diphosphate for introducing Agmatidine unit into 3'end of tRNA fragment by ligation method
- diphosphate of Agmatidine was synthesized. That is, Agmatidine-diphosphate (SS31, p(Agm)p) was synthesized according to the following scheme.
- tetrabutylammonium fluoride ( ⁇ 1 mol/L tetrahydrofuran solution) (638 ⁇ L, ⁇ 0.638 mmol) was added.
- DMSO DMSO was added to the reaction solution and the mixture was concentrated to remove THF.
- the mixture was stirred under a hydrogen atmosphere at room temperature for 7 hours.
- the reaction solution was filtered through Celite and washed several times with ultrapure water.
- 1 mol/L hydrochloric acid (2.78 mL, 2.78 mmol) was added to the obtained filtrate (25 mL), and the mixture was left standing at room temperature for 45 minutes.
- the powder obtained after freeze-drying the reaction solution was dissolved with ultrapure water, filtered through Celite, and washed several times with ultrapure water.
- the buffer solution A was prepared as follows. Acetic acid was added to an aqueous solution of N,N,N-trimethylhexadecane-1-aminium chloride (6.40 g, 20 mmol) and imidazole (6.81 g, 100 mmol) to obtain pH 8, 20 mM N,N,N-trimethylhexadecane- A buffer solution A (1 L) of 1-aminium and 100 mM imidazole was obtained.
- Trifluoroacetic acid (2.3 mL) was added to the reaction solution.
- the reaction solution was freeze-dried and then purified by reverse-phase silica gel column chromatography (0.05% trifluoroacetic acid aqueous solution/0.05% trifluoroacetic acid acetonitrile) to give the title compound (Compound SS39, F-Pnaz-F3Cl).
- -PCpA (25.3 mg, 1%) was obtained.
- LCMS(ESI) m/z 1117.4 (MH)- Retention time: 0.55 minutes (Analysis condition SQDFA05_01)
- N-(((4-(2-(4-fluorophenyl)acetamido)benzyl)oxy)carbonyl)-O-isopentyl-L-serine compound SS43, F-Pnaz-SiPen-OH
- DIPEA N-ethyl-isopropylpropan-2-amine
- Trifluoroacetic acid (2.3 mL) was added to the reaction solution.
- the reaction solution was freeze-dried and then purified by reverse-phase silica gel column chromatography (0.05% trifluoroacetic acid aqueous solution/0.05% trifluoroacetic acid acetonitrile) to give the title compound (Compound SS40, F-Pnaz-SiPen).
- -PCpA (39.5 mg, 3%) was obtained.
- LCMS (ESI) m/z 1093.5 (MH)- Retention time: 0.55 minutes (Analysis condition SQDFA05_01)
- Ethyl acetate (50 mL) and 0.05M aqueous phosphoric acid solution (140 mL) of pH 2.1 were added to the obtained total amount of sodium salt of Fmoc-Thr(THP)-OH, and the mixture was stirred at 25° C. for 5 minutes. The organic layer and the aqueous layer were separated. Ethyl acetate (50 mL) was added to the aqueous layer for extraction, then all the obtained organic layers were mixed and washed twice with a saturated aqueous sodium chloride solution (50 mL). The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was dried under reduced pressure by a pump at 25° C.
- Fukuc-Ala-OH-supported 2-kuguchiguchi lysyl resin (100 mg) was used, and Fmoc-Gly-OH, Fmoc-Thr(THP)-OH, Fmoc-Ile-OH, and Fmoc-Phe- were used as Fmoc amino acids.
- the peptide was extended using OH and Fmoc-Pro-OH on a peptide synthesizer (abbreviations of amino acids are described separately in this specification).
- the peptide was extended according to the peptide synthesis method by the Fmoc method (WO2013100132B2).
- the N-terminal Fmoc group was removed on a peptide synthesizer, and the resin was washed with DCM.
- TFE/DCM (1:1, v/v, 2 mL) was added to the resin, and the mixture was shaken for 1 hour to cut out the peptide from the resin.
- the resin in the tube was filtered through a synthesis column to remove the resin, and the resin was washed twice with TFE/DCM (1:1, v/v, 1 mL). All the extracts were mixed, DMF (2 mL) was added, and the mixture was concentrated under reduced pressure.
- Example 9 Preparation of tRNA-CA by ligation reaction
- the tRNA 5′ fragment, pNp (pUp, pLp, or p(Agm)p), and the tRNA 3′ fragment were ligated using the ligation reaction by the procedure described below.
- Various tRNA-CA were prepared.
- a chemically synthesized product (Gene Design Co., Ltd.) was used as the tRNA5′ fragment and the tRNA3′ fragment.
- Table 4 The combinations of each tRNA fragment and the full-length sequence and the sample used for ligation
- SEQ ID NO: 54 (FR-1) tRNA(Glu) 5'RNA sequence GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU SEQ ID NO: 55 (FR-2) tRNA(Glu) 3'ga RNA sequence GA ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC SEQ ID NO: 56 (UR-1) lig-tRNA(Glu)uga-CA RNA sequence GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU UGA ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC SEQ ID NO: 57 (LR-1) tRNA(Glu)Lga-CA RNA sequence GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU LGA ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC SEQ ID NO: 58 (FR-3) tRNA(Glu) 3'ag RNA sequence AG ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC SEQ
- sodium periodate NaIO 4
- the cleavage reaction was carried out by allowing to stand on ice for 30 minutes in the dark. After the reaction, 1/10 volume of 100 mM glucose was added, and the mixture was allowed to stand in the dark for 30 minutes on ice to decompose excess sodium periodate. The reaction product was recovered by ethanol precipitation.
- T4 PNK T4 polynucleotide kinase treatment was performed to phosphorylate the 5'end and dephosphorylate the 3'end of the ligation product.
- a ligation reaction was performed between the reaction product after PNK treatment and the tRNA 3′ fragment.
- the reaction product after treatment with 10 ⁇ M PNK, 10 ⁇ M tRNA3′ fragment, 50 mM HEPES-KOH (pH 7.5), and a solution of 15 mM MgCl 2 were heated at 65° C. for 7 minutes, and then at room temperature for 30 minutes.
- the reaction product after PNK treatment and the tRNA 3′ fragment were annealed by leaving them to stand for 1 hour.
- T4 PNK treatment was performed to phosphorylate the 5'end of the tRNA 3'fragment.
- T4 PNK treatment For T4 PNK treatment, add DTT (final concentration 3.5 mM), ATP (final concentration 300 ⁇ M), and T4 PNK (final concentration 0.5 U/ ⁇ L) to the annealed solution, and leave at 37°C for 30 minutes. I went by a thing. Subsequently, T4 RNA ligase (New England Biolabs) was added to this solution to a final concentration of 0.9 U/ ⁇ L, and the mixture was allowed to stand at 37° C. for 30 to 40 minutes to carry out a ligation reaction. The ligation product was extracted with phenol/chloroform and recovered by ethanol precipitation.
- DTT final concentration 3.5 mM
- ATP final concentration 300 ⁇ M
- T4 PNK final concentration 0.5 U/ ⁇ L
- the tRNA-CA produced by the ligation method was subjected to preparative purification by high-speed reverse phase chromatography (HPLC) (15 mM TEA and 400 mM HFIP aqueous solution/15 mM TEA and 400 mM HFIP methanol solution), and then denatured urea 10% It was confirmed by polyacrylamide electrophoresis that it had the desired length.
- HPLC reverse phase chromatography
- Example 10 Analysis of tRNA Fragment Cleaved by RNaseT 1
- Various tRNA-CA prepared by utilizing ligation reaction were fragmented and analyzed by RNase to analyze pUp, pLp, or U, L introduced at p(Agm)p. , Or (Agm) was confirmed to be introduced into each target site.
- Table 5 shows the combination of the sequence number of each tRNA-CA and the sequence of the RNA fragment containing U, L, or (Agm) introduced by pUp, pLp, or p(Agm)p.
- RNA 3′ of G base was made by The reaction solution containing 10 ⁇ M tRNA-CA, 5 U/ ⁇ L RNaseT 1 (Epicentre or ThermoFisher Scientific), and 10 mM ammonium acetate (pH 5.3) was allowed to stand at 37°C for 1 hour to make RNA 3′ of G base.
- CCCU L ACACGp (SEQ ID NO: 197)
- LCMS(ESI) m/z 1642 ((M-2H)/2)- Retention time: 5.78 minutes (Analysis condition LTQTEA/HFIP05_03)
- CCCUACACGp fragment expected when pLp was not ligated
- Uridine was present instead of Lysidine
- CCCU U ACACGp/SEQ ID NO: 198 It was confirmed that the ligation of partial pLp proceeded (Fig. 4).
- CCCU (Agm) AGp LCMS(ESI) m/z 1164 ((M-2H)/2)- Retention time: 4.02 minutes (Analysis condition LTQTEA/HFIP05_03) Compared with the mass chromatograms of the fragment (CCCUAGp) that is expected when p(Agm)p is not ligated and the fragment (CCCUUAGp) that is expected when Uridine is contained in place of Agmatidine, most of p(Agm)p It was confirmed that the ligation of Agm)p proceeded (Fig. 10).
- Example 11 Synthetic template DNA for aminoacyl-tRNA (SEQ ID NO: 64 (D-1) to SEQ ID NO: 76 (D-13), SEQ ID NO: 143 (D-26) to SEQ ID NO: 152 (D-35)) From an in vitro transcription reaction using T7 RNA polymerase (SEQ ID NO: 77 (TR-1) to SEQ ID NO: 89 (TR-13), SEQ ID NO: 153 (TR-14) to SEQ ID NO: 162 ( TR-23)) was synthesized and purified by RNeasy kit (Qiagen).
- tRNA SEQ ID NO: 77 (TR-1) tRNA(Glu)aga-CA RNA sequence: GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU AGA ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC tRNA SEQ ID NO: 78 (TR-2) tRNA(Glu)uga-CA RNA sequence: GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU UGA ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC tRNA SEQ ID NO: 79 (TR-3) tRNA(Glu)cga-CA RNA sequence: GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU CGA ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC tRNA SEQ ID NO: 80 (TR-4) tRNA(Glu)aag-CA RNA sequence: GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU AAG ACGGCGGUAACA
- aminoacyl-tRNA mixed solution using aminoacyl-pCpA 25 ⁇ M transcribed tRNA(Glu)aga-CA (SEQ ID NO: 77 (TR-1)), 50 mM HEPES-KOH pH 7.5, 20 mM MgCl 2 , 1 mM ATP, 0.6 unit / ⁇ l T4 RNA ligase (New england bio lab.), 0.25 mM aminoacylated pCpA (DMSO solution of compound TS24 synthesized by the method described in Patent Document (WO2018143145A1)) was added with Nuclease free water. A reaction solution was prepared and a ligation reaction was performed at 15°C for 45 minutes.
- reaction solution before addition of T4 RNA ligase and aminoacylated pCpA was heated at 95° C. for 2 minutes and then left at room temperature for 5 minutes to refold tRNA in advance.
- Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform to prepare the compound AAtR-1.
- the transcribed tRNA(Glu)uga-CA SEQ ID NO: 78 (TR-2) was subjected to ligation reaction with aminoacylated pCpA (SS15) by the method described above.
- lig-tRNA(Glu)uga-CA SEQ ID NO: 56 (UR-1) was subjected to ligation reaction with aminoacylated pCpA (SS15) by the method described above.
- Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform to prepare the compound AAtR-3.
- tRNA(Glu)Lga-CA (SEQ ID NO: 57 (LR-1)) was subjected to ligation reaction with aminoacylated pCpA (SS15) by the method described above.
- Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform to prepare the compound AAtR-4.
- the transcribed tRNA(Glu)cga-CA (SEQ ID NO: 79 (TR-3)) is ligated with aminoacylated pCpA (ts14; synthesized by the method described in Patent Document (WO2018143145A1)) by the method described above.
- the reaction was carried out.
- Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M and phenol/chloroform extraction was performed to prepare a compound AAtR-5.
- RNA(Glu)aag-CA 25 ⁇ M transcribed tRNA(Glu)aag-CA (SEQ ID NO: 80 (TR-4)), 50 mM HEPES-KOH pH 7.5, 20 mM MgCl 2 , 1 mM ATP, 0.6 unit/ ⁇ l T4 RNA ligase (New england bio lab. Co., Ltd.) to prepare 0.25 mM aminoacylated pCpA (DMSO solution of ts14), and a reaction solution prepared with Nuclease free water was prepared, and ligation reaction was carried out at 15° C. for 45 minutes. However, the reaction solution before addition of T4 RNA ligase and aminoacylated pCpA was heated at 95° C.
- RNA(Glu)uag-CA SEQ ID NO: 81 (TR-5)
- SS14 aminoacylated pCpA
- tRNA(Glu)Lag-CA (SEQ ID NO: 59 (LR-2) was subjected to ligation reaction with aminoacylated pCpA (SS14) by the method described above. Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform to prepare the compound AAtR-8.
- the transcribed tRNA(Glu)cag-CA SEQ ID NO: 82 (TR-6)
- Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform to prepare the compound AAtR-9.
- RNA(Glu)aac-CA 25 ⁇ M transcribed tRNA(Glu)aac-CA (SEQ ID NO: 83 (TR-7)), 50 mM HEPES-KOH pH 7.5, 20 mM MgCl 2 , 1 mM ATP, 0.6 unit/ ⁇ l T4 RNA ligase (New england bio lab. Co., Ltd.) to prepare 0.25 mM aminoacylated pCpA (ts14 in DMSO), and a reaction solution prepared with Nuclease free water was prepared, and ligation reaction was carried out at 15° C. for 45 minutes. However, the reaction solution before addition of T4 RNA ligase and aminoacylated pCpA was heated at 95° C.
- RNA(Glu)uac-CA SEQ ID NO: 84 (TR-8) was subjected to ligation reaction with aminoacylated pCpA (SS14) by the method described above.
- SS14 aminoacylated pCpA
- aminoacylated pCpA (SS14) was ligated to tRNA(Glu)Lac-CA (SEQ ID NO: 61 (LR-3)) by the method described above. Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform to prepare the compound AAtR-12.
- the transcribed tRNA(Glu)cac-CA (SEQ ID NO: 85 (TR-9) was subjected to ligation reaction with aminoacylated pCpA (TS24) by the method described above. Sodium acetate was added to the ligation reaction solution so as to have a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform to prepare a compound AAtR-13.
- RNA(Glu)gcc-CA 25 ⁇ M transcribed tRNA(Glu)gcc-CA (SEQ ID NO: 86 (TR-10)), 50 mM HEPES-KOH pH 7.5, 20 mM MgCl 2 , 1 mM ATP, 0.6 unit/ ⁇ l T4 RNA ligase (New england bio lab. Co., Ltd.) to prepare 0.25 mM aminoacylated pCpA (DMSO solution of TS24), and a reaction solution prepared with Nuclease free water was prepared, and ligation reaction was carried out at 15° C. for 45 minutes. However, the reaction solution before addition of T4 RNA ligase and aminoacylated pCpA was heated at 95° C.
- RNA(Glu)ucc-CA SEQ ID NO: 87 (TR-11)
- SS14 aminoacylated pCpA
- aminoacylated pCpA (SS14) was subjected to ligation reaction with tRNA(Glu)Lcc-CA (SEQ ID NO: 63 (LR-4)) by the method described above. Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform to prepare the compound AAtR-16.
- the transcribed tRNA(Glu)ccc-CA SEQ ID NO: 88 (TR-12) was subjected to ligation reaction with aminoacylated pCpA (SS16) by the method described above. Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform to prepare the compound AAtR-17.
- Compound AAtR-14, Compound AAtR-15, and Compound AAtR-17 were mixed in 3 types of phenol/chloroform extracts at a ratio of 1:2:1 to prepare an aminoacylated tRNA mixture (compound AAtR-14, compound AAtR-14 A mixed solution of AAtR-15 and compound AAtR-17) was recovered by ethanol precipitation.
- the aminoacylated tRNA mixture was dissolved in 1 mM sodium acetate immediately before being added to the translation mixture.
- reaction solution before addition of T4 RNA ligase and aminoacylated pCpA was heated at 95° C. for 2 minutes and then left at room temperature for 5 minutes to refold tRNA in advance.
- ligation reaction of aminoacylated pCpA (SS15) with transcribed tRNA(Asp)uag-CA (SEQ ID NO: 154 (TR-15)) by the method described above. went.
- ligation reaction of tRNA(Asp)Lag-CA (SEQ ID NO: 134(LR-5)) with aminoacylated pCpA(SS15) was carried out by the method described above.
- the aminoacylated pCpA (TS24) was ligated to the transcribed tRNA(Asp)cag-CA (SEQ ID NO: 155 (TR-16)) by the method described above. went. After 0.3M sodium acetate was added to the solution after each ligation reaction, each ligation product was mixed at the stage where the phenol/chloroform solution was added, and the mixture was subjected to phenol/chloroform extraction and ethanol precipitation to recover. did.
- 0.3M sodium acetate was added to the three types of ligation products of compound AAtR-19, compound AAtR-20, and compound AAtR-22, and a solution of phenol/chloroform solution was mixed in equal amounts to obtain phenol.
- Chloroform extraction and ethanol precipitation were performed to prepare an aminoacylated tRNA mixed solution (mixed solution of compound AAtR-19, compound AAtR-20, compound AAtR-22).
- 0.3M sodium acetate was added to the three kinds of ligation products of compound AAtR-19, compound AAtR-21, and compound AAtR-22, and a solution of phenol/chloroform solution was mixed in equal amounts to prepare phenol/chloroform.
- Extraction and ethanol precipitation were performed to prepare an aminoacylated tRNA mixed solution (mixed solution of compound AAtR-19, compound AAtR-21, compound AAtR-22).
- reaction solution before addition of T4 RNA ligase and aminoacylated pCpA was heated at 95° C. for 2 minutes and then left at room temperature for 5 minutes to refold tRNA in advance.
- ligation reaction of the aminoacylated pCpA (SS15) with the transcribed tRNA(AsnE2)uag-CA (SEQ ID NO: 157 (TR-18)) by the method described above. went.
- ligation reaction of tRNA(AsnE2)Lag-CA (SEQ ID NO: 137(LR-6)) with aminoacylated pCpA(SS15) was carried out by the method described above. It was Similarly, in order to prepare the compound AAtR-26, the aminoacylated pCpA (TS24) was ligated to the transcribed tRNA(AsnE2)cag-CA (SEQ ID NO: 158 (TR-19)) by the method described above. went.
- each ligation product was mixed at the stage where the phenol/chloroform solution was added, and the mixture was subjected to phenol/chloroform extraction and ethanol precipitation to recover. did.
- 0.3M sodium acetate was added to the three kinds of ligation products of compound AAtR-23, compound AAtR-24, and compound AAtR-26, and a solution of phenol/chloroform solution was mixed in equal amounts to obtain phenol.
- Chloroform extraction and ethanol precipitation were performed to prepare an aminoacylated tRNA mixed solution (mixed solution of compound AAtR-23, compound AAtR-24 and compound AAtR-26).
- reaction solution prepared by a Nuclease free water was prepared so as to obtain ⁇ l T4 RNA ligase (New england bio lab.) and 0.25 mM aminoacylated pCpA (DMSO solution of ts14), and ligation reaction was performed at 15° C. for 45 minutes. I went.
- reaction solution before addition of T4 RNA ligase and aminoacylated pCpA was heated at 95° C. for 2 minutes and then left at room temperature for 5 minutes to refold tRNA in advance.
- ligation reaction of aminoacylated pCpA (TS24) with the transcribed tRNA(Glu)cag-CA (SEQ ID NO: 82 (TR-6)) was carried out by the method described above. went.
- the aminoacylated pCpA (SS16) was ligated to the transcribed tRNA(Glu)uag-CA (SEQ ID NO: 81 (TR-5)) by the method described above. went.
- ligation reaction of tRNA(Glu)Lag-CA (SEQ ID NO: 59 (LR-2)) with aminoacylated pCpA (SS16) was carried out by the method described above.
- each ligation product was mixed at the stage of adding the phenol/chloroform solution, and the mixture of the ligation products or the phenol/chloroform solution was mixed in a single state. Chloroform extraction and ethanol precipitation were performed and it collect
- Chloroform extraction and ethanol precipitation were carried out to prepare an aminoacylated tRNA mixed solution (mixed solution of compound AAtR-6, compound AAtR-27, compound AAtR-9).
- 0.3M sodium acetate was added to the three types of ligation products of compound AAtR-6, compound AAtR-28, and compound AAtR-9, and a solution of phenol/chloroform solution was mixed in equal amounts to prepare phenol/chloroform.
- Extraction and ethanol precipitation were performed to prepare an aminoacylated tRNA mixed solution (mixed solution of compound AAtR-6, compound AAtR-28, compound AAtR-9).
- 0.3 M sodium acetate was added to the ligation product of the compound AAtR-9, and a solution containing a phenol/chloroform solution was subjected to phenol/chloroform extraction and ethanol precipitation to prepare an aminoacylated tRNA.
- compound AAtR-33 25 ⁇ M transcribed tRNA(Glu)gcg-CA (SEQ ID NO: 159(TR-20)), 50 mM HEPES-KOH pH 7.5, 20 mM MgCl 2 , 1 mM ATP, 0.6 unit/ ⁇ l T4 RNA ligase (New england bio lab.), 0.25 mM aminoacylated pCpA (DMSO solution of compound TS24 synthesized by the method described in the patent (WO2018143145A1)) was added to the reaction solution with Nuclease free water. Was prepared and a ligation reaction was carried out at 15° C. for 45 minutes.
- reaction solution before addition of T4 RNA ligase and aminoacylated pCpA was heated at 95° C. for 2 minutes and then left at room temperature for 5 minutes to refold tRNA in advance.
- ligation reaction of tRNA(Glu)Lcg-CA (SEQ ID NO: 140 (LR-7)) with aminoacylated pCpA (SS14) was carried out by the method described above.
- ligation reaction of aminoacylated pCpA(ts14) with transcribed tRNA(Glu)ccg-CA SEQ ID NO: 160 (TR-21)
- the aminoacylated pCpA (TS24) was ligated to the transcribed tRNA(Glu)cau-CA (SEQ ID NO: 162 (TR-23)) by the method described above. went. After 0.3M sodium acetate was added to the solution after each ligation reaction, each ligation product was mixed at the stage of adding the phenol/chloroform solution, and the mixture of the ligation products or the phenol/chloroform solution was mixed in a single state. Chloroform extraction and ethanol precipitation were performed and it collect
- 0.3M sodium acetate was added to two kinds of ligation products of compound AAtR-33 and compound AAtR-35, and a solution of phenol/chloroform solution was mixed in equal amounts, and extracted with phenol/chloroform and ethanol. Precipitation was performed to prepare an aminoacylated tRNA mixed solution (mixed solution of compound AAtR-33 and compound AAtR-35).
- 0.3M sodium acetate was added to the two kinds of ligation products of compound AAtR-36 and compound AAtR-38, and a solution of phenol/chloroform solution was mixed in equal amounts to perform phenol/chloroform extraction and ethanol precipitation.
- aminoacylated tRNA mixed solution (mixed solution of compound AAtR-36 and compound AAtR-38) was prepared.
- 0.3 M sodium acetate was added to each ligation product of compound AAtR-34 and compound AAtR-37, and a solution containing a phenol/chloroform solution was subjected to phenol/chloroform extraction and ethanol precipitation to prepare aminoacylated tRNA.
- the transcribed tRNA(Glu)aag-CA (SEQ ID NO: 80(TR-4)) was ligated with aminoacylated pCpA(ts14) by the method described above.
- a ligation reaction was performed on the transcribed tRNA(Glu)uag-CA (SEQ ID NO: 81 (TR-5)) with aminoacylated pCpA (SS15) by the method described above.
- the aminoacylated pCpA (SS15) was ligated to tRNA(Glu)(Agm)ag-CA (SEQ ID NO: 138(AR-1)) by the method described above. The reaction was carried out. After 0.3 M sodium acetate was added to the solution after each ligation reaction, a phenol/chloroform solution was added, and then phenol/chloroform extraction and ethanol precipitation were performed to recover.
- reaction solution before addition of T4 RNA ligase and aminoacylated pCpA was heated at 95° C. for 2 minutes and then left at room temperature for 5 minutes to refold tRNA in advance.
- Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and the mixture was extracted with phenol/chloroform, and the initiator aminoacyl-tRNA (Compound AAtR-18) was recovered by ethanol precipitation.
- the initiator aminoacylated tRNA was dissolved in 1 mM sodium acetate immediately before addition to the translation mixture.
- a template mRNA containing any one of three types of codons in the same codon box and having the same sequence except the above is an aminoacylated tRNA mixture containing no Lysine modified tRNA (compound AAtR-1, compound AAtR-2, compound AAtR-5 mixture, compound AAtR-1, compound AAtR-3, compound AAtR-5).
- the translation system used was PURE system, which is a prokaryote-derived reconstituted cell-free protein synthesis system. Specifically, a translation solution (1 mM GTP, 1 mM ATP, 20 mM creatine phosphate, 50 mM HEPES-KOH pH 7.6, 100 mM potassium acetate, 10 mM magnesium acetate, 2 mM spermidine, 1 mM dithiothreitol, 1.5 mg/ml E. E.
- coli MRE600 RNase negative derived tRNA (Roche), 0.26 ⁇ M EF-G, 0.24 ⁇ M RF2, 0.17 ⁇ M RF3, 0.5 ⁇ M RRF, 4 ⁇ g/ml creatine kinase, 3 ⁇ g/ml myokinase, 2 unit/ml inorganic Pyrophosphatase, 1.1 ⁇ g/ml nucleoside diphosphate kinase, 2.7 ⁇ M IF1, 0.4 ⁇ M IF2, 1.5 ⁇ M IF3, 40 ⁇ M EF-Tu, 54 ⁇ M EF-Ts, 1 ⁇ M EF-P-Lys, 0.4 unit/ 1 ⁇ M template for ⁇ l RNasein Ribonuclease inhibitor (Promega, N2111), 1.2 ⁇ M ribosome, 0.5 mM PGA, 0.09 ⁇ M GlyRS, 0.4 ⁇ M IleRS, 0.68 ⁇ M PheRS, 0.16
- an initiator aminoacylated tRNA (compound AAtR-18) at 10 ⁇ M
- an aminoacylated tRNA mixed solution (compound AAtR-1, compound AAtR-2, compound AAtR-5 mixed solution, compound AAtR-1, compound AAtR-3, A mixture of compound AAtR-5 or a mixture of compound AAtR-1, compound AAtR-4, compound AAtR-5) is added to the translation reaction mixture at 30 ⁇ M, and the mixture is allowed to stand at 37° C. for 1 hour. went.
- a translation solution (1 mM GTP, 1 mM ATP, 20 mM creatine phosphate, 50 mM HEPES-KOH pH 7.6, 100 mM potassium acetate, 10 mM magnesium acetate, 2 mM spermidine, 1 mM dithiothreitol, 1.5 mg/ml E.
- coli MRE600 RNase negative-derived tRNA (Roche), 0.26 ⁇ M EF-G, 0.24 ⁇ M RF2, 0.17 ⁇ M RF3, 0.5 ⁇ M RRF, 4 ⁇ g/ml creatine kinase, 3 ⁇ g/ml myokinase, 2 unit/ml inorganic Pyrophosphatase, 1.1 ⁇ g/ml nucleoside diphosphate kinase, 2.7 ⁇ M IF1, 0.4 ⁇ M IF2, 1.5 ⁇ M IF3, 40 ⁇ M EF-Tu, 35 ⁇ M EF-Ts, 1 ⁇ M EF-P-Lys, 0.4 unit/ ⁇ l RNasein Ribonuclease inhibitor (Promega, N2111), 1.2 ⁇ M ribosome, 0.5 mM PGA, 0.09 ⁇ M GlyRS, 0.4 ⁇ M IleRS, 0.68 ⁇ M PheRS, 0.16 ⁇ M ProRS,
- a translation solution (1 mM GTP, 1 mM ATP, 20 mM creatine phosphate, 50 mM HEPES-KOH pH 7.6, 100 mM potassium acetate, 10 mM magnesium acetate, 2 mM spermidine, 1 mM dithiothreitol, 1.5 mg/ml E.
- coli MRE600 RNase negative-derived tRNA (Roche), 0.26 ⁇ M EF-G, 0.24 ⁇ M RF2, 0.17 ⁇ M RF3, 0.5 ⁇ M RRF, 4 ⁇ g/ml creatine kinase, 3 ⁇ g/ml myokinase, 2 unit/ml inorganic Pyrophosphatase, 1.1 ⁇ g/ml nucleoside diphosphate kinase, 2.7 ⁇ M IF1, 0.4 ⁇ M IF2, 1.5 ⁇ M IF3, 40 ⁇ M EF-Tu, 35 ⁇ M EF-Ts, 1 ⁇ M EF-P-Lys, 0.4 unit/ ⁇ l RNasein Ribonuclease inhibitor (Promega, N2111), 1.2 ⁇ M ribosome, 0.5 mM PGA, 0.09 ⁇ M GlyRS, 0.4 ⁇ M IleRS, 0.68 ⁇ M PheRS, 0.16 ⁇ M ProRS,
- a translation solution (1 mM GTP, 1 mM ATP, 20 mM creatine phosphate, 50 mM HEPES-KOH pH 7.6, 100 mM potassium acetate, 10 mM magnesium acetate, 2 mM spermidine, 1 mM dithiothreitol, 1.5 mg/ml E.
- coli MRE600 RNase negative-derived tRNA (Roche), 0.26 ⁇ M EF-G, 0.24 ⁇ M RF2, 0.17 ⁇ M RF3, 0.5 ⁇ M RRF, 4 ⁇ g/ml creatine kinase, 3 ⁇ g/ml myokinase, 2 unit/ml inorganic Pyrophosphatase, 1.1 ⁇ g/ml nucleoside diphosphate kinase, 2.7 ⁇ M IF1, 0.4 ⁇ M IF2, 1.5 ⁇ M IF3, 40 ⁇ M EF-Tu, 54 ⁇ M EF-Ts, 1 ⁇ M EF-P-Lys, 0.4 unit/ 1 ⁇ M template for ⁇ l RNase in Ribonuclease inhibitor (Promega, N2111), 1.2 ⁇ M ribosome, 0.5 mM PGA, 0.4 ⁇ M IleRS, 0.04 ⁇ M LeuRS, 0.68 ⁇ M PheRS, 0.16
- a template mRNA containing any one of three types of codons within the same codon box and having the same sequence except the above is a mixture of aminoacylated tRNA containing no Lysidine modified tRNA (compound AAtR-19, compound AAtR-20, compound AAtR-22, compound AAtR-23).
- a compound AAtR-24, a compound AAtR-26 mixed solution, or an aminoacylated tRNA mixed solution containing a Lysidine-modified tRNA (compound AAtR-19, compound AAtR-21, compound AAtR-22 mixed solution, compound AAtR-23 , A mixture of Compound AAtR-25 and Compound AAtR-26) was used to translate and synthesize a peptide compound.
- the translation system used was PURE system, which is a prokaryote-derived reconstituted cell-free protein synthesis system. Specifically, a translation solution (1 mM GTP, 1 mM ATP, 20 mM creatine phosphate, 50 mM HEPES-KOH pH 7.6, 100 mM potassium acetate, 10 mM magnesium acetate, 2 mM spermidine, 1 mM dithiothreitol, 1.5 mg/ml E. E.
- coli MRE600 RNase negative derived tRNA (Roche), 0.26 ⁇ M EF-G, 0.24 ⁇ M RF2, 0.17 ⁇ M RF3, 0.5 ⁇ M RRF, 4 ⁇ g/ml creatine kinase, 3 ⁇ g/ml myokinase, 2 unit/ml inorganic Pyrophosphatase, 1.1 ⁇ g/ml nucleoside diphosphate kinase, 2.7 ⁇ M IF1, 0.4 ⁇ M IF2, 1.5 ⁇ M IF3, 40 ⁇ M EF-Tu, 54 ⁇ M EF-Ts, 1 ⁇ M EF-P-Lys, 0.4 unit/ 1 ⁇ M template for ⁇ l RNasein Ribonuclease inhibitor (Promega, N2111), 1.2 ⁇ M ribosome, 0.5 mM PGA, 0.09 ⁇ M GlyRS, 0.4 ⁇ M IleRS, 0.68 ⁇ M PheRS, 0.16
- an initiator aminoacylated tRNA (compound AAtR-18) at 10 ⁇ M
- the template mRNA, the expected translated peptide compound, and its molecular weight (calculated value) are shown in Table 7 below.
- amino acids other than those aminoacylated in the Lysidine modified tRNA in the previous section were aminoacylated in the Lysidine modified tRNA, and in the situation where three kinds of aminoacylated tRNA were present, the reading distinction of three kinds of amino acids in one codon box was confirmed. A translation experiment was conducted to achieve this.
- a template mRNA containing any one of three types of codons in the same codon box and having the same sequence except the above is a mixture of aminoacylated tRNA containing no Lysidine modified tRNA (compound AAtR-6, compound AAtR-27, compound AAtR-9, compound AAtR-6).
- the translation system used was PURE system, which is a prokaryote-derived reconstituted cell-free protein synthesis system. Specifically, a translation solution (1 mM GTP, 1 mM ATP, 20 mM creatine phosphate, 50 mM HEPES-KOH pH 7.6, 100 mM potassium acetate, 10 mM magnesium acetate, 2 mM spermidine, 1 mM dithiothreitol, 1.5 mg/ml E.
- coli MRE600 RNase negative-derived tRNA (Roche), 0.26 ⁇ M EF-G, 0.24 ⁇ M RF2, 0.17 ⁇ M RF3, 0.5 ⁇ M RRF, 4 ⁇ g/ml creatine kinase, 3 ⁇ g/ml myokinase, 2 unit/ml inorganic Pyrophosphatase, 1.1 ⁇ g/ml nucleoside diphosphate kinase, 2.7 ⁇ M IF1, 0.4 ⁇ M IF2, 1.5 ⁇ M IF3, 40 ⁇ M EF-Tu, 49.3 ⁇ M EF-Ts, 1 ⁇ M EF-P-Lys, 0.
- RNasein Ribonuclease inhibitor Promega, N21111
- 1.2 ⁇ M ribosome 0.5 mM PGA, 0.09 ⁇ M GlyRS, 0.4 ⁇ M IleRS, 0.68 ⁇ M PheRS, 0.16 ⁇ M ProRS, 0.09 ⁇ M ThrRS
- 1 ⁇ M template mRNA SEQ ID NO: 123 (mR-4), SEQ ID NO: 124 (mR-5), or SEQ ID NO: 125 (mR-6)
- natural amino acid groups encoded by each template mRNA respectively 0.25 mM
- initiator aminoacylated tRNA compound AAtR-18
- aminoacylated tRNA mixture (compound AAtR-6, compound AAtR-27, compound AAtR-9 mixture, or compound AAtR-6, compound AAtR-28 and a compound AAtR-9 mixture) were added to the translation reaction mixture at 30 ⁇ M, and the mixture was allowed to
- Table 8 shows the template mRNA, the expected translated peptide compound, and its molecular weight (calculated value).
- a template mRNA containing any one of three types of codons in the same codon box and having the same sequence except the above template mRNA sequence number: 169 (mR-13), sequence number: 170 (mR -14), SEQ ID NO: 171 (mR-15), or SEQ ID NO: 172 (mR-16), SEQ ID NO: 173 (mR-17), SEQ ID NO: 174 (mR-18)
- template mRNA sequence number: 169 (mR-13), sequence number: 170 (mR -14), SEQ ID NO: 171 (mR-15), or SEQ ID NO: 172 (mR-16), SEQ ID NO: 173 (mR-17), SEQ ID NO: 174 (mR-18) to Lysine modified tRNA was used for translation, and a mixture of aminoacylated tRNA not containing Lysine modified tRNA was used to translate and synthesize a peptide compound.
- the translation system used was PURE system, which is a prokaryote-derived reconstituted cell-free protein synthesis system. Specifically, a translation solution (1 mM GTP, 1 mM ATP, 20 mM creatine phosphate, 50 mM HEPES-KOH pH 7.6, 100 mM potassium acetate, 10 mM magnesium acetate, 2 mM spermidine, 1 mM dithiothreitol, 1.5 mg/ml E.
- coli MRE600 RNase negative-derived tRNA (Roche), 0.26 ⁇ M EF-G, 0.24 ⁇ M RF2, 0.17 ⁇ M RF3, 0.5 ⁇ M RRF, 4 ⁇ g/ml creatine kinase, 3 ⁇ g/ml myokinase, 2 unit/ml inorganic Pyrophosphatase, 1.1 ⁇ g/ml nucleoside diphosphate kinase, 2.7 ⁇ M IF1, 0.4 ⁇ M IF2, 1.5 ⁇ M IF3, 40 ⁇ M EF-Tu, 49.3 ⁇ M EF-Ts, 1 ⁇ M EF-P-Lys, 0.
- RNasein Ribonuclease inhibitor Promega, N21111, 1.2 ⁇ M ribosome, 0.5 mM PGA, 0.09 ⁇ M GlyRS, 0.4 ⁇ M IleRS, 0.68 ⁇ M PheRS, 0.16 ⁇ M ProRS, 0.09 ⁇ M ThrRS), 1 ⁇ M template mRNA (SEQ ID NO: 169 (mR-13), SEQ ID NO: 170 (mR-14), or SEQ ID NO: 171 (mR-15)), natural amino acid groups encoded by each template mRNA, respectively 0.25 mM, initiator aminoacylated tRNA (compound AAtR-18) 10 ⁇ M, aminoacylated tRNA mixture (compound AAtR-33, compound AAtR-35 mixture) 30 ⁇ M, aminoacylated tRNA (compound AAtR-34) It was added to the translation reaction mixture at 10 ⁇ M and left standing at 37° C.
- the PURE system which is a prokaryotic-derived reconstituted cell-free protein synthesis system, was used. Specifically, a translation solution (1 mM GTP, 1 mM ATP, 20 mM creatine phosphate, 50 mM HEPES-KOH pH 7.6, 100 mM potassium acetate, 10 mM magnesium acetate, 2 mM spermidine, 1 mM dithiothreitol, 1.5 mg/ml E.
- coli MRE600 RNase negative-derived tRNA (Roche), 0.26 ⁇ M EF-G, 0.24 ⁇ M RF2, 0.17 ⁇ M RF3, 0.5 ⁇ M RRF, 4 ⁇ g/ml creatine kinase, 3 ⁇ g/ml myokinase, 2 unit/ml inorganic Pyrophosphatase, 1.1 ⁇ g/ml nucleoside diphosphate kinase, 2.7 ⁇ M IF1, 0.4 ⁇ M IF2, 1.5 ⁇ M IF3, 40 ⁇ M EF-Tu, 49.3 ⁇ M EF-Ts, 1 ⁇ M EF-P-Lys, 0.
- RNasein Ribonuclease inhibitor Promega, N21111
- 1.2 ⁇ M ribosome 0.5 mM PGA, 0.09 ⁇ M GlyRS, 0.4 ⁇ M IleRS, 0.68 ⁇ M PheRS, 0.16 ⁇ M ProRS, 0.09 ⁇ M ThrRS, 0.
- Table 9 shows the template mRNA, the expected translated peptide compound, and its molecular weight (calculated value).
- the translation system used was PURE system, which is a prokaryote-derived reconstituted cell-free protein synthesis system. Specifically, a translation solution (1 mM GTP, 1 mM ATP, 20 mM creatine phosphate, 50 mM HEPES-KOH pH 7.6, 100 mM potassium acetate, 10 mM magnesium acetate, 2 mM spermidine, 1 mM dithiothreitol, 1.5 mg/ml E. E.
- coli MRE600 RNase negative derived tRNA (Roche), 0.26 ⁇ M EF-G, 0.24 ⁇ M RF2, 0.17 ⁇ M RF3, 0.5 ⁇ M RRF, 4 ⁇ g/ml creatine kinase, 3 ⁇ g/ml myokinase, 2 unit/ml inorganic Pyrophosphatase, 1.1 ⁇ g/ml nucleoside diphosphate kinase, 2.7 ⁇ M IF1, 0.4 ⁇ M IF2, 1.5 ⁇ M IF3, 40 ⁇ M EF-Tu, 49.3 ⁇ M EF-Ts, 1 ⁇ M EF-P-Lys, 0.
- RNasein Ribonuclease inhibitor Promega, N2111), 1.2 ⁇ M ribosome, 0.5 mM PGA, 0.09 ⁇ M GlyRS, 0.4 ⁇ M IleRS, 0.68 ⁇ M PheRS, 0.16 ⁇ M ProRS, 0.09 ⁇ M ThrRS), 1 ⁇ M template mRNA (SEQ ID NO: 123 (mR-4), SEQ ID NO: 124 (mR-5), or SEQ ID NO: 125 (mR-6)), natural amino acid group encoded by each template mRNA, respectively 0.25 mM, initiator aminoacylated tRNA (compound AAtR-18) 10 ⁇ M, aminoacylated tRNA mixture (compound AAtR-6, compound AAtR-9 mixture) 30 ⁇ M, aminoacylated tRNA (compound AAtR-39 or compound AAtR-39 or compound) AAtR-40) was added to the translation reaction mixture at 20 ⁇ M, and the
- Table 10 shows the template mRNA, the expected translated peptide compound, and its molecular weight (calculated value).
- RNA sequence GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUU UCU AUUAUUCCGAUUGGUUAAGCUUCG
- mRNA SEQ ID NO: 121 (mR-2) RNA sequence: GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUU UCA AUUAUUCCGAUUGGUUAAGCUUCG
- mRNA SEQ ID NO: 122 (mR-3) RNA sequence: GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUU UCG AUUAUUCCGAUUGGUUAAGCUUCG
- mRNA SEQ ID NO: 123 (mR-4) RNA sequence: GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUU CUUAUUCCGAUUGGUUAAGCUUCG
- Example 13 Analysis of Translated Peptide
- the unnatural peptide translation solution prepared in Example 12 was diluted 10-fold and analyzed using an LC-FLR-MS device. From the analysis data, the retention time of the target translated peptide was identified from the MS data, and the amount of peptide translation was evaluated by quantifying the fluorescence peak at the relevant retention time. In the quantitative evaluation, the LCT12 synthesized in Example 8 was used as a standard to prepare a calibration curve, and the content was calculated by relative quantification.
- the LC-MS was analyzed according to the conditions shown in Table 11 below by selecting the optimum conditions according to the target sample.
- the mutant tRNA of the present disclosure is useful in that it is possible to distinguish the NNA codon and the NNG codon, which are not distinguished in the natural genetic code table.
- the translation system of the present disclosure is useful in that it can translate more types of amino acids (codon extension) than a translation system using a natural genetic code table.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
〔1〕 tRNAを改変することにより作製されている変異tRNAであって、当該改変が、N1N2N3で表されるアンチコドンの改変後の1文字目のヌクレオシドN1がライシジン(k2C)、ライシジン誘導体、アグマチジン(agm2C)、またはアグマチジン誘導体のいずれかである改変を含み、N2およびN3はそれぞれ、該アンチコドンの2文字目および3文字目の任意のヌクレオシドである、変異tRNA。
〔2〕 改変前のN1がシチジン(C)であって、かつ当該シチジン(C)からライシジン(k2C)への改変が、配列番号:51のアミノ酸配列を有するライシジン合成酵素(tRNAIle-lysidine synthetase; TilS)では触媒され得ない、〔1〕に記載の変異tRNA。
〔3〕 改変前のN1がシチジン(C)であって、かつ当該シチジン(C)からアグマチジン(agm2C)への改変が、配列番号:52のアミノ酸配列を有するアグマチジン合成酵素(tRNAIle-agmatidine synthetase; TiaS)では触媒され得ない、〔1〕に記載の変異tRNA。
〔4〕 M1M2Aで表されるコドン(ここで、M1およびM2はそれぞれコドンの1文字目および2文字目のヌクレオシドを表し、M1およびM2はそれぞれアデノシン(A)、グアノシン(G)、シチジン(C)、ウリジン(U)のいずれかから選択され、3文字目のヌクレオシドはアデノシンである)に相補的なアンチコドンを有する、〔1〕から〔3〕のいずれかに記載の変異tRNA。
〔5〕 アンチコドンがk2CN2N3またはagm2CN2N3(ここで、アンチコドンの1文字目のヌクレオシドはライシジン(k2C)またはアグマチジン(agm2C)であり、2文字目のヌクレオシド(N2)、3文字目のヌクレオシド(N3)はそれぞれM2、M1に相補的である)で表される、〔4〕に記載の変異tRNA。
〔6〕 N2およびN3がそれぞれアデノシン(A)、グアノシン(G)、シチジン(C)、ウリジン(U)のいずれかから選択される、〔5〕に記載の変異tRNA。
〔7〕 tRNAが開始tRNAまたは伸長tRNAである、〔1〕から〔6〕のいずれかに記載の変異tRNA。
〔8〕 tRNAが原核または真核生物由来のtRNAである、〔1〕から〔7〕のいずれかに記載の変異tRNA。
〔9〕 天然の遺伝暗号表において、3文字目のヌクレオシドがAであるコドンとGであるコドンがともに同じアミノ酸をコードしているコドンボックスを構成するコドンから、M1およびM2が選択される、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔10〕 天然の遺伝暗号表において、3文字目のヌクレオシドがUであるコドンとAであるコドンがともに同じアミノ酸をコードしているコドンボックスを構成するコドンから、M1およびM2が選択される、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔11〕 天然の遺伝暗号表において、3文字目のヌクレオシドがUであるコドン、Cであるコドン、Aであるコドン、およびGであるコドンがいずれも同じアミノ酸をコードしているコドンボックスを構成するコドンから、M1およびM2が選択される、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔12〕 天然の遺伝暗号表において、3文字目のヌクレオシドがAであるコドンとGであるコドンが互いに異なるアミノ酸をコードしているコドンボックスを構成するコドンから、M1およびM2が選択される、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔13〕 天然の遺伝暗号表において、3文字目のヌクレオシドがAであるコドンおよび/またはGであるコドンが終止コドンであるコドンボックスを構成するコドンから、M1およびM2が選択される、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔14〕 M1がウリジン(U)であり、M2がシチジン(C)である、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔15〕 M1がシチジン(C)であり、M2がウリジン(U)である、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔16〕 M1がシチジン(C)であり、M2がシチジン(C)である、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔17〕 M1がシチジン(C)であり、M2がグアノシン(G)である、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔18〕 M1がアデノシン(A)であり、M2がウリジン(U)である、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔19〕 M1がグアノシン(G)であり、M2がウリジン(U)である、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔20〕 M1がグアノシン(G)であり、M2がシチジン(C)である、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔21〕 M1がグアノシン(G)であり、M2がグアノシン(G)である、〔4〕から〔8〕のいずれかに記載の変異tRNA。
〔22〕 N2がグアノシン(G)であり、N3がアデノシン(A)である、〔14〕に記載の変異tRNA。
〔23〕 N2がアデノシン(A)であり、N3がグアノシン(G)である、〔15〕に記載の変異tRNA。
〔24〕 N2がグアノシン(G)であり、N3がグアノシン(G)である、〔16〕に記載の変異tRNA。
〔25〕 N2がシチジン(C)であり、N3がグアノシン(G)である、〔17〕に記載の変異tRNA。
〔26〕 N2がアデノシン(A)であり、N3がウリジン(U)である、〔18〕に記載の変異tRNA。
〔27〕 N2がアデノシン(A)であり、N3がシチジン(C)である、〔19〕に記載の変異tRNA。
〔28〕 N2がグアノシン(G)であり、N3がシチジン(C)である、〔20〕に記載の変異tRNA。
〔29〕 N2がシチジン(C)であり、N3がシチジン(C)である、〔21〕に記載の変異tRNA。
〔30〕 3’末端にアミノ酸またはアミノ酸類縁体が結合している、〔1〕から〔29〕のいずれかに記載の変異tRNA。
〔31〕 アミノ酸が、天然アミノ酸または非天然アミノ酸である、〔30〕に記載の変異tRNA。
〔32〕 天然アミノ酸が、グリシン(Gly)、アラニン(Ala)、セリン(Ser)、トレオニン(Thr)、バリン(Val)、ロイシン(Leu)、イソロイシン(Ile)、フェニルアラニン(Phe)、チロシン(Tyr)、トリプトファン(Trp)、ヒスチジン(His)、グルタミン酸(Glu)、アスパラギン酸(Asp)、グルタミン(Gln)、アスパラギン(Asn)、システイン(Cys)、メチオニン(Met)、リジン(Lys)、アルギニン(Arg)、プロリン(Pro)からなる群より選択される、〔31〕に記載の変異tRNA。
〔33〕 天然アミノ酸が、グリシン(Gly)、アラニン(Ala)、セリン(Ser)、トレオニン(Thr)、バリン(Val)、ロイシン(Leu)、フェニルアラニン(Phe)、チロシン(Tyr)、トリプトファン(Trp)、ヒスチジン(His)、グルタミン酸(Glu)、アスパラギン酸(Asp)、グルタミン(Gln)、アスパラギン(Asn)、システイン(Cys)、リジン(Lys)、アルギニン(Arg)、プロリン(Pro)からなる群より選択される、〔32〕に記載の変異tRNA。
〔34〕 複数の異なる種類のtRNAを含む翻訳系であって、〔1〕から〔33〕のいずれかに記載の変異tRNAを含む、翻訳系。
〔35〕 変異tRNAが、M1M2Aで表されるコドンとは異なるコドンに比べて、M1M2Aで表されるコドンを選択的に翻訳することが可能であり、かつM1M2Aで表されるコドンが、前記変異tRNAとは異なるtRNAと比較して、前記変異tRNAによって選択的に翻訳され得る、〔34〕に記載の翻訳系。
〔36〕 (a)〔1〕から〔33〕のいずれかに記載の変異tRNA、および(b)M1M2Gで表されるコドンに相補的なアンチコドンを有するtRNAを含む、〔34〕または〔35〕に記載の翻訳系。
〔37〕 〔36〕(b)に記載のtRNAのアンチコドンがCN2N3、ac4CN2N3、またはCmN2N3(ここで、ac4CはN4-アセチルシチジン、Cmは2’-O-メチルシチジンを表す)である、〔36〕に記載の翻訳系。
〔38〕 〔36〕(b)に記載のtRNAが、M1M2Gで表されるコドンとは異なるコドンに比べて、M1M2Gで表されるコドンを選択的に翻訳することが可能であり、かつM1M2Gで表されるコドンが、〔36〕(b)に記載のtRNAとは異なるtRNAと比較して、〔36〕(b)に記載のtRNAによって選択的に翻訳され得る、〔36〕または〔37〕に記載の翻訳系。
〔39〕 〔36〕(a)および〔36〕(b)に記載のtRNAに結合しているアミノ酸またはアミノ酸類縁体が互いに異なる、〔36〕から〔38〕のいずれかに記載の翻訳系。
〔40〕 M1M2AおよびM1M2Gのコドンから、2種類のアミノ酸が翻訳可能である、〔39〕に記載の翻訳系。
〔41〕 M1M2AおよびM1M2Gのコドンが、互いに異なるアミノ酸またはアミノ酸類縁体をコードし得る、〔39〕に記載の翻訳系。
〔42〕 さらに、(c)M1M2UまたはM1M2Cで表されるコドンに相補的なアンチコドンを有するtRNAを含む、〔34〕から〔41〕に記載の翻訳系。
〔43〕 〔42〕(c)に記載のtRNAのアンチコドンがAN2N3、GN2N3、QN2N3、およびGluQN2N3(ここでQはキューオシン(queuosine)、GluQはグルタミルキューオシン(glutamyl-queuosine)を表す)からなる群より選択される、〔42〕に記載の翻訳系。
〔44〕 〔42〕(c)に記載のtRNAが、M1M2UまたはM1M2Cで表されるコドンとは異なるコドンに比べて、M1M2UまたはM1M2Cで表されるコドンを選択的に翻訳することが可能であり、かつM1M2UまたはM1M2Cで表されるコドンが、〔42〕(c)に記載のtRNAとは異なるtRNAと比較して、〔42〕(c)に記載のtRNAによって選択的に翻訳され得る、〔42〕または〔43〕に記載の翻訳系。
〔45〕 〔36〕(a)、〔36〕(b)、および〔42〕(c)に記載のtRNAに結合しているアミノ酸またはアミノ酸類縁体がいずれも互いに異なる、〔42〕から〔44〕のいずれかに記載の翻訳系。
〔46〕 M1M2U、M1M2C、M1M2A、およびM1M2Gによって構成されるコドンボックスから、3種類のアミノ酸が翻訳可能である、〔45〕に記載の翻訳系。
〔47〕 M1M2U、M1M2C、M1M2A、およびM1M2Gによって構成されるコドンボックスにおいて、
(i) M1M2A、M1M2GおよびM1M2Uが互いに異なるアミノ酸またはアミノ酸類縁体をコードし得る、または
(ii) M1M2A、M1M2GおよびM1M2Cが互いに異なるアミノ酸またはアミノ酸類縁体をコードし得る、
〔45〕に記載の翻訳系。
〔48〕 〔36〕(a)、〔36〕(b)、および〔42〕(c)に記載のtRNAのうち、少なくとも一つに非天然アミノ酸が結合している、〔45〕から〔47〕のいずれかに記載の翻訳系。
〔49〕 20種類より多くのアミノ酸を翻訳可能である、〔34〕から〔48〕のいずれかに記載の翻訳系。
〔50〕 無細胞翻訳系である、〔34〕から〔49〕のいずれかに記載の翻訳系。
〔51〕 再構成型の無細胞翻訳系である、〔50〕に記載の翻訳系。
〔52〕 大腸菌由来のリボソームを含む、〔50〕または〔51〕に記載の翻訳系。
〔53〕 〔34〕から〔52〕のいずれかに記載の翻訳系を用いて核酸を翻訳することを含む、ペプチドの製造方法。
〔54〕 ペプチドが環状部を有するペプチドである、〔53〕に記載の方法。
〔55〕 〔53〕または〔54〕に記載の方法により製造されたペプチド。
〔56〕 〔34〕から〔52〕のいずれかに記載の翻訳系を用いて核酸ライブラリーを翻訳することを含む、ペプチドライブラリーの製造方法。
〔57〕 〔56〕に記載の方法により製造されたペプチドライブラリー。
〔58〕 〔57〕に記載のペプチドライブラリーに標的分子を接触させることを含む、当該標的分子に対して結合活性を有するペプチドの同定方法。
〔59〕 ペプチドおよび該ペプチドをコードする核酸を含む核酸-ペプチド複合体であって、前記ペプチドをコードする核酸は以下の(A)または(B)のいずれかに記載の3種類のコドンを含み:
(A)M1M2U、M1M2A、およびM1M2G;
(B)M1M2C、M1M2A、およびM1M2G、
前記ペプチド上において、前記3種類のコドンに対応するアミノ酸の種類がいずれも異なる、前記核酸-ペプチド複合体。
〔60〕 〔59〕に記載の核酸-ペプチド複合体を含むライブラリー。
〔61〕 以下の化合物またはその塩。
〔62〕 〔61〕に記載の化合物とtRNAを構成する核酸断片とを酵素反応によって連結する工程を含む、ライシジンをtRNAナンバリング則の34位に有する変異tRNAの製造方法。
〔63〕 〔61〕に記載の化合物、tRNAを構成する1または複数の核酸断片、およびアミノ酸またはアミノ酸類縁体とを酵素反応によって連結する工程を含む、ライシジンをtRNAナンバリング則の34位に有する変異tRNAであって、3’末端にアミノ酸またはアミノ酸類縁体が結合している変異tRNAの製造方法。
〔64〕 以下の化合物またはその塩。
〔65〕 〔64〕に記載の化合物とtRNAを構成する核酸断片とを酵素反応によって連結する工程を含む、アグマチジンをtRNAナンバリング則の34位に有する変異tRNAの製造方法。
〔66〕 〔64〕に記載の化合物、tRNAを構成する1または複数の核酸断片、およびアミノ酸またはアミノ酸類縁体とを酵素反応によって連結する工程を含む、アグマチジンをtRNAナンバリング則の34位に有する変異tRNAであって、3’末端にアミノ酸またはアミノ酸類縁体が結合している変異tRNAの製造方法。
〔67〕 アミノ酸がメチオニン(Met)およびイソロシン(Ile)以外のアミノ酸である、〔63〕または〔66〕に記載の方法。
〔68〕 〔62〕または〔65〕に記載の方法により製造される、変異tRNA。
〔69〕 〔63〕、〔66〕、または〔67〕に記載の方法により製造される、3’末端にアミノ酸またはアミノ酸類縁体が結合している変異tRNA。
〔70〕 〔68〕および/または〔69〕に記載の変異tRNAを含む、翻訳系。
〔71〕 〔70〕に記載の翻訳系を用いて核酸を翻訳することを含む、ペプチドの製造方法。
〔72〕以下の工程を含む、下記式A:
(式中、
R1およびR2は、それぞれ独立してHまたはC1-C3アルキルであり、
Lは、ヒドロキシおよびC1-C3アルキルからなる群より選択される1つまたは複数の置換基によって置換されていてもよい、C2-C6直鎖アルキレンまたはC2-C6直鎖アルケニレンであり、該C2-C6直鎖アルキレンの炭素原子は、1個の酸素原子または硫黄原子によって置換されていてもよく、
Mは、単結合、
であり、波線は炭素原子との結合点を示し、*は、水素原子との結合点を示し、**は窒素原子との結合点を示し、ただしMが単結合である場合、Mに結合したHは存在しない。)
で表されるライシジン二リン酸もしくはその誘導体、またはアグマチジン二リン酸もしくはその誘導体の製造方法:
下記式B1:
(式中、PG11は、アミノ基の保護基である。)
で表される化合物を分子内で環化して、下記式C1:
(式中、PG11は上記と同じである。)
で表される化合物を得る工程、
式C1で表される化合物に、下記式D1:
(式中、R1、R2、L、およびMは上記と同じである。)
で表されるアミンまたはその塩を導入して、下記式E1:
(式中、R1、R2、L、M、およびPG11は上記と同じである。)
で表される化合物を得る工程、
式E1で表される化合物にPG12および/またはPG13を導入して、下記式F1Aまたは式F1B:
(式中、
R2は、C1-C3アルキルであり、
PG12は、アミノ基の保護基であり、
PG13は、カルボキシル基またはイミノ基の保護基であり、
R1、L、M、およびPG11は上記と同じであり、
但し、Mが単結合である場合、PG13は存在しない。)
で表される化合物を得る工程、
式F1AまたはF1Bで表される化合物からアセトニドを除去し、PG14およびPG15を導入して、下記式G1AまたはG1B:
(式中、
R2は、C1-C3アルキルであり、
PG14は、水酸基の保護基であり、
PG15は、水酸基の保護基であり、
R1、L、M、PG11、PG12、およびPG13は上記と同じである。)
で表される化合物を得る工程、
式G1AまたはG1Bで表される化合物にPG16を導入して、下記式H1AまたはH1B
(式中、
R2は、C1-C3アルキルであり、
PG16は、水酸基および/またはアミノ基の保護基であり、
R1、L、M、PG11、PG12、PG13、PG14、およびPG15は上記と同じである。)
で表される化合物を得る工程、
式H1AまたはH1Bで表される化合物からPG14およびPG15を除去して、下記式I1Aまたは式I1B:
(式中、
R2は、C1-C3アルキルであり、
R1、L、M、PG11、PG12、PG13、およびPG16は上記と同じである。)
で表される化合物を得る工程、
式I1AまたはI1Bで表される化合物を亜リン酸エステル化し、次いで酸化して、下記式J1AまたはJ1B:
(式中、
R2は、C1-C3アルキルであり、
PG17は、水酸基の保護基であり、
R1、L、M、PG11、PG12、PG13、およびPG16は上記と同じである。)
で表される化合物を得る工程、
式J1Aで表される化合物からPG11、PG12、PG13、およびPG17を除去して、あるいは式J1Bで表される化合物からPG11、PG13、およびPG17を除去して、下記式K1:
(式中、
R2は、HまたはC1-C3アルキルであり、
R1、R2、L、M、およびPG16は上記と同じである。)
で表される化合物を得る工程、および
式K1で表される化合物からPG16を除去して、式Aで表される化合物を得る工程。
〔73〕式Aで表される化合物が、ライシジン二リン酸:
またはアグマチジン二リン酸:
である、〔72〕記載の方法。
〔74〕PG11が、p-ブロモベンゾイル、置換されていてもよいベンゾイル、ピリジンカルボニル、またはアセチルである、〔72〕記載の方法。
〔75〕PG12が、Fmocである、〔72〕記載の方法。
〔76〕PG13が、Mが
の場合にはメチル、エチル、または置換されていてもよいベンジルであり、Mが
の場合には置換されていてもよいベンジル、Cbzまたは置換されていてもよいベンジルオキシカルボニルである、〔72〕記載の方法。
〔77〕PG14およびPG15は一緒になって、ジ-tert-ブチルシリルを形成する、〔72〕記載の方法。
〔78〕PG16が、TOMである、〔72〕記載の方法。
〔79〕PG17が、シアノエチルである、〔72〕記載の方法。
〔80〕分子内環化がアゾジカルボン酸ジイソプロピルおよびトリフェニルホスフィンの存在下で行われる、〔72〕記載の方法。
〔81〕式D1で表されるアミンまたはその塩の導入が塩化リチウムおよびDBUの存在下で行われる、〔72〕記載の方法。
〔82〕PG12がFmocであり、PG12の導入に用いられる試薬が、炭酸(2,5-ジオキソピロリジン-1-イル)(9H-フルオレン-9-イル)メチルおよび炭酸ナトリウムである、〔72〕記載の方法。
〔83〕PG13がメチルであり、PG13の導入に用いられる試薬が、N,N’-ジイソプロピルカルボジイミド、メタノール、およびN,N-ジメチル-4-アミノピリジンである、〔72〕記載の方法。
〔84〕アセトニドの除去に用いられる試薬が、TFAである、〔72〕記載の方法。
〔85〕PG14およびPG15が一緒になってジ-tert-ブチルシリルを形成し、ジ-tert-ブチルシリルの導入に用いられる試薬が、ビス(トリフルオロメタンスルホン酸)ジ-tert-ブチルシリルである、〔72〕記載の方法。
〔86〕PG16がTOMであり、PG16の導入に用いられる試薬が、DIPEA、および塩化(トリイソプロピルシロキシ)メチルである、〔72〕記載の方法。
〔87〕PG14およびPG15の除去に用いられる試薬が、フッ化水素ピリジンコンプレックスである、〔72〕記載の方法。
〔88〕亜リン酸エステル化に用いられる試薬が、ビス(2-シアノエチル)-N,N-ジイソプロピルアミノホスホルアミジットである、〔72〕記載の方法。
〔89〕酸化に用いられる試薬が、tert-ブチルヒドロペルオキシドである、〔72〕記載の方法。
〔90〕PG11、PG12、PG13、およびPG17の除去に用いられる試薬が、ビス-(トリメチルシリル)アセトアミドおよびDBUである、〔72〕記載の方法。
〔91〕PG16の除去に用いられる試薬が、フッ化アンモニウムである、〔72〕記載の方法。
〔92〕R1がHである、〔72〕記載の方法。
〔93〕R2がHである、〔72〕記載の方法。
〔94〕C2-C6直鎖アルキレンまたはC2-C6直鎖アルケニレンが、C4-C5直鎖アルキレンまたはC4-C5直鎖アルケニレンである、〔72〕記載の方法。
〔95〕Lが-(CH2)3-、-(CH2)4-、-(CH2)5、-(CH2)2-O-CH2-、-(CH2)2-S-CH2-、-CH2CH(OH)(CH2)2-、または-CH2CH=CH-(シスまたはトランス)である、〔72〕記載の方法。
〔96〕以下の工程を含む、下記式A:
(式中、
R1およびR2は、それぞれ独立してHまたはC1-C3アルキルであり、
Lは、ヒドロキシおよびC1-C3アルキルからなる群より選択される1つまたは複数の置換基によって置換されていてもよい、C2-C6直鎖アルキレンまたはC2-C6直鎖アルケニレンであり、該C2-C6直鎖アルキレンの炭素原子は、1個の酸素原子または硫黄原子によって置換されていてもよく、
Mは、単結合、
であり、波線は炭素原子との結合点を示し、*は、水素原子との結合点を示し、**は窒素原子との結合点を示し、ただしMが単結合である場合、Mに結合したHは存在しない)
で表されるライシジン二リン酸もしくはその誘導体、またはアグマチジン二リン酸もしくはその誘導体の製造方法:
下記式B2:
(式中、PG21は、アミノ基の保護基である。)
で表される化合物を分子内で環化して、下記式C2:
(式中、PG21は上記と同じである。)
で表される化合物を得る工程、
式C2で表される化合物に、下記式D2AまたはD2B:
(式中、
R2は、C1-C3アルキルであり、
PG22は、アミノ基の保護基であり、
PG23は、カルボキシル基またはイミノ基の保護基であり、
R1、L、およびMは上記と同じであり、
但し、Mが単結合である場合、PG23は存在しない。)
で表されるアミンまたはその塩を導入して、下記式E2AまたはE2B:
(式中、
R2は、C1-C3アルキルであり、
R1、L、M、PG21、PG22、およびPG23は上記と同じである。)
で表される化合物を得る工程、
式E2AまたはE2Bで表される化合物からアセトニドを除去し、PG24およびPG25を導入して、下記式F2AまたはF2B:
(式中、
R2は、C1-C3アルキルであり、
PG24は、水酸基の保護基であり、
PG25は、水酸基の保護基であり、
R1、R2、L、M、PG21、PG22、およびPG23は上記と同じである。)
で表される化合物を得る工程、
式F2AまたはF2Bで表される化合物にPG26を導入して、下記式G2AまたはG2B
(式中、
R2は、C1-C3アルキルであり、
PG26は、水酸基の保護基であり、
R1、R2、L、M、PG21、PG22、PG23、PG24、およびPG25は上記と同じである。)
で表される化合物を得る工程、
式G2AまたはG2Bで表される化合物からPG24およびPG25を除去して、下記式H2AまたはH2B:
で表される化合物を得る工程、
(式中、
R2は、C1-C3アルキルであり、
R1、L、M、PG21、PG22、PG23、およびPG26は上記と同じである。)
式H2AまたはH2Bで表される化合物を亜リン酸エステル化し、次いで酸化して、下記式I2AまたはI2B:
(式中、
R2は、C1-C3アルキルであり、
PG27は、水酸基の保護基であり、
R1、L、M、PG21、PG22、PG23、およびPG26は上記と同じである。)
で表される化合物を得る工程、
式I2Aで表される化合物からPG21、PG22、PG23、およびPG27を除去して、あるいは式I2Bで表される化合物からPG21、PG23、およびPG27を除去して、下記式J2:
(式中、
R2は、HまたはC1-C3アルキルであり、
R1、L、M、およびPG26は上記と同じである。)
で表される化合物を得る工程、および
式J2で表される化合物からPG26を除去して、式Aで表される化合物を得る工程。
〔97〕式Aで表される化合物が、ライシジン二リン酸:
またはアグマチジン二リン酸:
である、〔96〕記載の方法。
〔98〕PG21が、Cbz、置換されていてもよいベンジルオキシカルボニル、または置換されていてもよいベンジルである、〔96〕記載の方法。
〔99〕PG22が、Cbz、置換されていてもよいベンジルオキシカルボニル、または置換されていてもよいベンジルである、〔96〕記載の方法。
〔100〕PG23が、Mが
の場合には置換されていてもよいベンジルであり、Mが
の場合には置換されていてもよいベンジル、Cbz、または置換されていてもよいベンジルオキシカルボニルである、〔96〕記載の方法。
〔101〕PG24およびPG25は一緒になって、ジ-tert-ブチルシリルを形成する、〔96〕記載の方法。
〔102〕PG26が、テトラヒドロピラニル、テトラヒドロフラニル、またはメトキシメチルである、〔96〕記載の方法。
〔103〕PG27が、ベンジルである、〔96〕記載の方法。
〔104〕分子内環化がアゾジカルボン酸ジイソプロピルおよびトリフェニルホスフィンの存在下で行われる、〔96〕記載の方法。
〔105〕式D2で表されるアミンまたはその塩の導入が塩化リチウムおよびDBUの存在下で行われる、〔96〕記載の方法。
〔106〕アセトニドの除去に用いられる試薬が、TFAである、〔96〕記載の方法。
〔107〕PG24およびPG25が一緒になってジ-tert-ブチルシリルを形成し、ジ-tert-ブチルシリルの導入に用いられる試薬が、ビス(トリフルオロメタンスルホン酸)ジ-tert-ブチルシリルである、〔96〕記載の方法。
〔108〕PG26がテトラヒドロピラニルであり、PG26の導入に用いられる試薬が、TFA、および3,4-ジヒドロ-2H-ピランである、〔96〕記載の方法。
〔109〕PG24およびPG25の除去に用いられる試薬が、テトラブチルアンモニウムフルオリドである、〔96〕記載の方法。
〔110〕亜リン酸エステル化に用いられる試薬が、ジベンジル N,N-ジイソプロピルホスホロアミダイトである、〔96〕記載の方法。
〔111〕酸化に用いられる試薬が、デス-マーチンペルヨージナンである、〔96〕記載の方法。
〔112〕PG21、PG22、PG23、およびPG27が、接触水素化によって除去される、〔96〕記載の方法。
〔113〕PG26の除去に用いられる試薬が、塩酸である、〔96〕記載の方法。
〔114〕R1がHである、〔96〕記載の方法。
〔115〕R2がHである、〔96〕記載の方法。
〔116〕C2-C6直鎖アルキレンまたはC2-C6直鎖アルケニレンが、C4-C5直鎖アルキレンまたはC4-C5直鎖アルケニレンである、〔96〕記載の方法。
〔117〕Lが-(CH2)3-、-(CH2)4-、-(CH2)5、-(CH2)2-O-CH2-、-(CH2)2-S-CH2-、-CH2CH(OH)(CH2)2-、または-CH2CH=CH-(シスまたはトランス)である、〔96〕記載の方法。
本明細書を解釈する目的のために、以下の定義が適用され、該当する場合はいつでも、単数形で使用された用語は複数形をも含み、その逆もまた同様である。本明細書で使用される用語は、特定の態様を説明することのみを目的としており、限定を意図したものではないことが、理解されるべきである。下記の定義のいずれかが、参照により本明細書に組み入れられた任意の文書と矛盾する場合には、下記の定義が優先するものとする。
本開示において「アルキル」とは、脂肪族炭化水素から任意の水素原子を1個除いて誘導される1価の基であり、骨格中にヘテロ原子または不飽和の炭素-炭素結合を含有せず、水素および炭素原子を含有するヒドロカルビルまたは炭化水素基構造の部分集合を有する。炭素鎖の長さnは1~20個の範囲であり、アルキルとしては、例えばC2-C10アルキル、C1-C6アルキル、C1-C3アルキルなどが挙げられ、具体的には、メチル、エチル、プロピル、ブチル、ペンチル、ヘキシル、イソプロピル、t-ブチル、sec-ブチル、1-メチルプロピル、1,1-ジメチルプロピル、2,2-ジメチルプロピル、1,2-ジメチルプロピル、1,1,2-トリメチルプロピル、1,2,2-トリメチルプロピル、1,1,2,2-テトラメチルプロピル、1-メチルブチル、2-メチルブチル、3-メチルブチル、1,1-ジメチルブチル、1,2-ジメチルブチル、1,3-ジメチルブチル、2,2-ジメチルブチル、2,3-ジメチルブチル、3,3-ジメチルブチル、1-エチルブチル、2-エチルブチル、イソペンチル、ネオペンチルなどが挙げられる。
<変異tRNA>
一局面において、本開示は、改変されたtRNAを提供する。具体的には、本発明は、tRNAを改変することにより作製されている変異tRNAを提供する。改変されるtRNAは、任意の生物(例えば大腸菌など)に由来する天然tRNAであってもよいし、または天然tRNAとは異なる配列を人工的に合成した非天然tRNAであってもよい。あるいは、天然tRNAと同じ配列を人工的に合成したtRNAであってもよい。本開示においてtRNAに導入される改変はいずれも人工的な改変であって、当該改変により作製される変異tRNAはいずれも天然には存在しない核酸配列を有していることを特徴とする。
・「tRNA Xxx」あるいは「tRNA(Xxx)」・・・アミノ酸Xxxに対応したtRNA(全長)を示す(例えばtRNA GluやtRNA(Glu)など)。
・「tRNA(Xxx)nnn」・・・アミノ酸Xxxに対応したtRNAであって、アンチコドン配列がnnnであるtRNA(全長)を示す(例えばtRNA(Glu)ugaやtRNA(Glu)Lgaなど)。
・「tRNA(Xxx)nnn-CA」・・・アミノ酸Xxxに対応したtRNAであって、アンチコドン配列がnnnであるtRNA(3’末端のCA配列が除去されたもの)を示す(例えばtRNA(Glu)uga-CAやtRNA(Glu)Lga-CAなど)。
tRNAは、例えば、所望のtRNA遺伝子をコードするDNAを用意し、その上流にT7、T3、あるいはSP6などの適切なプロモーターを配置して、当該DNAを鋳型に各プロモーターに適応したRNAポリメラーゼを用いて転写反応を行うことによって合成することができる。また、tRNAは生物学的材料からの精製によっても調製することができる。例えば、細胞などのtRNAを含む材料から抽出液を調製して、そこにtRNAの核酸配列に相補的な配列を含むプローブを添加することによってtRNAを回収することができる。この際、所望のtRNAを発現可能な発現ベクターを用意して、当該発現ベクターで形質転換した細胞を材料に調製を行うこともできる。in vitroの転写によって合成されたtRNAには、通常、4つの典型的なヌクレオシドであるアデノシン、グアノシン、シチジン、およびウリジンのみが含まれている。一方、細胞内で合成されたtRNAには、それらを修飾して得られた修飾ヌクレオシドなども含まれていることがある。天然tRNAにおける修飾ヌクレオシド(例えばライシジンなど)は、tRNAが転写により合成された後に、その修飾を行うための酵素(例えばTilSなど)の作用によって、当該tRNAに特異的に導入されると考えられている。あるいは、転写によって合成された断片もしくは、後述の実施例に記載のように、化学合成された断片等を酵素反応によって連結する手法によってもtRNAを調製することができる。
一局面において、本開示は、ペプチド翻訳に適した一揃いのtRNAを提供する。一揃いのtRNAには、複数の異なる種類のtRNAが含まれ、それらのtRNAから複数の異なる種類のアミノ酸を翻訳することができる。一局面において、本開示は、ペプチド翻訳に適した複数の異なる種類のtRNAを含む組成物を提供する。別の局面において、本開示は、ペプチド翻訳に適した複数の異なる種類のtRNAを提供することを含む、ペプチドの翻訳方法を提供する。一局面において、本開示は、ペプチド翻訳に適した複数の異なる種類のtRNAを含む翻訳系を提供する。特定の局面において、前記の複数の異なる種類のtRNAの中に、本開示の変異tRNAが含まれる。以下の記載は、これらのペプチド翻訳に適したtRNA、組成物、翻訳方法、および翻訳系に関するものである。
(i) ペプチドをコードする核酸配列の中に、M1M2AおよびM1M2Gの2つのコドンが含まれていて、かつ、
(ii) ペプチドのアミノ酸配列において、M1M2Aのコドンに対応するアミノ酸およびM1M2Gのコドンに対応するアミノ酸の種類が互いに異なる。
ここで、M1およびM2は、ある特定のコドンの1文字目および2文字目をそれぞれ表す(ただし、M1がAであり、かつM2がUであるコドンは除く)。
(i) ペプチドをコードする核酸配列の中に、M1M2U、M1M2AおよびM1M2Gの3つのコドンが含まれていて、かつ、
(ii) ペプチドのアミノ酸配列において、M1M2Uのコドンに対応するアミノ酸、M1M2Aのコドンに対応するアミノ酸、およびM1M2Gのコドンに対応するアミノ酸の種類がいずれも互いに異なる。
ここで、M1およびM2は、ある特定のコドンの1文字目および2文字目をそれぞれ表す。
(i) ペプチドをコードする核酸配列の中に、M1M2C、M1M2AおよびM1M2Gの3つのコドンが含まれていて、かつ、
(ii) ペプチドのアミノ酸配列において、M1M2Cのコドンに対応するアミノ酸、M1M2Aのコドンに対応するアミノ酸、およびM1M2Gのコドンに対応するアミノ酸の種類がいずれも互いに異なる。
ここで、M1およびM2は、ある特定のコドンの1文字目および2文字目をそれぞれ表す。
このような化合物は、ライシジンが導入された変異tRNAの調製に用いることができる。したがって本開示は、ライシジン‐ジホスフェートを用いて、ライシジンが導入された変異tRNAを製造する方法、および当該方法によって製造される変異tRNAに関する。また本開示は、ライシジン‐ジホスフェートを用いて、ライシジンが導入された変異tRNAであって、アミノ酸またはアミノ酸類縁体が結合している変異tRNA(アミノアシル変異tRNA)を製造する方法、および当該方法によって製造されるアミノアシル変異tRNAに関する。このような変異tRNAおよび/またはアミノアシル変異tRNAは、本開示における翻訳系において使用することができる。したがって本開示は、このような変異tRNAおよび/またはアミノアシル変異tRNAを含む翻訳系に関する。さらに本開示は、当該翻訳系を使用してペプチドまたはペプチドライブラリーを製造する方法をも提供する。また本開示は、当該方法によって製造されるペプチドまたはペプチドライブラリーをも提供する。
本開示においては、ライシジンはtRNAの34位(tRNAナンバリング則に基づく)に導入されていてもよい。一態様において、tRNAナンバリング則の34位にライシジンが導入された変異tRNAは、1または複数(例えば、2、3、4、5、またはそれ以上)のtRNAの核酸断片とライシジン‐ジホスフェートを調製し、これらを当業者に公知の手法によりライゲーションすることにより取得することができる。具体的には、一例として、tRNAの1位から33位の塩基からなる核酸断片、ライシジン‐ジホスフェート、tRNAの35位から76位(またはtRNAの35位から75位、tRNAの35位から74位)の塩基からなる核酸断片を、5’側からこれらの順にライゲーションすることが挙げられる。3’末端のCA配列は除去されていてもよい。
このような化合物は、アグマチジンが導入された変異tRNAの調製に用いることができる。したがって本開示は、アグマチジン‐ジホスフェートを用いて、アグマチジンが導入された変異tRNAを製造する方法、および当該方法によって製造される変異tRNAに関する。また本開示は、アグマチジン‐ジホスフェートを用いて、アグマチジンが導入された変異tRNAであって、アミノ酸またはアミノ酸類縁体が結合している変異tRNA(アミノアシル変異tRNA)を製造する方法、および当該方法によって製造されるアミノアシル変異tRNAに関する。このような変異tRNAおよび/またはアミノアシル変異tRNAは、本開示における翻訳系において使用することができる。したがって本開示は、このような変異tRNAおよび/またはアミノアシル変異tRNAを含む翻訳系に関する。さらに本開示は、当該翻訳系を使用してペプチドまたはペプチドライブラリーを製造する方法をも提供する。また本開示は、当該方法によって製造されるペプチドまたはペプチドライブラリーをも提供する。
本開示においては、アグマチジンはtRNAの34位(tRNAナンバリング則に基づく)に導入されていてもよい。一態様において、tRNAナンバリング則の34位にアグマチジンが導入された変異tRNAは、1または複数(例えば、2、3、4、5、またはそれ以上)のtRNAの核酸断片とアグマチジン‐ジホスフェートを調製し、これらを当業者に公知の手法によりライゲーションすることにより取得することができる。具体的には、一例として、tRNAの1位から33位の塩基からなる核酸断片、アグマチジン‐ジホスフェート、tRNAの35位から76位(またはtRNAの35位から75位、tRNAの35位から74位)の塩基からなる核酸断片を、5’側からこれらの順にライゲーションすることが挙げられる。3’末端のCA配列は除去されていてもよい。
である。波線は炭素原子との結合点を示し、*は、水素原子との結合点を示し、**は窒素原子との結合点を示す。Mが単結合である場合、Mに結合したHは存在しない。たとえば、Mが
である場合、式Aの化合物は、以下:
のとおりに表すことができ、Mが
である場合、式Aの化合物は、以下:
のとおりに表すことができ、Mが単結合である場合、式Aの化合物は以下:
のとおりに表すことができる。
式B1で表される化合物は、商業的供給業者から入手するか、あるいは文献既知の方法を用いて製造することができる。式B1中のPG11は、アミノ基の保護基であり、上記スキーム1に沿った反応の進行に支障がないかぎり、任意の保護基を使用することができ、たとえば、酸やフッ化物イオンによって脱保護されない保護基が好ましい。PG11として具体的には、たとえば、p-ブロモベンゾイル、置換されていてもよいベンゾイル、ピリジンカルボニル、アセチルなどが例示される。
分子内環化試薬は、特に限定されないが、アゾジカルボン酸ジイソプロピルおよびトリフェニルホスフィンを好ましく用いることができる。
溶媒としては、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒を挙げることができ、ジクロロメタンを好ましく用いることができる。
アミン導入試薬は、特に限定されないが、塩化リチウムおよびDBUを好ましく用いることができる。
溶媒としては、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒を挙げることができ、本工程ではテトラヒドロフランが好ましく用いられる。
PG12はアミノ基の保護基であり、PG13はカルボキシル基またはイミノ基の保護基である。これらの保護基は、上記スキーム1に沿った反応の進行に支障がないかぎり、任意の保護基を使用することができ、たとえば、酸やフッ化物イオンによって脱保護されない保護基が好ましい。PG12としてはFmocが好ましく用いられ、PG13としてはMが
の場合にはメチル、エチル、または置換されていてもよいベンジルが、Mが
の場合には置換されていてもよいベンジル、Cbzまたは置換されていてもよいベンジルオキシカルボニルが好ましく用いられる。PG12とPG13は同時に導入してもよく、順番に導入してもよい。順番に導入する場合には、PG12とPG13のどちらを先に導入してもよいが、PG12を導入し、次いでPG13を導入することが好ましい。保護基の導入には、例えば、「Greene’s,“Protective Groups in Organic Synthesis”(第5版,John Wiley & Sons 2014)」に記載の方法を利用することができるが、PG12がFmocである場合には、その導入に、炭酸 (2,5-ジオキソピロリジン-1-イル) (9H-フルオレン-9-イル)メチルおよび炭酸ナトリウムを用いることが好ましく、PG13がメチルである場合には、その導入にN,N'-ジイソプロピルカルボジイミド、メタノール、およびN,N-ジメチル-4-アミノピリジンを用いることが好ましい。
溶媒としては、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒を挙げることができ、Fmocの導入にはジオキサンが、メチルの導入にはジクロロメタンがそれぞれ好ましく用いられる。
PG14およびPG15はそれぞれ独立して水酸基の保護基であり、上記スキーム1に沿った反応の進行に支障がないかぎり、任意の保護基を使用することができ、例えばフッ化物イオンによって脱保護されるシリル系の保護基を好ましく用いることができる。PG14およびPG15としてはこれらが一緒になって二価の保護基を形成することが好ましく、そのような保護基として具体的には、たとえば、ジ-tert-ブチルシリルが挙げられる。アセトニドの除去、および保護基の導入には、例えば、「Greene’s,“Protective Groups in Organic Synthesis”(第5版,John Wiley & Sons 2014)」に記載の方法を利用することができるが、アセトニドの除去に用いる酸としてはTFAが好ましい。またPG14およびPG15が一緒になってジ-tert-ブチルシリルを形成する場合には、その導入には、ビス(トリフルオロメタンスルホン酸)ジ-tert-ブチルシリルを用いることが好ましい。
アセトニドの除去に用いる溶媒としては、水、カルボン酸系溶媒を挙げることができ、水とTFAの混合溶媒を好ましく用いることができる。また、PG14およびPG15の導入には、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、アミド系溶媒を挙げることができ、DMFが好ましく用いられる。
PG16は、水酸基および/またはアミノ基の保護基であり、上記スキーム1に沿った反応の進行に支障がないかぎり、任意の保護基を使用することができ、たとえば、フッ化物イオンによって脱保護されない保護基が好ましい。PG16としてはTOMが好ましい。保護基の導入には、例えば、「Greene’s,“Protective Groups in Organic Synthesis”(第5版,John Wiley & Sons 2014)」に記載の方法を利用することができるが、PG16がTOMである場合には、その導入に、DIPEA、および塩化 (トリイソプロピルシロキシ)メチルを用いることが好ましい。
溶媒としては、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、アミド系溶媒を挙げることができ、ジクロロメタンが好ましく用いられる。
脱保護試薬は、PG14およびPG15のみを選択的に除去することができれば、任意の試薬を用いることができるが、PG14およびPG15が一緒になってジ-tert-ブチルシリルを形成する場合には、その除去にフッ化物イオンを生じる試薬、具体的には、たとえばフッ化水素ピリジンコンプレックスを用いることが好ましい。
溶媒としては、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、アミド系溶媒を挙げることができ、THFが好ましく用いられる。
式J1AまたはJ1B中、PG17は、水酸基の保護基であり、上記スキーム1に沿った反応の進行に支障がないかぎり、任意の保護基を使用することができ、PG11、PG12、PG13と同時に脱保護できる保護基が好ましい。PG17としては具体的には、たとえば、シアノエチルが挙げられる。水酸基が保護基で保護された亜リン酸エステル化試薬を用いてもよく、無保護の亜リン酸エステル化試薬を用いたのちに、水酸基に保護基を導入してもよい。保護基の導入には、例えば、「Greene’s,“Protective Groups in Organic Synthesis”(第5版,John Wiley & Sons 2014)」に記載の方法を利用することができる。水酸基がシアノエチル基で保護された亜リン酸エステル化試薬を用いる場合、亜リン酸エステル化試薬としては、ビス(2-シアノエチル)-N,N-ジイソプロピルアミノホスホルアミジットが好ましく用いられる。亜リン酸エステル化に続く酸化に用いる酸化剤は、特に限定されないが、tert-ブチルヒドロペルオキシドを好ましく用いることができる。
溶媒としては、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、ニトリル系溶媒を挙げることができ、アセトニトリルが好ましく用いられる。
脱保護試薬は、上記の保護基が選択的に除去することができれば任意の試薬を使用することができる。このような試薬として、具体的には、たとえば、ビス-(トリメチルシリル)アセトアミドおよびDBUを組み合わせて用いることが挙げられる。
溶媒としては、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、ニトリル系溶媒、アミン系溶媒を挙げることができ、ピリジンが好ましく用いられる。
脱保護試薬は、PG16が選択的に除去することができれば任意の試薬を使用することができ、フッ化アンモニウムを好ましく用いることができる。
溶媒としては、例えば、水、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、ニトリル系溶媒を挙げることができ、水とアセトニトリルの混合溶媒を好ましく用いることができる。
式B2で表される化合物は、商業的供給業者から入手するか、あるいは文献既知の方法を用いて製造することができる。式B2中のPG21は、アミノ基の保護基であり、上記スキーム2に沿った反応の進行に支障がないかぎり、任意の保護基を使用することができ、たとえば、酸やフッ化物イオンによって脱保護されない保護基が好ましい。PG21として具体的には、たとえば、Cbz、置換されていてもよいベンジルオキシカルボニル、または置換されていてもよいベンジルなどが例示される。
分子内環化試薬は、特に限定されないが、アゾジカルボン酸ジイソプロピルおよびトリフェニルホスフィンを好ましく用いることができる。
溶媒としては、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒を挙げることができ、ジクロロメタンを好ましく用いることができる。
アミン導入試薬は、特に限定されないが、塩化リチウムおよびDBUを好ましく用いることができる。
溶媒としては、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒を挙げることができ、本工程ではTHFが好ましく用いられる。
PG24およびPG25はそれぞれ独立して水酸基の保護基であり、上記スキーム2に沿った反応の進行に支障がないかぎり、任意の保護基を使用することができ、例えばフッ化物イオンによって脱保護されるシリル系の保護基を好ましく用いることができる。PG24およびPG25としてはこれらが一緒になって二価の保護基を形成することが好ましく、そのような保護基として具体的には、たとえば、ジ-tert-ブチルシリルが挙げられる。アセトニドの除去、および保護基の導入には、例えば、「Greene’s,“Protective Groups in Organic Synthesis”(第5版,John Wiley & Sons 2014)」に記載の方法を利用することができるが、アセトニドの除去に用いる酸としてはTFAが好ましい。またPG24およびPG25が一緒になってジ-tert-ブチルシリルを形成する場合には、その導入には、ビス(トリフルオロメタンスルホン酸)ジ-tert-ブチルシリルを用いることが好ましい。
アセトニドの除去に用いる溶媒としては、水、カルボン酸系溶媒を挙げることができ、水とTFAの混合溶媒を好ましく用いることができ、PG24およびPG25の導入には、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、アミド系溶媒を挙げることができ、DMFが好ましく用いられる。
PG26は、水酸基の保護基であり、上記スキーム2に沿った反応の進行に支障がないかぎり、任意の保護基を使用することができ、たとえば、フッ化物イオンによって脱保護されない保護基が好ましい。PG26としてはテトラヒドロピラニル、テトラヒドロフラニル、またはメトキシメチルが好ましい。保護基の導入には、例えば、「Greene’s,“Protective Groups in Organic Synthesis”(第5版,John Wiley & Sons 2014)」に記載の方法を利用することができるが、PG16がテトラヒドロピラニルである場合には、その導入に、TFA、および3,4-ジヒドロ-2H-ピランを用いることが好ましい。
溶媒としては、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、アミド系溶媒を挙げることができ、ジクロロメタンが好ましく用いられる。
脱保護試薬は、PG24およびPG25のみを選択的に除去することができれば、任意の試薬を用いることができるが、PG24およびPG25が一緒になってジ-tert-ブチルシリルを形成する場合には、その除去にフッ化物イオンを生じる試薬、具体的には、たとえばテトラブチルアンモニウムフルオリドを用いることが好ましい。
溶媒としては、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、アミド系溶媒を挙げることができ、THFが好ましく用いられる。
式I2AまたはI2B中、PG27は、水酸基の保護基であり、上記スキーム2に沿った反応の進行に支障がないかぎり、任意の保護基を使用することができ、PG21、PG22、PG23と同時に脱保護できる保護基が好ましい。PG27としては具体的には、たとえば、ベンジルが挙げられる。水酸基が保護基で保護された亜リン酸エステル化試薬を用いてもよく、無保護の亜リン酸エステル化試薬を用いたのちに、水酸基に保護基を導入してもよい。保護基の導入には、例えば、「Greene’s,“Protective Groups in Organic Synthesis”(第5版,John Wiley & Sons 2014)」に記載の方法を利用することができる。水酸基がベンジルで保護された亜リン酸エステル化試薬を用いる場合、亜リン酸エステル化試薬としては、ジベンジルN,N-ジイソプロピルホスホロアミダイトが好ましく用いられる。亜リン酸エステル化に続く酸化に用いる酸化剤は、特に限定されないが、デス-マーチンペルヨージナンを好ましく用いることができる。
溶媒としては、例えば、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、ニトリル系溶媒を挙げることができ、アセトニトリルが好ましく用いられる。
上記の保護基を選択的に除去することができれば、脱保護には任意の方法を使用することができる。このような方法として具体的には、たとえば、接触水素化が挙げられる。接触水素化には、Pd系触媒、例えばパラジウム/炭素を好ましく用いることができる。
溶媒としては、例えば、水、アルコール系溶媒、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、ニトリル系溶媒、アミン系溶媒を挙げることができ、水とメタノールの混合溶媒を好ましく用いることができる。
脱保護試薬は、PG26が選択的に除去することができれば任意の試薬を使用することができ、塩酸を好ましく用いることができる。
溶媒としては、例えば、水、ハロゲン化溶媒、エーテル系溶媒、ベンゼン系溶媒、エステル系溶媒、ケトン系溶媒、ニトリル系溶媒を挙げることができ、水を好ましく用いることができる。
なお、本明細書において引用された全ての先行技術文献は、参照として本明細書に組み入れられる。
なお、実施例中では以下の略号を使用した。
AA 酢酸アンモニウム
CH2CN シアノメチル基
DBU 1,8-ジアザビシクロ[5.4.0]-7-ウンデセン
DCM ジクロロメタン
DIC N,N-ジイソプロピルカルボジイミド
DIPEA N,N-ジイソプロピルエチルアミン
DMF ジメチルホルムアミド
DMSO ジメチルスルホキシド
FA ギ酸
Fmoc 9-フルオレニルメチルオキシカルボニル基
F-Pnaz 4-(2-(4-フルオロフェニル)アセトアミド)ベンジルオキシカルボニル基:
HFIP 1,1,1,3,3,3-ヘキサフルオロ-2-プロパノール
MeCN アセトニトリル
NMP N-メチル-2-ピロリドン
TEA トリエチルアミン
TFA トリフルオロ酢酸
TFE 2,2,2-トリフルオロエタノール
THF テトラヒドロフラン
tRNA断片の3’末端にUridineユニットをligation法により導入するために、文献(Nucleic Acids Research 2003, 31(22), e145)記載の方法を参考にしUridine-diphosphate(SS01、pUp)を合成した。
LCMS(ESI) m/z = 403 (M-H)-
保持時間:1.79分、1.89分(分析条件LTQTEA/HFIP05_01)
tRNA断片の3’末端にLysidineユニットをligation法により導入するために、Lysidineのdiphosphateを合成した。すなわち、以下のスキームに従い、Lysidine-diphosphate(SS04、pLp)を合成した。
LCMS(ESI) m/z = 594 (M+H)+
保持時間:0.41分(分析条件SQDFA05_01)
LCMS(ESI) m/z = 816 (M+H)+
保持時間:0.68分(分析条件SQDFA05_01)
LCMS(ESI) m/z = 828 (M-H)-
保持時間:0.76分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 790 (M+H)+
保持時間:0.70分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 928.5 (M-H)-
保持時間:0.92分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 1303 (M+H)+
保持時間:0.84分(分析条件SQDFA50)
LCMS(ESI) m/z = 1162.8 (M+H)+
保持時間:3.69分(分析条件SQDFA05long)
LCMS(ESI) m/z = 1534.9 (M+H)+
保持時間:3.62分(分析条件SQDFA05long)
LCMS(ESI) m/z = 904.7 (M+H)+
保持時間:0.79分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 530 (M-H)-
保持時間:1.64分(分析条件LTQTEA/HFIP05_02)
tRNA断片の3’末端にLysidineユニットをligation法により導入するために用いるLysidineのdiphosphateの合成法を改良した。すなわち、以下のスキームに従い、Lysidine-diphosphate(SS04、pLp)を合成した。
LCMS(ESI) m/z = 400.3 (M+H)+
保持時間:0.48分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 768.6 (M-H)-
保持時間:0.74分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 728.5 (M-H)-
保持時間:0.69分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 868.8 (M-H)-
保持時間:0.88分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 952.8 (M-H)-
保持時間:3.17分、3.38分(分析条件SQDAA50long)
LCMS(ESI) m/z = 812.7 (M-H)-
保持時間:1.74分(分析条件SQDAA50long)
LCMS(ESI) m/z = 1332.8 (M-H)-
保持時間:3.08分、3.11分(分析条件SQDAA50long)
LCMS(ESI) m/z = 530.1 (M-H)-
保持時間:1.60分(分析条件LTQTEA/HFIP05_02)
実施例2にて合成した化合物SS04を分析してから実施例3にて合成した化合物SS04を分析するまでの間にカラムの交換を実施している。実施例2にて合成した化合物SS04をカラム交換後に再分析し、実施例3にて合成した化合物SS04と同一であることを確認した。その結果を以下に示す。
LCMS(ESI) m/z = 530.1 (M-H)-
保持時間:1.60分(分析条件LTQTEA/HFIP05_02)
tRNA断片の3’末端にAgmatidineユニットをligation法により導入するために、Agmatidineのdiphosphateを合成した。すなわち、以下のスキームに従い、Agmatidine-diphosphate(SS31、p(Agm)p)を合成した。
LCMS(ESI) m/z = 399.4 (M+H)+
保持時間:0.61分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 796.6 (M-H)-
保持時間:0.78分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 756.5 (M-H)-
保持時間:0.71分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 896.7 (M-H)-
保持時間:0.91分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 980.9 (M-H)-
保持時間:3.51分、3.72分(分析条件SQDAA50long)
LCMS(ESI) m/z = 840.7 (M-H)-
保持時間:2.27分(分析条件SQDAA50long)
LCMS(ESI) m/z = 1363.0 (M+H)+
保持時間:4.11分、4.14分(分析条件SQDAA05long)
LCMS(ESI) m/z = 514.1 (M-H)-
保持時間:1.58分(分析条件LTQTEA/HFIP05_02)
LCMS(ESI) m/z = 413 (M-H)-
保持時間:0.70分(分析条件SQDFA05_01)
LCMS(ESI) m/z = 452 (M-H)-
保持時間:0.79分(分析条件SQDFA05_01)
LCMS(ESI) m/z = 1047.5 (M-H)-
保持時間:0.50分(分析条件SQDFA05_01)
N,N,N-トリメチルヘキサデカン-1-アミニウム 塩化物(6.40g、20mmol)とイミダゾール(6.81g、100mmol)の水溶液に酢酸を添加し、pH8、20mM N,N,N-トリメチルヘキサデカン-1-アミニウム、100mMイミダゾールの緩衝液A(1L)を得た。
LCMS(ESI) m/z = 523 (M+Na)+
保持時間:1.26分(分析条件SMD method1)
LCMS(ESI) m/z = 562 (M+Na)+
保持時間:1.15分(分析条件SMD method2)
LCMS(ESI) m/z = 1133.4 (M-H)-
保持時間:0.55分(分析条件SQDFA05_01)
LCMS(ESI) m/z = 192 (M-H)-
保持時間:0.15分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 477 (M-H)-
保持時間:0.85分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 516 (M-H)-
保持時間:0.92分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 1111.5 (M-H)-
保持時間:0.64分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 507 (M+Na)+
保持時間:1.06分(分析条件SMD method3)
LCMS(ESI) m/z = 546 (M+Na)+
保持時間:1.13分(分析条件SMD method3)
LCMS(ESI) m/z = 1117.4 (M-H)-
保持時間:0.55分(分析条件SQDFA05_01)
LCMS(ESI) m/z = 483 (M+Na)+
保持時間:1.04分(分析条件SMD method3)
LCMS(ESI) m/z = 522 (M+Na)+
保持時間:1.35分(分析条件SMD method4)
LCMS(ESI) m/z = 1093.5 (M-H)-
保持時間:0.55分(分析条件SQDFA05_01)
(3-(5,5-ジフルオロ-7,9-ジメチル-5H-4λ4,5λ4-ジピロロ[1,2-c:2',1'-f][1,3,2]ジアザボリニン-3-イル)プロパノイル)-L-フェニルアラニン(化合物MT02、BdpFL-Phe-OH)の合成
LCMS(ESI) m/z = 438.3 (M-H)-
保持時間:0.78分(分析条件SQDFA05_02)
LCMS(ESI) m/z = 477.3(M-H)-
保持時間:0.86分(分析条件SQDFA05_01)
LCMS(ESI) m/z = 1072.5 (M-H)-
保持時間:0.56分(分析条件SQDFA05_02)
LCMS(ESI)m/z=424.2(M-H)-
保持時間:0.84分、0.85分(分析条件SQDFA05_01)
レジンにTFE/DCM(1:1、v/v、2mL)を加えて1時間振とうし、ペプチドのレジンからの切り出しを行った。反応終了後、チューブ内の溶液を合成用カラムでろ過することによりレジンを除き、レジンをTFE/DCM(1:1、v/v、1mL)にて2回洗浄した。全ての抽出液を混合し、DMF(2mL)を加えた後、減圧下濃縮した。得られた残査をNMP(0.5mL)に溶解し、そのうち1/4(125μL)を次の反応に使用した。ペプチドのNMP溶液に76.5mMに調製したBdpFLスクシンイミドエステル(140μL)を室温にて加え、40℃で終夜撹拌した後、減圧下濃縮した。得られた残査を0.05M テトラメチルアンモニウム硫酸水素塩 in HFIP(1.2 ml, 0.060 mmol)に溶解し、室温で2時間撹拌した。反応液を逆相シリカゲルカラムクロマトグラフィー(0.1%FA MeCN/H2O)にて精製し、表題化合物(LCT-12)(0.3mg)を得た。LCT-12のアミノ酸配列を配列番号:53に示す。
LCMS(ESI) m/z = 1972.9 (M-H)-
保持時間:0.74分(分析条件SQDFA05_01)
tRNA5’断片、pNp(pUp、pLp、あるいはp(Agm)p)、およびtRNA3’断片を以下に記載の手順により、ライゲーション反応を用いて連結することで各種tRNA-CAを作製した。tRNA5’断片およびtRNA3’断片は化学合成品(株式会社ジーンデザイン)を用いた。各tRNA断片および全長の配列と、ライゲーションに用いたサンプルの組み合わせ(表4)を下記に示す。
配列番号:54(FR-1)
tRNA(Glu)5’ RNA配列
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU
配列番号:55(FR-2)
tRNA(Glu)3’ga RNA配列
GAACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:56(UR-1)
lig-tRNA(Glu)uga-CA RNA配列
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUUGAACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:57(LR-1)
tRNA(Glu)Lga-CA RNA配列
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCULGAACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:58(FR-3)
tRNA(Glu)3’ag RNA配列
AGACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:59(LR-2)
tRNA(Glu)Lag-CA RNA配列
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCULAGACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:60(FR-4)
tRNA(Glu)3’ac RNA配列
ACACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:61(LR-3)
tRNA(Glu)Lac-CA RNA配列
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCULACACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:62(FR-5)
tRNA(Glu)3’cc RNA配列
CCACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:63(LR-4)
tRNA(Glu)Lcc-CA RNA配列
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCULCCACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:132(FR-6)
tRNA(Asp)5’ RNA配列
GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUU
配列番号:133(FR-7)
tRNA(Asp)3’ag RNA配列
AGGUGCAGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC
配列番号:134(LR-5)
tRNA(Asp)Lag-CA RNA配列
GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUULAGGUGCAGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC
配列番号:135(FR-8)
tRNA(AsnE2)5’ RNA配列
GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUU
配列番号:136(FR-9)
tRNA(AsnE2)3’ag RNA配列
AGGUUCCGUAUGUCACUGGUUCGAGUCCAGUCAGAGCCGC
配列番号:137(LR-6)
tRNA(AsnE2)Lag-CA RNA配列
GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUULAGGUUCCGUAUGUCACUGGUUCGAGUCCAGUCAGAGCCGC
配列番号:139(FR-10)
tRNA(Glu)3’cg RNA配列
CGACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:140(LR-7)
tRNA(Glu)Lcg-CA RNA配列
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCULCGACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:141(FR-11)
tRNA(Glu)3’au RNA配列
AUACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
配列番号:142(LR-8)
tRNA(Glu)Lau-CA RNA配列
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCULAUACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC配列番号:138(AR-1)
tRNA(Glu)(Agm)ag-CA RNA配列
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU(Agm)AGACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
ライゲーション反応を利用して調製した各種tRNA-CAをRNaseで断片化し分析することで、pUp、pLp、あるいはp(Agm)p で導入したU、L、あるいは(Agm)がそれぞれ目的の部位に導入されていることを確認した。
各tRNA-CAの配列番号と、pUp、pLp、あるいはp(Agm)pで導入したU、L、あるいは(Agm)を含むRNA断片の配列の組み合わせを下記の表5に示す。
LCMS(ESI) m/z = 944 ((M-2H)/2)-
保持時間:4.22分(分析条件LTQTEA/HFIP05_03)
pUpがligationされていない場合に想定される断片(CCCUGp)のマスクロマトグラムと比較し、大部分pUpのligationが進行したことを確認した(図1)。
LCMS(ESI) m/z = 1008 ((M-2H)/2)-
保持時間:2.34分(分析条件LTQTEA/HFIP05_03)
pLpがligationされていない場合に想定される断片(CCCUGp)およびLysidineの代わりにUridineが入っていた場合に想定される断片(CCCUUGp)のマスクロマトグラムと比較し、大部分pLpのligationが進行したことを確認した(図2)。
LCMS(ESI) m/z = 1172 ((M-2H)/2)-
保持時間:3.81分(分析条件LTQTEA/HFIP05_03)
pLpがligationされていない場合に想定される断片(CCCUAGp)およびLysidineの代わりにUridineが入っていた場合に想定される断片(CCCUUAGp)のマスクロマトグラムと比較し、大部分pLpのligationが進行したことを確認した(図3)。
LCMS(ESI) m/z = 1642 ((M-2H)/2)-
保持時間:5.78分(分析条件LTQTEA/HFIP05_03)
pLpがligationされていない場合に想定される断片(CCCUACACGp)およびLysidineの代わりにUridineが入っていた場合に想定される断片(CCCUUACACGp/配列番号:198)のマスクロマトグラムと比較し、大部分pLpのligationが進行したことを確認した(図4)。
LCMS(ESI) m/z = 1630 ((M-2H)/2)-
保持時間:5.64分(分析条件LTQTEA/HFIP05_03)
pLpがligationされていない場合に想定される断片(CCCUCCACGp)およびLysidineの代わりにUridineが入っていた場合に想定される断片(CCCUUCCACGp/配列番号:200)のマスクロマトグラムと比較し、大部分pLpのligationが進行したことを確認した(図5)。
LCMS(ESI) m/z = 1020 ((M-2H)/2)-
保持時間:3.84分(分析条件LTQTEA/HFIP05_03)
pLpがligationされていない場合に想定される断片(CUUAGp)とRNAの他の部分由来の断片(UUCAGp)の分子量が等しいため、断片化していない状態のRNAの分析も併せて行った。
pGGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUULAGGUGCAGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC(配列番号:134)
LCMS(ESI) m/z = 1109 ((M-22H)/22)-
保持時間:3.92分(分析条件LTQTEA/HFIP05_01)
pLpがligationされていない場合に想定されるRNAおよびLysidineの代わりにUridineが入っていた場合に想定されるRNAのマスクロマトグラムと比較し、大部分pLpのligationが進行したことを確認した(図6)。
LCMS(ESI) m/z = 1032 ((M-2H)/2)-
保持時間:4.16分(分析条件LTQTEA/HFIP05_03)
pLpがligationされていない場合に想定される断片(AUUAGp)およびLysidineの代わりにUridineが入っていた場合に想定される断片(AUUUAGp)のマスクロマトグラムと比較し、大部分pLpのligationが進行したことを確認した(図7)。
LCMS(ESI) m/z = 1160 ((M-2H)/2)-
保持時間:4.21分(分析条件LTQTEA/HFIP05_03)
pLpがligationされていない場合に想定される断片(CCCUCGp)およびLysidineの代わりにUridineが入っていた場合に想定される断片(CCCUUCGp)のマスクロマトグラムと比較し、大部分pLpのligationが進行したことを確認した(図8)。
LCMS(ESI) m/z = 1642 ((M-2H)/2)-
保持時間:5.95分(分析条件LTQTEA/HFIP05_03)
pLpがligationされていない場合に想定される断片(CCCUAUACGp)およびLysidineの代わりにUridineが入っていた場合に想定される断片(CCCUUAUACGp/配列番号:203)のマスクロマトグラムと比較し、大部分pLpのligationが進行したことを確認した(図9)。
LCMS(ESI) m/z = 1164 ((M-2H)/2)-
保持時間:4.02分(分析条件LTQTEA/HFIP05_03)
p(Agm)pがligationされていない場合に想定される断片(CCCUAGp)およびAgmatidineの代わりにUridineが入っていた場合に想定される断片(CCCUUAGp)のマスクロマトグラムと比較し、大部分p(Agm)pのligationが進行したことを確認した(図10)。
鋳型DNA(配列番号:64(D-1)~配列番号:76(D-13)、配列番号:143(D-26)~配列番号:152(D-35))から、T7 RNA polymeraseを用いたin vitro 転写反応によりtRNA(配列番号:77(TR-1)~配列番号:89(TR-13)、配列番号:153(TR-14)~配列番号:162(TR-23))を合成し、RNeasy kit(Qiagen社)により精製した。
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTAGAACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:65(D-2)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTTGAACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:66(D-3)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTCGAACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:67(D-4)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTAAGACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:68(D-5)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTTAGACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:69(D-6)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTCAGACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:70(D-7)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTAACACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:71(D-8)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTTACACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:72(D-9)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTCACACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:73(D-10)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTGCCACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:74(D-11)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTTCCACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:75(D-12)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTCCCACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:76(D-13)
DNA配列:
GGCGTAATACGACTCACTATAGGCGGGGTGGAGCAGCCTGGTAGCTCGTCGGGCTCATAACCCGAAGATCGTCGGTTCAAATCCGGCCCCCGCAAC
鋳型DNA 配列番号:143(D-26)
DNA配列:
GGCGTAATACGACTCACTATAGGAGCGGTAGTTCAGTCGGTTAGAATACCTGCTTaagGTGCAGGGGGTCGCGGGTTCGAGTCCCGTCCGTTCCGC
鋳型DNA 配列番号:144(D-27)
DNA配列:
GGCGTAATACGACTCACTATAGGAGCGGTAGTTCAGTCGGTTAGAATACCTGCTTTagGTGCAGGGGGTCGCGGGTTCGAGTCCCGTCCGTTCCGC
鋳型DNA 配列番号:145(D-28)
DNA配列:
GGCGTAATACGACTCACTATAGGAGCGGTAGTTCAGTCGGTTAGAATACCTGCTTcagGTGCAGGGGGTCGCGGGTTCGAGTCCCGTCCGTTCCGC
鋳型DNA 配列番号:146(D-29)
DNA配列:
GGCGTAATACGACTCACTATAGGCTCTGTAGTTCAGTCGGTAGAACGGCGGATTaagGTTCCGTATGTCACTGGTTCGAGTCCAGTCAGAGCCGC
鋳型DNA 配列番号:147(D-30)
DNA配列:
GGCGTAATACGACTCACTATAGGCTCTGTAGTTCAGTCGGTAGAACGGCGGATTtagGTTCCGTATGTCACTGGTTCGAGTCCAGTCAGAGCCGC
鋳型DNA 配列番号:148(D-31)
DNA配列:
GGCGTAATACGACTCACTATAGGCTCTGTAGTTCAGTCGGTAGAACGGCGGATTcagGTTCCGTATGTCACTGGTTCGAGTCCAGTCAGAGCCGC
鋳型DNA 配列番号:149(D-32)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTgcgACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:150(D-33)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTccgACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:151(D-34)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTaauACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
鋳型DNA 配列番号:152(D-35)
DNA配列:
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTcauACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGC
tRNA(Glu)aga-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUAGAACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:78(TR-2)
tRNA(Glu)uga-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUUGAACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:79(TR-3)
tRNA(Glu)cga-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUCGAACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:80(TR-4)
tRNA(Glu)aag-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUAAGACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:81(TR-5)
tRNA(Glu)uag-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUUAGACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:82(TR-6)
tRNA(Glu)cag-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUCAGACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:83(TR-7)
tRNA(Glu)aac-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUAACACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:84(TR-8)
tRNA(Glu)uac-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUUACACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:85(TR-9)
tRNA(Glu)cac-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUCACACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:86(TR-10)
tRNA(Glu)gcc-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUGCCACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:87(TR-11)
tRNA(Glu)ucc-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUUCCACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:88(TR-12)
tRNA(Glu)ccc-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUCCCACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:89(TR-13)
tRNA(fMet)cau-CA RNA配列:
GGCGGGGUGGAGCAGCCUGGUAGCUCGUCGGGCUCAUAACCCGAAGAUCGUCGGUUCAAAUCCGGCCCCCGCAA
tRNA 配列番号:153(TR-14)
tRNA(Asp)aag-CA RNA配列:
GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUUaagGUGCAGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC
tRNA 配列番号:154(TR-15)
tRNA(Asp)uag-CA RNA配列:
GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUUuagGUGCAGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC
tRNA 配列番号:155(TR-16)
tRNA(Asp)cag-CA RNA配列:
GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUUcagGUGCAGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC
tRNA 配列番号:156(TR-17)
tRNA(AsnE2)aag-CA RNA配列:
GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUUaagGUUCCGUAUGUCACUGGUUCGAGUCCAGUCAGAGCCGC
tRNA 配列番号:157(TR-18)
tRNA(AsnE2)uag-CA RNA配列:
GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUUuagGUUCCGUAUGUCACUGGUUCGAGUCCAGUCAGAGCCGC
tRNA 配列番号:158(TR-19)
tRNA(AsnE2)cag-CA RNA配列:
GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUUcagGUUCCGUAUGUCACUGGUUCGAGUCCAGUCAGAGCCGC
tRNA 配列番号:159(TR-20)
tRNA(Glu)gcg-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUgcgACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:160(TR-21)
tRNA(Glu)ccg-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUccgACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:161(TR-22)
tRNA(Glu)aau-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUaauACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
tRNA 配列番号:162(TR-23)
tRNA(Glu)cau-CA RNA配列:
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUcauACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC
25μM 転写tRNA(Glu)aga-CA(配列番号:77(TR-1))、50mM HEPES-KOH pH7.5、20mM MgCl2、1mM ATP、0.6unit/μl T4 RNAリガーゼ(New england bio lab.社)、0.25mM アミノアシル化pCpA(特許文献(WO2018143145A1)記載の方法で合成した化合物TS24のDMSO溶液)となるように、Nuclease free waterでメスアップした反応液を調製し、15℃で45分間ライゲーション反応を行った。ただし、T4 RNAリガーゼおよびアミノアシル化pCpAを加える前の反応液は、95℃で2分間加熱後、室温で5分間放置し、予めtRNAのリフォールディングを行った。
ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-1を調製した。
同様に、転写tRNA(Glu)uga-CA(配列番号:78(TR-2))に対して、アミノアシル化pCpA(SS15)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-2を調製した。
同様に、lig-tRNA(Glu)uga-CA(配列番号:56(UR-1))に対して、アミノアシル化pCpA(SS15)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-3を調製した。
同様に、tRNA(Glu)Lga-CA(配列番号:57(LR-1))に対して、アミノアシル化pCpA(SS15)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-4を調製した。
同様に、転写tRNA(Glu)cga-CA(配列番号:79(TR-3))に対して、アミノアシル化pCpA(ts14;特許文献(WO2018143145A1)に記載の方法により合成)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-5を調製した。
ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-6を調製した。
同様に、転写tRNA(Glu)uag-CA(配列番号:81(TR-5))に対して、アミノアシル化pCpA(SS14)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-7を調製した。
同様に、tRNA(Glu)Lag-CA(配列番号:59(LR-2))に対して、アミノアシル化pCpA(SS14)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-8を調製した。
同様に、転写tRNA(Glu)cag-CA(配列番号:82(TR-6))に対して、アミノアシル化pCpA(TS24)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-9を調製した。
ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-10を調製した。
同様に、転写tRNA(Glu)uac-CA(配列番号:84(TR-8))に対して、アミノアシル化pCpA(SS14)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-11を調製した。
同様に、tRNA(Glu)Lac-CA(配列番号:61(LR-3))に対して、アミノアシル化pCpA(SS14)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-12を調製した。
同様に、転写tRNA(Glu)cac-CA(配列番号:85(TR-9))に対して、アミノアシル化pCpA(TS24)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-13を調製した。
ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-14を調製した。
同様に、転写tRNA(Glu)ucc-CA(配列番号:87(TR-11))に対して、アミノアシル化pCpA(SS14)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-15を調製した。
同様に、tRNA(Glu)Lcc-CA(配列番号:63(LR-4))に対して、アミノアシル化pCpA(SS14)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-16を調製した。
同様に、転写tRNA(Glu)ccc-CA(配列番号:88(TR-12))に対して、アミノアシル化pCpA(SS16)を前述の方法でライゲーション反応を行った。ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出を行い、化合物AAtR-17を調製した。
同様に、化合物AAtR-20を調製するために、転写tRNA(Asp)uag-CA(配列番号:154(TR-15))に対して、アミノアシル化pCpA(SS15)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-21を調製するために、tRNA(Asp)Lag-CA(配列番号:134(LR-5))に対して、アミノアシル化pCpA(SS15)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-22を調製するために、転写tRNA(Asp)cag-CA(配列番号:155(TR-16))に対して、アミノアシル化pCpA(TS24)を前述の方法でライゲーション反応を行った。
それぞれのligation反応後の溶液に0.3M酢酸ナトリウムを加えたあと、フェノール・クロロホルム溶液を加えた段階で、各ligation産物を混合し、混合物の状態でフェノール・クロロホルム抽出およびエタノール沈殿を行い、回収した。
具体的には、化合物AAtR-19、化合物AAtR-20、化合物AAtR-22の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-19、化合物AAtR-20、化合物AAtR-22の混合液)を調製した。
同様に、化合物AAtR-19、化合物AAtR-21、化合物AAtR-22の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-19、化合物AAtR-21、化合物AAtR-22の混合液)を調製した。
同様に、化合物AAtR-24を調製するために、転写tRNA(AsnE2)uag-CA(配列番号:157(TR-18))に対して、アミノアシル化pCpA(SS15)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-25を調製するために、tRNA(AsnE2)Lag-CA(配列番号:137(LR-6))に対して、アミノアシル化pCpA(SS15)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-26を調製するために、転写tRNA(AsnE2)cag-CA(配列番号:158(TR-19))に対して、アミノアシル化pCpA(TS24)を前述の方法でライゲーション反応を行った。
それぞれのligation反応後の溶液に0.3M酢酸ナトリウムを加えたあと、フェノール・クロロホルム溶液を加えた段階で、各ligation産物を混合し、混合物の状態でフェノール・クロロホルム抽出およびエタノール沈殿を行い、回収した。
具体的には、化合物AAtR-23、化合物AAtR-24、化合物AAtR-26の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-23、化合物AAtR-24、化合物AAtR-26の混合液)を調製した。
同様に、化合物AAtR-23、化合物AAtR-25、化合物AAtR-26の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-23、化合物AAtR-25、化合物AAtR-26の混合液)を調製した。
同様に、化合物AAtR-9を調製するために、転写tRNA(Glu)cag-CA(配列番号:82(TR-6))に対して、アミノアシル化pCpA(TS24)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-27を調製するために、転写tRNA(Glu)uag-CA(配列番号:81(TR-5))に対して、アミノアシル化pCpA(SS16)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-28を調製するために、tRNA(Glu)Lag-CA(配列番号:59(LR-2))に対して、アミノアシル化pCpA(SS16)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-29を調製するために、転写tRNA(Glu)uag-CA(配列番号:81(TR-5))に対して、アミノアシル化pCpA(SS39)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-30を調製するために、tRNA(Glu)Lag-CA(配列番号:59(LR-2))に対して、アミノアシル化pCpA(SS39)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-31を調製するために、転写tRNA(Glu)uag-CA(配列番号:81(TR-5))に対して、アミノアシル化pCpA(SS40)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-32を調製するために、tRNA(Glu)Lag-CA(配列番号:59(LR-2))に対して、アミノアシル化pCpA(SS40)を前述の方法でライゲーション反応を行った。
それぞれのligation反応後の溶液に0.3M酢酸ナトリウムを加えたあと、フェノール・クロロホルム溶液を加えた段階で、各ligation産物を混合し、混合物の状態で、もしくは単一の状態のまま、フェノール・クロロホルム抽出およびエタノール沈殿を行い、回収した。
具体的には、化合物AAtR-6、化合物AAtR-27、化合物AAtR-9の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-6、化合物AAtR-27、化合物AAtR-9の混合液)を調製した。
同様に、化合物AAtR-6、化合物AAtR-28、化合物AAtR-9の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-6、化合物AAtR-28、化合物AAtR-9の混合液)を調製した。
同様に、化合物AAtR-6、化合物AAtR-29、化合物AAtR-9の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-6、化合物AAtR-29、化合物AAtR-9の混合液)を調製した。
同様に、化合物AAtR-6、化合物AAtR-30、化合物AAtR-9の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-6、化合物AAtR-30、化合物AAtR-9の混合液)を調製した。
同様に、化合物AAtR-6、化合物AAtR-31、化合物AAtR-9の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-6、化合物AAtR-31、化合物AAtR-9の混合液)を調製した。
同様に、化合物AAtR-6、化合物AAtR-32、化合物AAtR-9の3種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-6、化合物AAtR-32、化合物AAtR-9の混合液)を調製した。
化合物AAtR-9のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNAを調製した。
同様に、化合物AAtR-34を調製するために、tRNA(Glu)Lcg-CA(配列番号:140(LR-7))に対して、アミノアシル化pCpA(SS14)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-35を調製するために、転写tRNA(Glu)ccg-CA(配列番号:160(TR-21))に対して、アミノアシル化pCpA(ts14)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-36を調製するために、転写tRNA(Glu)aau-CA(配列番号:161(TR-22))に対して、アミノアシル化pCpA(ts14)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-37を調製するために、tRNA(Glu)Lau-CA(配列番号:142(LR-8))に対して、アミノアシル化pCpA(SS14)を前述の方法でライゲーション反応を行った。
同様に、化合物AAtR-38を調製するために、転写tRNA(Glu)cau-CA(配列番号:162(TR-23))に対して、アミノアシル化pCpA(TS24)を前述の方法でライゲーション反応を行った。
それぞれのligation反応後の溶液に0.3M酢酸ナトリウムを加えたあと、フェノール・クロロホルム溶液を加えた段階で、各ligation産物を混合し、混合物の状態で、もしくは単一の状態のまま、フェノール・クロロホルム抽出およびエタノール沈殿を行い、回収した。
具体的には、化合物AAtR-33、化合物AAtR-35の2種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-33、化合物AAtR-35の混合液)を調製した。
同様に、化合物AAtR-36、化合物AAtR-38の2種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、等量で混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-36、化合物AAtR-38の混合液)を調製した。
化合物AAtR-34、化合物AAtR-37のそれぞれのligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNAを調製した。
同様に、化合物AAtR-9を調製するために、tRNA(Glu)cag-CA(配列番号:82(TR-6))に対して、アミノアシル化pCpA(TS24)を前述の方法でライゲーション反応を行った。
それぞれのligation反応後の溶液に0.3M酢酸ナトリウムを加えたあと、フェノール・クロロホルム溶液を加えた段階で、各ligation産物を1:2になるように混合し、混合物の状態でフェノール・クロロホルム抽出およびエタノール沈殿を行い、回収した。
具体的には、化合物AAtR-6、化合物AAtR-9の2種類のligation産物に0.3M酢酸ナトリウムを加え、フェノール・クロロホルム溶液を加えた液を、1:2となるように混合し、フェノール・クロロホルム抽出およびエタノール沈殿を行い、アミノアシル化tRNA混合液(化合物AAtR-6、化合物AAtR-9の混合液)を調製した。
同様に、化合物AAtR-40を調製するために、tRNA(Glu)(Agm)ag-CA(配列番号:138(AR-1))に対して、アミノアシル化pCpA(SS15)を前述の方法でライゲーション反応を行った。
それぞれのligation反応後の溶液に0.3M酢酸ナトリウムを加えたあと、フェノール・クロロホルム溶液を加えた後、フェノール・クロロホルム抽出およびエタノール沈殿を行い、回収した。
25μM 転写tRNA(fMet)cau-CA(配列番号:89(TR-13))、50mM HEPES-KOH pH7.5、20mM MgCl2、1mM ATP、0.6unit/μl T4 RNAリガーゼ(New england bio lab.社)、0.25mM アミノアシル化pCpA(MT01のDMSO溶液)となるように、Nuclease free waterでメスアップした反応液を調製し、15℃で45分間ライゲーション反応を行った。ただし、T4 RNAリガーゼおよびアミノアシル化pCpAを加える前の反応液は、95℃で2分間加熱後、室温で5分間放置し、予めtRNAのリフォールディングを行った。
ライゲーション反応液に、酢酸ナトリウムを0.3Mになるように加え、フェノール・クロロホルム抽出し、initiatorアミノアシルtRNA(化合物AAtR-18)をエタノール沈殿により回収した。
initiatorアミノアシル化tRNAは、翻訳混合物に添加する直前に1mM酢酸ナトリウムに溶解した。
次に、3種類のアミノアシル化tRNAが存在する状況で、1つのコドンボックスにおける3種類のアミノ酸の読み分けを確認するための実験を実施した。具体的には、同一コドンボックス内の3種類のコドンのうちいずれか1つを含み、それ以外は同一配列の鋳型mRNA(鋳型mRNA 配列番号:120(mR-1)~配列番号:131(mR-12))を、Lysidine修飾tRNAを含まないアミノアシル化tRNA混合液(化合物AAtR-1、化合物AAtR-2、化合物AAtR-5の混合液、化合物AAtR-1、化合物AAtR-3、化合物AAtR-5の混合液、化合物AAtR-6、化合物AAtR-7、化合物AAtR-9の混合液、化合物AAtR-10、化合物AAtR-11、化合物AAtR-13の混合液、化合物AAtR-14、化合物AAtR-15、化合物AAtR-17の混合液)、もしくはLysidine修飾tRNAを含むアミノアシル化tRNA混合液(化合物AAtR-1、化合物AAtR-4、化合物AAtR-5の混合液、化合物AAtR-6、化合物AAtR-8、化合物AAtR-9の混合液、化合物AAtR-10、化合物AAtR-12、化合物AAtR-13の混合液、化合物AAtR-14、化合物AAtR-16、化合物AAtR-17の混合液)を用いて翻訳し、ペプチド化合物を翻訳合成した。
具体的には、翻訳液(1mM GTP,1mM ATP,20mM クレアチンリン酸,50mM HEPES-KOH pH7.6,100mM 酢酸カリウム,10mM 酢酸マグネシウム,2mM スペルミジン,1mM ジチオスレイトール,1.5mg/ml E.coli MRE600(RNaseネガティブ)由来tRNA(Roche社),0.26μM EF-G,0.24μM RF2,0.17μM RF3,0.5μM RRF,4μg/ml クレアチンキナーゼ,3μg/ml ミオキナーゼ,2unit/ml 無機ピロフォスファターゼ,1.1μg/ml ヌクレオシド二リン酸キナーゼ,2.7μM IF1,0.4μM IF2,1.5μM IF3,40μM EF-Tu,35μM EF-Ts,1μM EF-P-Lys,0.4unit/μl RNasein Ribonuclease inhibitor(Promega社,N2111),1.2μM リボソーム,0.5mM PGA,0.09μM GlyRS,0.4μM IleRS,0.68μM PheRS,0.16μM ProRS,0.09μM ThrRS)に、1μM 鋳型mRNA(配列番号:123(mR-4)、配列番号:124(mR-5)、もしくは配列番号:125(mR-6))、それぞれの鋳型mRNAにコードされている天然アミノ酸群をそれぞれ0.25mMずつ、initiatorアミノアシル化tRNA(化合物AAtR-18)を10μM、アミノアシル化tRNA混合液(化合物AAtR-6、化合物AAtR-7、化合物AAtR-9の混合液、もしくは化合物AAtR-6、化合物AAtR-8、化合物AAtR-9の混合液)を30μMになるように翻訳反応混合物に添加し、37℃で1時間静置することで行った。
具体的には、翻訳液(1mM GTP,1mM ATP,20mM クレアチンリン酸,50mM HEPES-KOH pH7.6,100mM 酢酸カリウム,10mM 酢酸マグネシウム,2mM スペルミジン,1mM ジチオスレイトール,1.5mg/ml E.coli MRE600(RNaseネガティブ)由来tRNA(Roche社),0.26μM EF-G,0.24μM RF2,0.17μM RF3,0.5μM RRF,4μg/ml クレアチンキナーゼ,3μg/ml ミオキナーゼ,2unit/ml 無機ピロフォスファターゼ,1.1μg/ml ヌクレオシド二リン酸キナーゼ,2.7μM IF1,0.4μM IF2,1.5μM IF3,40μM EF-Tu,35μM EF-Ts,1μM EF-P-Lys,0.4unit/μl RNasein Ribonuclease inhibitor(Promega社,N2111),1.2μM リボソーム,0.5mM PGA,0.09μM GlyRS,0.4μM IleRS,0.68μM PheRS,0.16μM ProRS,0.09μM ThrRS)に、1μM 鋳型mRNA(配列番号:126(mR-7)、配列番号:127(mR-8)、もしくは配列番号:128(mR-9))、それぞれの鋳型mRNAにコードされている天然アミノ酸群をそれぞれ0.25mMずつ、initiatorアミノアシル化tRNA(化合物AAtR-18)を10μM、アミノアシル化tRNA混合液(化合物AAtR-10、化合物AAtR-11、化合物AAtR-13の混合液、もしくは化合物AAtR-10、化合物AAtR-12、化合物AAtR-13の混合液)を30μMになるように翻訳反応混合物に添加し、37℃で1時間静置することで行った。
具体的には、翻訳液(1mM GTP,1mM ATP,20mM クレアチンリン酸,50mM HEPES-KOH pH7.6,100mM 酢酸カリウム,10mM 酢酸マグネシウム,2mM スペルミジン,1mM ジチオスレイトール,1.5mg/ml E.coli MRE600(RNaseネガティブ)由来tRNA(Roche社),0.26μM EF-G,0.24μM RF2,0.17μM RF3,0.5μM RRF,4μg/ml クレアチンキナーゼ,3μg/ml ミオキナーゼ,2unit/ml 無機ピロフォスファターゼ,1.1μg/ml ヌクレオシド二リン酸キナーゼ,2.7μM IF1,0.4μM IF2,1.5μM IF3,40μM EF-Tu,54μM EF-Ts,1μM EF-P-Lys,0.4unit/μl RNasein Ribonuclease inhibitor(Promega社,N2111),1.2μM リボソーム,0.5mM PGA,0.4μM IleRS,0.04μM LeuRS,0.68μM PheRS,0.16μM ProRS,0.09μM ThrRS)に、1μM 鋳型mRNA(配列番号:129(mR-10)、配列番号:130(mR-11)、もしくは配列番号:131(mR-12))、それぞれの鋳型mRNAにコードされている天然アミノ酸群をそれぞれ0.25mMずつ、initiatorアミノアシル化tRNA(化合物AAtR-18)を10μM、アミノアシル化tRNA混合液(化合物AAtR-14、化合物AAtR-15、化合物AAtR-17の混合液、もしくは化合物AAtR-14、化合物AAtR-16、化合物AAtR-17の混合液)を40μMになるように翻訳反応混合物に添加し、37℃で1時間静置することで行った。
鋳型mRNAと期待される翻訳ペプチド化合物、その分子量(計算値)に関しては、以下の表6に記載した。
同様に、上述のinitiatorアミノアシル化tRNAまでの翻訳反応混合物に対して、化合物AAtR-6、化合物AAtR-29、化合物AAtR-9の混合液、もしくは、化合物AAtR-6、化合物AAtR-30、化合物AAtR-9の混合液を30μM、化合物AAtR-9を10μMになるように添加し、37℃で1時間静置することで行った。
同様に、上述のinitiatorアミノアシル化tRNAまでの翻訳反応混合物に対して、化合物AAtR-6、化合物AAtR-31、化合物AAtR-9の混合液、もしくは、化合物AAtR-6、化合物AAtR-32、化合物AAtR-9の混合液を30μM、化合物AAtR-9を10μMになるように添加し、37℃で1時間静置することで行った。
具体的には、同一コドンボックス内の3種類のコドンのうちいずれか1つを含み、それ以外は同一配列の鋳型mRNA(鋳型mRNA配列番号:169(mR-13)、配列番号:170(mR-14)、配列番号:171(mR-15)、もしくは配列番号:172(mR-16)、配列番号:173(mR-17)、配列番号:174(mR-18))を、Lysidine修飾tRNAを含むアミノアシル化tRNA混合液と、Lysidine修飾tRNAを含まないアミノアシル化tRNA混合液を用いて翻訳し、ペプチド化合物を翻訳合成した。
もう一つのコドンボックスにおいても同様に、翻訳系は、原核生物由来の再構成無細胞タンパク質合成系であるPURE systemを用いた。具体的には、翻訳液(1mM GTP,1mM ATP,20mM クレアチンリン酸,50mM HEPES-KOH pH7.6,100mM 酢酸カリウム,10mM 酢酸マグネシウム,2mMスペルミジン,1mM ジチオスレイトール,1.5mg/ml E.coli MRE600(RNaseネガティブ)由来tRNA(Roche社),0.26μM EF-G,0.24μM RF2,0.17μM RF3,0.5μM RRF,4μg/ml クレアチンキナーゼ,3μg/ml ミオキナーゼ,2unit/ml 無機ピロフォスファターゼ,1.1μg/ml ヌクレオシド二リン酸キナーゼ,2.7μM IF1,0.4μM IF2,1.5μM IF3,40μM EF-Tu,49.3μM EF-Ts,1μM EF-P-Lys,0.4unit/μl RNasein Ribonuclease inhibitor(Promega社,N2111),1.2μM リボソーム,0.5mM PGA,0.09μM GlyRS,0.4μM IleRS,0.68μM PheRS,0.16μM ProRS,0.09μM ThrRS,0.02μM ValRS,2.73μM AlaRS,0.04μM LeuRS,0.04μM SerRS)に、1μM 鋳型mRNA(配列番号:172(mR-16)、配列番号:173(mR-17)、もしくは配列番号:174(mR-18))、それぞれの鋳型mRNAにコードされている天然アミノ酸群をそれぞれ0.25mMずつ、initiatorアミノアシル化tRNA(化合物AAtR-18)を10μM、アミノアシル化tRNA混合液(化合物AAtR-36、化合物AAtR-38の混合液)を30μM、アミノアシル化tRNA(化合物AAtR-37)を10μMになるように翻訳反応混合物に添加し、37℃で1時間静置することで行った。
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTTCTATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:109(D-15)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTTCAATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:110(D-16)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTTCGATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:111(D-17)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTCTTATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:112(D-18)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTCTAATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:113(D-19)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTCTGATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:114(D-20)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTGTTATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:115(D-21)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTGTAATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:116(D-22)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTGTGATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:117(D-23)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTCTATTTGGTATTATTCCGATTCTATAAGCTTCG
鋳型DNA 配列番号:118(D-24)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTCTATTTGGAATTATTCCGATTCTATAAGCTTCG
鋳型DNA 配列番号:119(D-25)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTCTATTTGGGATTATTCCGATTCTATAAGCTTCG
鋳型DNA 配列番号:163(D-36)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTCGTATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:164(D-37)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTCGAATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:165(D-38)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTATTATTGGTTTTCGGATTATTCCGATTGGTTAAGCTTCG
鋳型DNA 配列番号:166(D-39)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTCTACTAGGTTTTATTCTACTACCGCTAGGTTAAGCTTCG
鋳型DNA 配列番号:167(D-40)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTCTACTAGGTTTTATACTACTACCGCTAGGTTAAGCTTCG
鋳型DNA 配列番号:168(D-41)
DNA配列:
GGCGTAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGACTTTTCTACTAGGTTTTATGCTACTACCGCTAGGTTAAGCTTCG
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUUCUAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:121(mR-2)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUUCAAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:122(mR-3)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUUCGAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:123(mR-4)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUCUUAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:124(mR-5)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUCUAAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:125(mR-6)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUCUGAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:126(mR-7)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUGUUAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:127(mR-8)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUGUAAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:128(mR-9)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUGUGAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:129(mR-10)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUCUAUUUGGUAUUAUUCCGAUUCUAUAAGCUUCG
鋳型mRNA 配列番号:130(mR-11)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUCUAUUUGGAAUUAUUCCGAUUCUAUAAGCUUCG
鋳型mRNA 配列番号:131(mR-12)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUCUAUUUGGGAUUAUUCCGAUUCUAUAAGCUUCG
鋳型mRNA 配列番号:169(mR-13)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUCGUAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:170(mR-14)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUCGAAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:171(mR-15)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUAUUAUUGGUUUUCGGAUUAUUCCGAUUGGUUAAGCUUCG
鋳型mRNA 配列番号:172(mR-16)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUCUACUAGGUUUUAUUCUACUACCGCUAGGUUAAGCUUCG
鋳型mRNA 配列番号:173(mR-17)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUCUACUAGGUUUUAUACUACUACCGCUAGGUUAAGCUUCG
鋳型mRNA 配列番号:174(mR-18)
RNA配列:
GGGUUAACUUUAAGAAGGAGAUAUACAUAUGACUUUUCUACUAGGUUUUAUGCUACUACCGCUAGGUUAAGCUUCG
実施例12にて調製した非天然ペプチド翻訳溶液を10倍希釈し、LC-FLR-MSの装置を用いて分析した。分析データはMSデータより対象となる翻訳ペプチドの保持時間を同定し、該当保持時時間の蛍光ピークを定量することで、ペプチド翻訳量を評価した。なお、定量評価は実施例8にて合成したLCT12を標品により検量線を作成し、相対定量により含有量を算出した。LC-MSは下記の表11の条件に従い、対象となるサンプルに応じて最適な条件を選択して分析した。
Claims (15)
- tRNAを改変することにより作製されている変異tRNAであって、当該改変が、N1N2N3で表されるアンチコドンの改変後の1文字目のヌクレオシドN1がライシジン(k2C)、ライシジン誘導体、アグマチジン(agm2C)、またはアグマチジン誘導体のいずれかである改変を含み、N2およびN3はそれぞれ、該アンチコドンの2文字目および3文字目の任意のヌクレオシドである、変異tRNA。
- 改変前のN1がシチジン(C)であって、かつ当該シチジン(C)からライシジン(k2C)への改変が、配列番号:51のアミノ酸配列を有するライシジン合成酵素(tRNAIle-lysidine synthetase; TilS)では触媒され得ない、請求項1に記載の変異tRNA。
- 改変前のN1がシチジン(C)であって、かつ当該シチジン(C)からアグマチジン(agm2C)への改変が、配列番号:52のアミノ酸配列を有するアグマチジン合成酵素(tRNAIle-agmatidine synthetase; TiaS)では触媒され得ない、請求項1に記載の変異tRNA。
- M1M2Aで表されるコドン(ここで、M1およびM2はそれぞれコドンの1文字目および2文字目のヌクレオシドを表し、M1およびM2はそれぞれアデノシン(A)、グアノシン(G)、シチジン(C)、ウリジン(U)のいずれかから選択され、3文字目のヌクレオシドはアデノシンである)に相補的なアンチコドンを有する、請求項1から3のいずれかに記載の変異tRNA。
- アンチコドンがk2CN2N3またはagm2CN2N3(ここで、アンチコドンの1文字目のヌクレオシドはライシジン(k2C)またはアグマチジン(agm2C)であり、2文字目のヌクレオシド(N2)、3文字目のヌクレオシド(N3)はそれぞれM2、M1に相補的である)で表される、請求項4に記載の変異tRNA。
- 天然の遺伝暗号表において、3文字目のヌクレオシドがAであるコドンとGであるコドンがともに同じアミノ酸をコードしているコドンボックスを構成するコドンから、M1およびM2が選択される、請求項4または5に記載の変異tRNA。
- 天然の遺伝暗号表において、3文字目のヌクレオシドがUであるコドン、Cであるコドン、Aであるコドン、およびGであるコドンがいずれも同じアミノ酸をコードしているコドンボックスを構成するコドンから、M1およびM2が選択される、請求項4または5に記載の変異tRNA。
- M1およびM2が以下(i)から(vi)からなる群より選択される、請求項4または5に記載の変異tRNA;
(i) M1がウリジン(U)であり、M2がシチジン(C)である、
(ii) M1がシチジン(C)であり、M2がウリジン(U)である、
(iii) M1がシチジン(C)であり、M2がシチジン(C)である、
(iv) M1がシチジン(C)であり、M2がグアノシン(G)である、
(v) M1がアデノシン(A)であり、M2がウリジン(U)である、
(vi) M1がグアノシン(G)であり、M2がウリジン(U)である、
(vii) M1がグアノシン(G)であり、M2がシチジン(C)である、および
(viii) M1がグアノシン(G)であり、M2がグアノシン(G)である。 - 3’末端にアミノ酸またはアミノ酸類縁体が結合している、請求項1から8のいずれかに記載の変異tRNA。
- 複数の異なる種類のtRNAを含む翻訳系であって、請求項1から9のいずれかに記載の変異tRNAを含む、翻訳系。
- (a)請求項1から9のいずれかに記載の変異tRNA、および(b)M1M2Gで表されるコドンに相補的なアンチコドンを有するtRNAを含む、請求項10に記載の翻訳系。
- さらに、(c)M1M2UまたはM1M2Cで表されるコドンに相補的なアンチコドンを有するtRNAを含む、請求項10または11に記載の翻訳系。
- 請求項11(a)、請求項11(b)、および請求項12(c)に記載のtRNAに結合しているアミノ酸またはアミノ酸類縁体がいずれも互いに異なる、請求項12に記載の翻訳系。
- 請求項10から13のいずれかに記載の翻訳系を用いて核酸を翻訳することを含む、ペプチドの製造方法。
- ペプチドおよび該ペプチドをコードする核酸を含む核酸-ペプチド複合体であって、前記ペプチドをコードする核酸は以下の(A)または(B)のいずれかに記載の3種類のコドンを含み:
(A)M1M2U、M1M2A、およびM1M2G;
(B)M1M2C、M1M2A、およびM1M2G、
前記ペプチド上において、前記3種類のコドンに対応するアミノ酸の種類がいずれも異なる、前記核酸-ペプチド複合体。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217023325A KR20210108994A (ko) | 2018-12-26 | 2019-12-26 | 코돈 확장을 위한 변이 tRNA |
SG11202106747WA SG11202106747WA (en) | 2018-12-26 | 2019-12-26 | Mutated trna for codon expansion |
EP19901650.2A EP3904568A4 (en) | 2018-12-26 | 2019-12-26 | ARNT MUTATED FOR CODON EXPANSION |
JP2020562434A JP7357642B2 (ja) | 2018-12-26 | 2019-12-26 | コドン拡張のための変異tRNA |
US17/417,822 US20220205009A1 (en) | 2018-12-26 | 2019-12-26 | MUTATED tRNA FOR CODON EXPANSION |
CN201980090364.4A CN113423877A (zh) | 2018-12-26 | 2019-12-26 | 用于密码子扩展的突变tRNA |
US17/787,809 US20230108274A1 (en) | 2019-12-26 | 2020-12-25 | Composition for translation, and method for producing peptide |
KR1020227023690A KR20220121831A (ko) | 2019-12-26 | 2020-12-25 | 번역용 조성물 및 펩타이드의 제조 방법 |
PCT/JP2020/048652 WO2021132546A1 (ja) | 2019-12-26 | 2020-12-25 | 翻訳用組成物及びペプチドの製造方法 |
EP20906472.4A EP4026906A4 (en) | 2019-12-26 | 2020-12-25 | COMPOSITION FOR TRANSLATION AND METHOD FOR PRODUCING PEPTIDES |
CN202080076538.4A CN114641569A (zh) | 2019-12-26 | 2020-12-25 | 翻译用组合物及肽的制备方法 |
JP2021567657A JPWO2021132546A1 (ja) | 2019-12-26 | 2020-12-25 | |
JP2023163077A JP2023182649A (ja) | 2018-12-26 | 2023-09-26 | コドン拡張のための変異tRNA |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-243478 | 2018-12-26 | ||
JP2018243478 | 2018-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020138336A1 true WO2020138336A1 (ja) | 2020-07-02 |
Family
ID=71125953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/051241 WO2020138336A1 (ja) | 2018-12-26 | 2019-12-26 | コドン拡張のための変異tRNA |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220205009A1 (ja) |
EP (1) | EP3904568A4 (ja) |
JP (2) | JP7357642B2 (ja) |
KR (1) | KR20210108994A (ja) |
CN (1) | CN113423877A (ja) |
SG (1) | SG11202106747WA (ja) |
WO (1) | WO2020138336A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021117848A1 (ja) | 2019-12-12 | 2021-06-17 | 中外製薬株式会社 | 非天然アミノ酸を含むペプチドの製造方法 |
WO2022104001A1 (en) * | 2020-11-13 | 2022-05-19 | Bristol-Myers Squibb Company | Expanded protein libraries and uses thereof |
WO2022138892A1 (ja) | 2020-12-25 | 2022-06-30 | 中外製薬株式会社 | 複数の標的分子と共に複合体を形成し得る候補分子のスクリーニング方法 |
US11492369B2 (en) | 2017-12-15 | 2022-11-08 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide, and method for processing bases |
US11542299B2 (en) | 2017-06-09 | 2023-01-03 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
US11732002B2 (en) | 2018-11-30 | 2023-08-22 | Chugai Seiyaku Kabushiki Kaisha | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound |
US11891457B2 (en) | 2011-12-28 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Peptide-compound cyclization method |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220121831A (ko) * | 2019-12-26 | 2022-09-01 | 추가이 세이야쿠 가부시키가이샤 | 번역용 조성물 및 펩타이드의 제조 방법 |
CN113862269B (zh) * | 2021-10-25 | 2023-12-22 | 中南大学湘雅三医院 | tsRNA分子及其用途 |
CN117070512B (zh) * | 2023-10-16 | 2024-04-26 | 吉林凯莱英医药化学有限公司 | tRNA及其生物合成方法 |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005095013A (ja) * | 2003-09-22 | 2005-04-14 | Tsutomu Suzuki | イソロイシンtRNA(tRNAIle)のライシジン合成酵素(TilS)としてのmesJ遺伝子産物及びその相同性遺伝子(COG0037) |
WO2006135096A1 (ja) | 2005-06-14 | 2006-12-21 | Gifu University | 部位特異的にタンパク質にチロシンアナログを導入する方法 |
WO2007061136A1 (ja) | 2005-11-24 | 2007-05-31 | Riken | 非天然型アミノ酸を組み込んだタンパク質の製造方法 |
WO2007066627A1 (ja) | 2005-12-06 | 2007-06-14 | The University Of Tokyo | 多目的アシル化触媒とその用途 |
WO2007103307A2 (en) | 2006-03-03 | 2007-09-13 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
WO2008001947A1 (fr) | 2006-06-28 | 2008-01-03 | Riken | SepRS MUTANTE, ET PROCÉDÉ D'INTRODUCTION SITO-SPÉCIFIQUE D'UNE PHOSPHOSÉRINE DANS UNE PROTÉINE EN UTILISANT CETTE SepRS |
WO2010141851A1 (en) | 2009-06-05 | 2010-12-09 | Salk Institute For Biological Studies | Improving unnatural amino acid incorporation in eukaryotic cells |
WO2012026566A1 (ja) | 2010-08-27 | 2012-03-01 | 国立大学法人 東京大学 | 新規人工翻訳合成系 |
WO2012033154A1 (ja) | 2010-09-09 | 2012-03-15 | 国立大学法人 東京大学 | N-メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
WO2012074130A1 (ja) | 2010-12-03 | 2012-06-07 | 国立大学法人東京大学 | ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法 |
WO2013100132A1 (ja) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ペプチド化合物の環化方法 |
WO2015030014A1 (ja) | 2013-08-26 | 2015-03-05 | 国立大学法人東京大学 | 大環状ペプチド、その製造方法、及び大環状ペプチドライブラリを用いるスクリーニング方法 |
WO2015120287A2 (en) | 2014-02-06 | 2015-08-13 | Yale University | Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids |
WO2018052002A1 (ja) | 2016-09-13 | 2018-03-22 | 第一三共株式会社 | Thrombospondin 1結合ペプチド |
JP2018509172A (ja) * | 2015-03-27 | 2018-04-05 | ザ ユニバーシティ オブ クィーンズランド | タンパク質への非天然アミノ酸組込みのためのプラットフォーム |
WO2018143145A1 (ja) | 2017-01-31 | 2018-08-09 | 中外製薬株式会社 | 無細胞翻訳系におけるペプチドの合成方法 |
WO2018225864A1 (ja) | 2017-06-09 | 2018-12-13 | 中外製薬株式会社 | 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2498776A1 (en) * | 2002-09-13 | 2004-03-25 | The University Of Queensland | Gene expression system based on codon translation efficiency |
CN102586287A (zh) * | 2012-01-16 | 2012-07-18 | 天津超然生物技术有限公司 | 一种hpv16l1多核苷酸序列及其表达载体、宿主细胞和应用 |
JP6440055B2 (ja) * | 2013-05-10 | 2018-12-19 | 国立大学法人 東京大学 | ペプチドライブラリの製造方法、ペプチドライブラリ、及びスクリーニング方法 |
-
2019
- 2019-12-26 CN CN201980090364.4A patent/CN113423877A/zh active Pending
- 2019-12-26 US US17/417,822 patent/US20220205009A1/en active Pending
- 2019-12-26 KR KR1020217023325A patent/KR20210108994A/ko unknown
- 2019-12-26 WO PCT/JP2019/051241 patent/WO2020138336A1/ja unknown
- 2019-12-26 SG SG11202106747WA patent/SG11202106747WA/en unknown
- 2019-12-26 EP EP19901650.2A patent/EP3904568A4/en active Pending
- 2019-12-26 JP JP2020562434A patent/JP7357642B2/ja active Active
-
2023
- 2023-09-26 JP JP2023163077A patent/JP2023182649A/ja active Pending
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005095013A (ja) * | 2003-09-22 | 2005-04-14 | Tsutomu Suzuki | イソロイシンtRNA(tRNAIle)のライシジン合成酵素(TilS)としてのmesJ遺伝子産物及びその相同性遺伝子(COG0037) |
WO2006135096A1 (ja) | 2005-06-14 | 2006-12-21 | Gifu University | 部位特異的にタンパク質にチロシンアナログを導入する方法 |
WO2007061136A1 (ja) | 2005-11-24 | 2007-05-31 | Riken | 非天然型アミノ酸を組み込んだタンパク質の製造方法 |
WO2007066627A1 (ja) | 2005-12-06 | 2007-06-14 | The University Of Tokyo | 多目的アシル化触媒とその用途 |
WO2007103307A2 (en) | 2006-03-03 | 2007-09-13 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
WO2008001947A1 (fr) | 2006-06-28 | 2008-01-03 | Riken | SepRS MUTANTE, ET PROCÉDÉ D'INTRODUCTION SITO-SPÉCIFIQUE D'UNE PHOSPHOSÉRINE DANS UNE PROTÉINE EN UTILISANT CETTE SepRS |
WO2010141851A1 (en) | 2009-06-05 | 2010-12-09 | Salk Institute For Biological Studies | Improving unnatural amino acid incorporation in eukaryotic cells |
WO2012026566A1 (ja) | 2010-08-27 | 2012-03-01 | 国立大学法人 東京大学 | 新規人工翻訳合成系 |
WO2012033154A1 (ja) | 2010-09-09 | 2012-03-15 | 国立大学法人 東京大学 | N-メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
WO2012074130A1 (ja) | 2010-12-03 | 2012-06-07 | 国立大学法人東京大学 | ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法 |
WO2013100132A1 (ja) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ペプチド化合物の環化方法 |
WO2015030014A1 (ja) | 2013-08-26 | 2015-03-05 | 国立大学法人東京大学 | 大環状ペプチド、その製造方法、及び大環状ペプチドライブラリを用いるスクリーニング方法 |
WO2015120287A2 (en) | 2014-02-06 | 2015-08-13 | Yale University | Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids |
JP2018509172A (ja) * | 2015-03-27 | 2018-04-05 | ザ ユニバーシティ オブ クィーンズランド | タンパク質への非天然アミノ酸組込みのためのプラットフォーム |
WO2018052002A1 (ja) | 2016-09-13 | 2018-03-22 | 第一三共株式会社 | Thrombospondin 1結合ペプチド |
WO2018143145A1 (ja) | 2017-01-31 | 2018-08-09 | 中外製薬株式会社 | 無細胞翻訳系におけるペプチドの合成方法 |
WO2018225864A1 (ja) | 2017-06-09 | 2018-12-13 | 中外製薬株式会社 | 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ |
Non-Patent Citations (43)
Title |
---|
"Greene's, ''Protective Groups in Organic Synthesis", 2014, JOHN WILEY & SONS |
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 14, no. 4, 2003, pages 183 - 194 |
BARTON ET AL., METHODS ENZYMOL, vol. 275, 1996, pages 35 - 57 |
BIOCONJUG CHEM, vol. 18, 2007, pages 469 - 476 |
CHEM BIO CHEM, vol. 10, 2009, pages 787 - 798 |
CHEM. COMMUN. (CAMB, vol. 47, 2011, pages 9946 - 9958 |
CHEMISTRY A EUROPEAN JOURNAL, vol. 21, no. 26, 2015, pages 9370 - 9379 |
COMB CHEM HIGH THROUGHPUT SCREEN, vol. 13, 2010, pages 75 - 87 |
ERICKSON ET AL., METHODS ENZYMOL, vol. 101, 1983, pages 674 - 690 |
GASIOR ET AL., J BIOL CHEM, vol. 254, 1979, pages 3965 - 3969 |
GOTOSUGA, J AM CHEM SOC, vol. 131, no. 14, 2009, pages 5040 - 5041 |
GROSJEAN ET AL., TRENDS BIOCHEM SCI., vol. 29, no. 4, April 2004 (2004-04-01), pages 165 - 168 |
HECHT ET AL., J BIOL CHEM, vol. 253, 1978, pages 4517 - 4520 |
HELV. CHIM. ACTA, vol. 90, pages 297 - 310 |
IKEUCHI ET AL., MOL CELL, vol. 19, 2005, pages 235 - 246 |
IKEUCHI ET AL., NAT CHEM BIOL, vol. 6, no. 4, 2010, pages 277 - 282 |
IWANE ET AL., NAT CHEM., vol. 8, no. 4, April 2016 (2016-04-01), pages 317 - 325 |
LAJOIE ET AL., J MOL BIOL., vol. 428, no. 5, 27 February 2016 (2016-02-27), pages 1004 - 1021 |
MATTHEAKIS ET AL., PROC NATL ACAD SCI USA, vol. 91, 1994, pages 9022 - 9026 |
MEINNEL ET AL., BIOCHIMIE, vol. 75, 1993, pages 1061 - 1075 |
MURAMATSU ET AL., J BIOL CHEM, vol. 263, 1988, pages 9261 - 9267 |
MURAMATSU, T. ET AL.: "A novel lysine-substituted nucleoside in the first position of the anticodon of minor isoleucine tRNA from Escherichia coli", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 19, 1988, pages 9261 - 9267, XP055721921 * |
NAT CHEM BIOL, vol. 5, 2009, pages 888 - 507 |
NEMOTO ET AL., FEBS LETT, vol. 414, 1997, pages 405 - 408 |
NOWAK ET AL., SCIENCE, vol. 268, 1995, pages 439 - 442 |
NUCLEIC ACIDS RESEARCH, vol. 31, no. 22, 2003, pages el45 |
ODEGRIP, PROC NATL ACAD SCI USA, vol. 101, 2004, pages 2806 - 2810 |
ORG. LETT., vol. 14, no. 16, 2012, pages 4118 - 4121 |
OSAWA ET AL., NAT STRUCT MOL BIOL, vol. 18, 2011, pages 1275 - 1280 |
REIERSEN, NUCLEIC ACIDS RES, vol. 33, 2005, pages e10 |
ROBERTSSZOSTAK, PROC NATL ACAD SCI USA, vol. 94, 1997, pages 12297 - 12302 |
See also references of EP3904568A4 |
SHIMIZU ET AL., NAT BIOTECH, vol. 19, 2001, pages 751 - 755 |
SHIMIZU ET AL., NAT BIOTECHNOL., vol. 19, no. 8, August 2001 (2001-08-01), pages 751 - 755 |
SPRINZL ET AL., NUCLEIC ACIDS RES, vol. 26, 1998, pages 148 - 153 |
SUZUKI ET AL., FEBS LETT, vol. 584, 2010, pages 272 - 277 |
SUZUKI T ET AL., FEBS LETT., vol. 584, no. 2, 21 January 2010 (2010-01-21), pages 272 - 277 |
SUZUKI, TSUTOMU: "How to decipher AUA codon in archaea", KAGAKU TO SEIBUTSU - CHEMISTRY AND BIOLOGY, vol. 50, no. 1, 1 January 2012 (2012-01-01), pages 36 - 43, XP009529004, ISSN: 0453-073X * |
SWERDEL ET AL., COMP BIOCHEM PHYSIOL B, vol. 93, 1989, pages 803 - 806 |
TAWFIKGRIFFITHS, NAT BIOTECHNOL, vol. 16, 1998, pages 652 - 656 |
WANG ET AL., ACS CHEM BIOL, vol. 10, 2015, pages 2187 - 2192 |
WEBER, F. ET AL.: "A potato mitochondrial isoleucine tRNA is coded for by a mitochondrial gene possessing a methionine anticodon", NUCLEIC ACIDS RESEARCH, vol. 18, no. 17, 1990, pages 5027 - 5030, XP055721918 * |
YAMAGUCHI ET AL., NUCLEIC ACIDS RES, vol. 37, 2009, pages e108 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11891457B2 (en) | 2011-12-28 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Peptide-compound cyclization method |
US11542299B2 (en) | 2017-06-09 | 2023-01-03 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
US11787836B2 (en) | 2017-06-09 | 2023-10-17 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
US11492369B2 (en) | 2017-12-15 | 2022-11-08 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide, and method for processing bases |
US11732002B2 (en) | 2018-11-30 | 2023-08-22 | Chugai Seiyaku Kabushiki Kaisha | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound |
WO2021117848A1 (ja) | 2019-12-12 | 2021-06-17 | 中外製薬株式会社 | 非天然アミノ酸を含むペプチドの製造方法 |
WO2022104001A1 (en) * | 2020-11-13 | 2022-05-19 | Bristol-Myers Squibb Company | Expanded protein libraries and uses thereof |
WO2022138892A1 (ja) | 2020-12-25 | 2022-06-30 | 中外製薬株式会社 | 複数の標的分子と共に複合体を形成し得る候補分子のスクリーニング方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3904568A1 (en) | 2021-11-03 |
CN113423877A (zh) | 2021-09-21 |
SG11202106747WA (en) | 2021-07-29 |
KR20210108994A (ko) | 2021-09-03 |
EP3904568A4 (en) | 2024-03-20 |
US20220205009A1 (en) | 2022-06-30 |
JP2023182649A (ja) | 2023-12-26 |
JPWO2020138336A1 (ja) | 2021-11-18 |
JP7357642B2 (ja) | 2023-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020138336A1 (ja) | コドン拡張のための変異tRNA | |
JP7187323B2 (ja) | 無細胞翻訳系におけるペプチドの合成方法 | |
EP3636807A1 (en) | Cyclic peptide compound having high membrane permeability, and library containing same | |
EP3040417A1 (en) | Macrocyclic peptide, method for producing same, and screening method using macrocyclic peptide library | |
WO2012033154A1 (ja) | N-メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 | |
Dedkova et al. | Expanding the scope of protein synthesis using modified ribosomes | |
EP2952582A1 (en) | Flexible display method | |
Zhang et al. | Facilitated synthesis of proteins containing modified dipeptides | |
EP4166675A1 (en) | Translation system provided with modified genetic code table | |
JP6618534B2 (ja) | アミノ酸修飾核酸とその利用 | |
EP4026906A1 (en) | Composition for translation, and method for producing peptide | |
EP3103881A1 (en) | Method for producing peptides having azole-derived skeleton | |
US20220002719A1 (en) | Oligonucleotide-mediated sense codon reassignment | |
JP7267458B2 (ja) | 非天然アミノ酸を含むペプチドの製造方法 | |
EP4389890A1 (en) | Trna, aminoacyl-trna, polypeptide synthesis reagent, unnatural amino acid incorporation method, polypeptide production method, nucleic acid display library production method, nucleic acid/polypeptide conjugate, and screening method | |
Klimova | Recoding of bacteriophage T4 gene 60 mRNA by programmed translational bypassing | |
JP2007151482A (ja) | 相補的オリゴヌクレオチドを用いた無細胞タンパク質合成方法 | |
Stojanovic | The development of reconstituted translation system for peptidomimetic mRNA display synthesis | |
Zhou | Development of peptide-like library |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19901650 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020562434 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217023325 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019901650 Country of ref document: EP Effective date: 20210726 |